2014 Surveys Catalog - College of American Pathologists · Glass Slide Program with Online PAP...

and Anatomic Pathology Education Programs

Surveys

Welcome to the 2014 Surveys catalog Health care providers, including all of us in pathology and laboratory medicine, are feeling the pressure of the changing health care landscape. We need to learn new methods and technologies for the advancement of laboratory medicine and the patients we serve in this ever-changing world. Along with everything new, there is new language, for example, related to next-generation sequencing, accountable care organizations, and a myriad ��

Quality is the one constant to which despite all of the changes, the College of American Pathologists (CAP) dedicates itself. The CAP partners with laboratories to continually help them improve and ascend on the continuum of quality.

CAP laboratory improvement programs, including Surveys, accreditation, and learning, are critical components in a laboratory’s quality journey. Together,

these programs provide a comprehensive view of the laboratory quality process with insight, knowledge and peer-based educational coaching. The CAP aims to foster collaboration �� accurate patient diagnoses.

Using CAP laboratory improvement programs represents a badge of quality for laboratories. It’s no coincidence that the highest-rated health care providers utilize CAP laboratory improvement programs and are recognized by:

• The Best Hospitals: U.S. News & World Report

• Baldrige Health Care Award winners

• Leapfrog Top Hospitals

• Becker’s 100 Great Hospitals

• Truven Health Analytics Top 100 Hospitals

With more than 50 years of experience developing laboratory improvement programs, we are well positioned to continue to develop cutting-edge programs to meet your laboratory’s changing needs. We thank you for letting us be your partner in your laboratory’s quality journey.

Sincerely,

R. Bruce Williams, MD, FCAP ��

��!"�� #��$�� #� �

� ��!"�#�� %&'

$ �� *&��#�$�� #� � �� !��#� �� !+/4��64�9��$��

% &�� %�";/��<9=$�64�� +/�6<��>�?�� %�/�49@J69<�64�� "�K4J�? �� "��KJ@>�64�� ""

' ��(��(�� "+�N�

) *��+��+��"�� N%�+"

O�� 6�� V��#�4��# �� N"

X�� ;%�� ;;

, ��+N�'�

- 3��*��5��5��67�� '%�';

8 ��7�� '+�*'

9 ��(3��**�!�;�� = ��#� � �� !��Y �� 4 �� !�"

�: ��;�� !�+�!�;� �� Y�� ZK�� !�'J�� /� ��

4 � #��#� �� !��

�� <��!�+�!"�

[� ��#� �� !�'�� 4�� !%"

�$ ��#�� !"!�!""��#�� $��#�� !"�

�% �� !"N�!N�

�' ��!N%�!'�

= ��#�� !N"

4�� #�� !;N

4��#�� !;;

� � ��#�� !;*

Y��#�� 4��

4��#��6��#�� !+�

Y��#�� !+%

4�� 4��#�� !+N

J��V�� #�� !'�

�) ��=��!�� !'!�!*�

J��#� �� !'�

\��]�� !'*

�, ��5;��>��5

�� !*%��"

6� ��4�� !*"

Y�� 4 �^�� !

� �� #��6��# �� "

�- <�� N��'

�8 *��+�� *��

��#�� !�

=�� 4�� O�� !%

4�� 9��#��&��6�� !*

4�� 9��#��&�[� ��#��

�9 ��+�� %��""

��#�� #� �� "

O�� J�� %�

��4 �^�� %"

�� #�� %N

�� #� �� %;

$: =��@�� "N��"'

$� ��A��7��"*��''

��B��$:�'K��^��# ��#��

�� #��$�� #� �

��

��

��

�

��

��B

�� _ @�]�V��

`X��#�� #� ��

�� #��{� �� |�� N�

�� }��#��

��#� ��]�� ]��

��#��#��#� �� ~�

�� #��#��

�D3��B��5�"5=��

@�]�V��

' ��#�� #�� !"�� #��$�� #� �

��B

� ��! "�#��

&�� @�� F�G

Q-PROBES Technical Staffing Ratios QP141 28

Q-PROBES Validating Laboratory Results in Electronic Health Records QP142 29

Q-PROBES Physician Satisfaction with Clinical Laboratory Services QP143 30

Q-PROBES Use and Effectiveness of Delta Checks QP144 31

Q-TRACKSMislabeled Cases, Specimens, Blocks, and Slides in

Surgical PathologyQT19 39

��(��(�� @�� F�G

Point-of-Care Programs POC Blood Gases Competency POC10 49

Point-of-Care Programs POC Blood Gases, i-STAT Competency POC11 49

Point-of-Care Programs POC Plasma Cardiac Markers Competency POC12 49

Point-of-Care Programs POC H. pylori Antibody Competency POC13 49

Point-of-Care Programs POC Medtronic ACT/ACT, i-STAT Competency POC14 49

Point-of-Care Programs POC Hemochron Jr IL GEM ACT-LR Competency POC15 49

Point-of-Care Programs POC Hemochron Jr Signature IL GEM PCL ACT Competency POC16 49

��@�� F�G

Endocrinology Anti-Müllerian Hormone AMH 77

��7��@�� F�G

Toxicology Vitreous Fluid, Postmortem VF 92

Toxicology Synthetic Cannabinoid/Designer Drugs SCDD 96

New for 2014—per the Centers for Medicare and Medicaid Services (CMS), second instrument data may not be used forreporting proficiency testing (PT) results. The data is for internal laboratory purposes only.

@�]�V��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # )

��B

��(3��@�� F�G

Accuracy-Based Programs Accuracy-Based Thyroid ABTH 102

�� ;��@�� F�G

Calibration Verification/Linearity CMV Viral Load CVL LN38 120

Calibration Verification/Linearity HIV Viral Load CVL LN39 120

Calibration Verification/Linearity Vitamin D CVL LN40 120

Calibration Verification/Linearity Procalcitonin CVL LN41 121

Calibration Verification/Linearity D-Dimer CVL LN42 121

<�� @�� F�G

Hematology Erythrocyte Sedimentation Rate, ALCOR ESR3 128

Clinical Microscopy Clinical Microscopy for iCHEM Instruments CMP1 134

Clinical Microscopy Rupture of Fetal Membranes Testing ROM1 138

Clinical Microscopy Urinalysis Benchtop Reference Guide UABRG 139

��@�� F�G

Coagulation Heparin-Induced Thrombocytopenia – Akers Bioscience CGS6 147

@�]�V��

, ��#�� #�� !"�� #��$�� #� �

��B

� ��@�� F�G

BacteriologyGram-Positive Blood Culture Panel for Molecular

Multiplex TestingGPBC 160

Mycology Candida Culture F3 167

Parasitology Parasitology Benchtop Reference Guide PBRG 170

Molecular Microbiology Gastrointestinal Panel for Molecular Multiplex Testing GIP 179

��=��! ��@�� F�G

Immunology Antifilamentous Actin IgG Antibody FCN 184

�� 5;�� >��5 ��@�� F�G

Transfusion Medicine Transfusion Medicine Automated, Educational Challenges JATE1 195

Transfusion Medicine Transfusion Medicine Automated, Electronic Crossmatch EXM2 197

Transfusion Medicine Bacterial Detection in Platelets, Rapid BDPV, BDPV5 198

Transfusion Medicine Red Blood Cell Antigen Genotyping RAG 200

*��+��@�� F�G

Biochemical and Molecular Genetics CAP/ACMG Alpha-1 Antitrypsin (SERPINA1) Genotyping AAT 214

Biochemical and Molecular Genetics CAP/ACMG Apolipoprotein E Genotyping APOE 214

Biochemical and Molecular Genetics CAP/ACMG Hemoglobinopathies, Molecular Methods HGM 214

Biochemical and Molecular Genetics IL28B Genotyping PGx1 217

Biochemical and Molecular Genetics HLA-B*5701 Genotyping PGx2 217

Biochemical and Molecular Genetics CAP/ACMG Rett Syndrome (MECP2) Genotyping RETT 217

Biochemical and Molecular Genetics CAP/ACMG Thrombophilia Mutations TPM 217

Molecular - Solid Tumors Neoplastic Cellularity NEO 220

Molecular - Solid Tumors Multigene Tumor Panel MTP 221

@�]�V��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # -

��B

�� +��@�� F�G

Surgical Pathology CAP/NSH HistoQIP - IHC HQIHC 231

CytopathologyGlass Slide Program with Online PAP Education,

Laboratory, SurePathPTGDK 236

CytopathologyGlass Slide Program with Online PAP Education, Individual,

SurePathAPTGDK 236


Laboratory, ThinPrep + SurePathPTGDL 236

CytopathologyGlass Slide Program with Online PAP Education, Individual,

ThinPrep + SurePathAPTGDL 236


Laboratory, ThinPrepPTGDM 236


Individual, ThinPrepAPTGDM 236

CytopathologyGlass Slide Gynecologic Cytopathology PAP PT Program

with Glass Slide PAP Education, Laboratory, SurePath andThinPrep Combination

PAPLPTSeries 1 or 2

237

CytopathologyGlass Slide Gynecologic Cytopathology PAP PT Programwith Glass Slide PAP Education, Individual, SurePath and

ThinPrep Combination

APAPLPTSeries 1 or 2

237

CytopathologyGynecologic Cytopathology Education Program,Laboratory, SurePath and ThinPrep Combination

PAPLESeries 1 or 2

239

Cytopathology Gynecologic Cytopathology Education Program, Individual,

SurePath and ThinPrep CombinationAPAPLE

Series 1 or 2239

"��#��+��#��H��[�� K �� #� ��{�� KJ�� #��

��I� �� ]��

�� #� ��$��

� <� ��

� �� #��]��$��

� J�� ^�� #

� ��#� ��#��

� 4 � #�� ^��#� ��#

� J��

@��J��+��

\�� 6�� ^ #�� #� �� #�� ]�� #��#��

@�� ^ #��]��#� �� 6�� $��

@��D��A��D

��

��

��

��

��

��

�

$

��# $�� Continuing Education Programs .........................................................................................................10Competency Assessment Program ......................................................................................................17QMEd™ Online Educational Courses..................................................................................................20

$ _ ��#�$��

`6��

��#��

��#�� {��

��

� �� #��]��

��

�}��]��^�]�� #��

��

��{� ��

�}�� #�� 6��

� �� #� ��^��

#��#�� ]��

"�#�KD3��>��5�"5=�� $��

��#�$�� #� �

�: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

��

M�� H�� +�� @��#��DM��N�� +��#��H��+�� D

K��

This activity is eligible for continuing medical education (CME) credit.

This activity is eligible for continuing education (CE) credit.

This activity is eligible for continuing medical education (CME) credit or continuing education (CE) credit.

��3��+��

��The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical education for physicians.

��The College of American Pathologists designates these enduring materials educational activities for a maximum of the statednumber of AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of theirparticipation in the activity.

��O��IA new AMA requirement mandates that all physicians wishing to claim AMA PRA Category I Credits™ for an enduringmaterials activity accredited for CME must pass a scored assessment. The CAP is adding scored assessments to qualifyingCME activities.

* Enduring courses are those courses that endure over time such as print or Internet courses.

��F��+��G��3��+��The College of American Pathologists designates these educational activities for a maximum of the stated number of credits ofcontinuing education. Participants should claim only the credit commensurate with the extent of their participation in the activity.

The American Society for Clinical Pathology (ASCP) Board of Certification (BOC) Certification Maintenance Program (CMP)accepts this activity to meet its continuing education requirements. The states of California and Florida also approve these activitiesfor continuing education credit.

Cytotechnologists may apply the credits from the PAPCE/PAPJE/PAPKE/PAPLE/PAPME Series 1 or 2, PAP PT, and NGCprograms toward the required educational activities for the American Society of Cytopathology (ASC) Continuing Education CreditProgram (CECC) and the International Academy of Cytology (IAC).

��#�$�� #� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��

��

��

��

��

��

��

�

$

@��#��#��When your laboratory participates in CAP Surveys, every member of your team can enroll in education activities and earncontinuing education (CE) credit at no additional charge. Simply follow these steps:

1. Establish a free Web account.2. Complete a reading provided in the Participant Summary or Final Critique.3. Answer online learning assessment questions.

Each member of your staff can access the Surveys education activities for a maximum of 12 months.

@��#��#��

�� @�� F�G

General Chemistry and Therapeutic DrugsC1/C3/C3X,

CZ/CZX/CZ2/CZ2X, C7Participant Summary 54, 71

Maternal Screening FP Participant Summary 80

First Trimester Maternal Screening, Free Beta hCG FP1B Participant Summary 80

First Trimester Maternal Screening, Total hCG FP1T Participant Summary 80

Toxicology T Participant Summary 88

Urine Toxicology UT Participant Summary 88

Urine Drug Testing, Screening UDS, UDS6 Participant Summary 90

CAP/AACC Forensic Urine Drug Testing, Confirmatory UDC Participant Summary 91

Drug Monitoring for Pain Management DMPM Participant Summary 97

Basic Hematology HE, HEP Participant Summary 128

Blood Cell Identification BCP Participant Summary 128

Hematology Automated Differentials FH Series FH1-FH10, FH1P-FH10P Participant Summary 129

Bone Marrow Cell Differential BMD Participant Summary 130

Virtual Body Fluid VBF Participant Summary 135

Virtual Peripheral Blood Smear VPBS Participant Summary 132

Semen Analysis SC, SC1, PV, SM, SV, ASA Participant Summary 142

Sperm Motility, Morphology, and Viability SMCD, SM1CD, SM2CD Participant Summary 142

Coagulation, Limited CGL, CGDF Participant Summary 146

Bacteriology D Final Critique 154

Mycology F Final Critique 166

C-Reactive Protein, High-Sensitivity C-Reactive Protein CRP, hsCRP Participant Summary 182, 60

Special Immunology S2 Participant Summary 183

M. tuberculosis-Stimulated Infection Detection QF Participant Summary 187

Transfusion Medicine, Comprehensive, Limited J, J1 Participant Summary 194

Transfusion Medicine, Educational Challenges JE1, JATE1 Participant Summary 194, 195

Transfusion Medicine, Electronic Crossmatch EXM, EXM2 Participant Summary 197

Transfusion Medicine, Automated Testing JAT Participant Summary 194

CAP/NSH HistoQIP HQIP Final Critique 229

CAP/ACMG Cytogenetics CY, CYBK Participant Summary 210

��#�$�� #� �

�$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

@��#��@��(��6��When your laboratory participates in CAP Surveys, every member of your team can receive self-reported training opportunities.

@��(��6��O

�� @�� F�G

Hematology and Clinical Microscopy

Blood Cell Identification BCP Participant Summary 128

Bone Marrow Cell Differential BMD Participant Summary 130

Hematology Automated Differentials FH Series FH1-FH10, FH1P-FH10P Participant Summary 129

Basic Hematology HE, HEP Participant Summary 128

Hemoglobinopathy HG Participant Summary 131

Virtual Peripheral Blood Smear VPBS Participant Summary 132

Clinical Microscopy CMP, CMMP Participant Summary 134

Microbiology

Blood Parasite BP Participant Summary 170

Expanded Bacteriology DEX Participant Summary/Final Critique 155

Mycobacteriology E Participant Summary/Final Critique 165

Yeast F1 Participant Summary/Final Critique 166

Parasitology P Participant Summary/Final Critique 169

Ticks, Mites, and Other Arthropods TMO Participant Summary 171

Genetics and Molecular Pathology

CAP/ACMG Cytogenetics CY Participant Summary 210

CAP/ACMG FISH for Constitutional/HematologicDisorders

CYF Participant Summary 210

CAP/ACMG FISH for Paraffin-Embedded Tissue CYJ, CYK, CYL Participant Summary 211

CAP/ACMG Cytogenomic Microarray Analysis CYCGH Participant Summary 211

*Notes:

��#�$�� #� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%

��

��

��

��

��

��

�

$

��F�6�GMaintenance of Certification (MOC) is the board certification program that involves continuous professional development andensures that an American Board of Pathology (ABP) board-certified pathologist is committed to lifelong learning and competencyin a specialty and/or subspecialty.

There are six competency categories defined by the American Board of Medical Specialties (ABMS) and endorsed by the ABPto fulfill specific MOC requirements. They are listed below with their icons and descriptions. Select CAP education activities arelabeled with one or more MOC icons indicating the competencies addressed in that education activity. You can use these icons todevelop a learning plan that meets your needs and fulfills your MOC Part II: Lifelong Learning and Part IV: Practice PerformanceAssessment requirements.

All CAP education activities providing CME credits meet the MOC Part II: Lifelong Learning requirements. Some programs willmeet the requirements for Self-Assessment Module (SAM) and/or MOC Part IV at the laboratory or the individual levels. Programsthat meet Part IV are identified within the description of the program. Visit the CAP website for the current list of programs thatmeet the requirements for MOC Part II and Part IV.

Interpersonal and Communication SkillsDemonstrate interpersonal and communication skills that result in effective information exchange and teaming withpatients, patients’ families, and professional associates.

Medical KnowledgeDemonstrate knowledge of established and evolving biomedical, clinical, and cognate sciences and the application of thisknowledge to pathology.

Practice-Based Learning and ImprovementDemonstrate ability to investigate and evaluate diagnostic and laboratory practices in your own lab, appraise andassimilate scientific evidence, and improve laboratory practices and patient care.

Patient CareDemonstrate a satisfactory level of diagnostic competence and provide appropriate and effective consultation in thecontext of pathology services.

ProfessionalismDemonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity todiverse patient population.

Systems-Based PracticeDemonstrate understanding of and contribution to local, regional, and national health care systems, and support healthcare in systems-based practice definition.

This activity fulfills the SAM credit requirements for MOC and is therefore eligible for SAM credit. Participants whosuccessfully complete an online assessment may apply their earned credit(s) to the ABP’s SAM requirements.

Note to CME/CE participants:��P��5$:��5�+��+��#��F��+��+��G��H��H��O��D��#��A��!��H��H��+��D

=��A��#��I��!��+�#��+��D

=��A@��#��6�KMI��!��+�#��+��+��5!��+��>��#��+��D��A@��+��+��+��D

*Enduring programs are those courses that endure over time such as print or online courses.

��#�$�� #� �

�' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

��

�� 7��

��OOOO

��7��

=��

Autopsy Pathology AUCD/AUCD1 12 NA CD-ROM 235

Clinical Pathology ImprovementProgram*

CPIP/CPIP1 15 NA Online 15

Online Digital Slide Programin Dermatopathology*

DPATH/DPATH1 14 NA Online (DigitalScope) 227

Online Digital Slide Programin Fine-Needle Aspiration*

FNA/FNA1 10 10 Online (DigitalScope) 243

Fine-Needle AspirationGlass Slide

FNAG/FNAG1 10 10 Glass Slides 244

Gynecologic Cytopathology –Fields of View

FOVK/FOVK1,FOVM/FOVM1

NA 10 Online 240

Forensic Pathology FR/FR1 12 12 CD-ROM 247

NongynecologicCytopathology Education**

NGC/NGC1 25 25Glass Slides

With Online Cases242

Neuropathology Program NP/NP1 10 NA CD-ROM 235

Glass Slide Cytopathology PAPPT Program (with Glass SlidePAP Education)***

PAPCPT/APAPCPTPAPJPT/APAPJPTPAPKPT/APAPKPTPAPLPT/APAPLPT

PAPMPT/APAPMPT

13 13Glass Slides

With Online Cases237

Glass Slide Cytopathology PAPPT Program (with Online PAPEducation)

PTGDK/APTGDKPTGDL/APTGDL

PTGDM/APTGDM13 13

Glass Slides WithOnline Cases

236

Gynecologic CytopathologyPAP Education Program***

PAPCE/APAPCEPAPJE/APAPJEPAPKE/APAPKEPAPLE/APAPLE

PAPME/APAPMESeries 1 or 2

13 13Glass Slides With

Online Cases239

Online PAP EducationPEDK/APEDK,PEDL/APEDL,

PEDM/APEDM13 13 Online (DigitalScope) 238

Performance ImprovementProgram in Surgical Pathology

PIP/PIP1 40 NA Glass Slides 224

Online PerformanceImprovement Program inSurgical Pathology

PIPW/PIPW1 40 NA Online (DigitalScope) 225

Practicum in Cancer SurgicalPathology*

PCSP/PCSP1 5 NA Online (DigitalScope) 228

��#�$�� #� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �)

��

��

��

��

��

��

�

$

��

�� 7��

��OOOO

��7��

=��

Nongynecologic CytopathologyIntraoperative Touch Imprint/Crush Preparation Program*

TICP/TICP1 10 10 Online (DigitalScope) 241

Online Virtual Biopsy Program* VBP/VBP1 23 NA Online (DigitalScope) 226

*Also available for purchase online at cap.org/learning.**NGC provides up to 20 CME/CE credits for the glass slides and 5 CME/CE credits for the online slide portion of the program.*** PAP provides up to 8 CME/CE credits for glass slides and 5 CME/CE credits for the online slide portion of the program.**** SAM credits are included in CME totals for the appropriate programs.

��+��#��F��GThe Clinical Pathology Improvement Program (CPIP) delivers 12 online clinical laboratory cases to study—one per month—and anopportunity to earn up to 15 CME/SAM credits annually. Assess and improve clinical pathology skills and fulfill Maintenance ofCertification (MOC) requirements.

CPIP cases feature real-life case scenarios, including images and clinical background. Participants work through sequentially-revealed information and a series of prompts to arrive at a resolution—just as in the laboratory.

Cases include immediate feedback after each knowledge check and a multiple-choice post-test. Participants who earn passingscores on post-tests may apply their earned credits to the ABP’s MOC SAM requirements.

�� +��#��A��

�� AM��

��A��

Online cases in clinical pathology ❚ 12

��Pathologists and residents can use CPIP online to assess and improve their skills inclinical pathology.

including laboratory administration and operations, transfusion medicine,chemistry, coagulation, hematology, immunology, microbiology, and moleculargenetic pathology.

slide images.

To purchase both CPIP and CPIP1, please call 800-323-4040 or 847-832-7000option 1.

��

case per month

pathologist (within the same institution) reportingoption with CME/SAM credit;must order in conjunction with CPIP

CME/SAM credits (AMA PRACategory 1 Credits™) per year

ABP MOC Part IV PracticePerformance Assessmentrequirements

��#�$�� #� �

�, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

System RequirementsMany of our education programs utilize online whole slide images that simulate the use of a microscope. This allows you to scanand use multiple magnifications to view the image.

To best view these programs, we recommend the following.

trusted websites.

computer’s power, and browser. The use of a Macintosh is not recommended regardless of the browser version.

"��N��+��Q

|�� #� �� #�� #� �� #�� $�� #� �� #��

� <�� :�� (��#��O

� �� }��!��

� \�� ^�� ^��]��

�� !��"�!��#$��%�� $

��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �-

��

��

��

��

��

��

�

$��@��J��Online Competency Assessment Program helps you meet CAP Laboratory Accreditation Program requirements andCLIA-mandated competency assessment regulations. Also available for 2014 are Safety & Compliance courses specific to theclinical laboratory.

��I

@��J��+�K��The package includes all seven courses, which are appropriate for annual laboratory compliance training and for clinicallaboratory science students prior to clinical rotations. Access Safety & Compliance courses throughout the subscription period;the CAP updates these courses when necessary to reflect changes in regulations or best practices.

Note: You must purchase the Safety & Compliance course package in conjunction with the Competency Assessment Programsubscription; it is not available for purchase separately.

The Safety & Compliance courses listed above do not offer CE credit.

Please see next pages for all course descriptions. For more information, visit cap.org/competency.

��

��#�

�8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

�� @�+��"�� P��$:�'�� P��$:�'��

Blood Banking/Transfusion Medicine Direct antiglobulin test ABO typing discrepancies

Chemistry Clinical toxicology Electrolytes, acid, base, and anion gap

Hematology and Coagulation Erythrocyte morphology White blood cell inclusions

Histology Immunohistochemistry part 2 Histology specimen handling

ImmunologyMonitoring the testing process in

immunologyHuman chorionic gonadotropin and

fetal fibronectin

Microbiology Genital cultures Microbiology of wounds

Phlebotomy/Specimen Processing Phlebotomy professionalism and ethics Routine venipuncture performance

Point-of-Care Testing Provider performed testing Point-of-care urine reagent strip testing

Quality Programs/Management Document control New instrument method validation

Safety Hazardous chemicals Laboratory waste and spill management

Urinalysis/Body Fluids Microscopic urinalysis part 2 Serous and synovial fluids

��@�+��"�� P��$:�'�� P��$:�'��

Blood Banking/Transfusion MedicineHemolytic disease of the fetus and

newborn and perinatal testingQuality control in the

blood bank laboratory

Chemistry Cardiac biomarkers Therapeutic drug monitoring

Hematology and Coagulation Erythrocyte inclusions White blood cells

Histology Ensuring quality in the histology laboratory Immunohistochemistry part 1

Immunology Hepatitis testing Serology kit tests

MicrobiologyMonitoring the testing process: quality

control (QC) and quality assurance (QA)in the microbiology laboratory

Microbiology of the gastrointestinal tract

Phlebotomy/Specimen Processing Common pitfalls in specimen processing General specimen handling andtransportation requirements

Point-of-Care Testing Point-of-care whole blood glucose testing Point-of-care blood gases

Quality Programs/ManagementLaboratory management—investigating

occurrencesDevelopment and implementation of a

quality management program

Safety Bloodborne pathogens General laboratory safety

Urinalysis/Body Fluids Physical and chemical urinalysis Microscopic urinalysis part 1

��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �9

��

��

��

��

��

��

�

$

@��J��6@<�3��+�� Addresses the OSHA Bloodborne Pathogens standard as it applies to clinical and medicallaboratories. Covers major bloodborne pathogens, including hepatitis B and HIV. Focuses on proper handling of sharps, personalprotective equipment (PPE), engineering controls such as microbiological safety cabinets, and proper work practices like hand-washing.

6@<��+��<�� Describes the OSHA Chemical Hygiene Standard and helps satisfy OSHA requirements for annualtraining. Explains Haz-Com, the National Fire Protection Agency diamond, the Material Safety Data Sheet, and common-senselaboratory safety rules applied to clinical laboratory practice.

6@<��@�� Addresses electrical safety and electrical hazards commonly found in the clinical laboratory. Coversprevention and safety measures, fighting electrical fires, and treatment of electrical injuries.

6@<�=��@�� Teaches the basics of fire safety in the clinical laboratory, including classes of fire and key acronyms such asPASS and RACE. Addresses fire prevention, drills, and firefighting techniques.

6@<�=��+�� Covers essentials for any laboratory that uses formaldehyde or formalin. Shares facts aboutformaldehyde, safety risks, proper handling procedure, monitoring, spill clean-up, and personal protective equipment.

��!�� Provides background information about spread of TB, PPD testing procedures, CDC guidelines, andmethods of control.

��@�� Includes potential causes of medical errors in the clinical laboratory, important legislationand definitions, and steps laboratory professionals can take to reduce the impact of medical errors in their workplace. Servesas an ideal part of an effective medical error reduction program and is appropriate for both experienced and newer laboratorypersonnel.Note: The Safety & Compliance courses are not available for purchase separately. The courses listed above do not offer CE credit.

$: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

��

$

/4��9��$��

K��H�� +��H��!��+ ��7�� D

��Ed) courses support you in implementing quality tools that will improve

your processes and eliminate waste.Ed courses help you build a quality system—one piece at a time—that enhances your continuous improvement and

Lean efforts.Ed courses are delivered online via a highly interactive user interface that allows you to learn at your own pace.

Ed courses are licensed for one year, allow sharing of logins, and include continuing education (CE) credit.

��#�&��!��+��I

��+��)�89B��>�+��+Order ISOEDWTDesigned for lab quality managers (along with your medical and administration decision makers) considering implementation of

SM

in the quality management system.

2 CE credits available

&�@��Order ISOEDRM

Designed for lab quality managers, plus your implementation team members.


��Order ISOEDRCLearn real-world methodology to conduct a general root cause analysis, along with the tools necessary to implement it. Learn from

participant case study. The course is designed for laboratory quality managers and implementation team members.


&��R6��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $�

��

��

��

��

��

��

�

$

/4��9��$��

��Order ISOEDIAIncrease your capabilities for internal auditing with a proven methodology for process audits, tracer audits, and laser audits. Learnfrom CAP 15189 assessors how to prepare for interviews, communicate findings to your internal quality management team, anduse audits to drive process improvements.


"��Order ISOEDDCThis “how-to” course on document control systems details how to control documents in a way that meets ISO 15189 requirements,how to accomplish document control even with minimal resources (such as spreadsheets), and how document control contributes tocost containment. All this from CAP 15189 assessors who give examples and commentary on common pitfalls and issues.


&��"�#��Order ISOEDQMThis course provides guidance on how to go beyond a quality plan to develop a manual that organizes and communicates yourlaboratory’s quality management system. You will see an example of an effectively structured and written manual so you canorganize and create your own. Plus, CAP 15189 assessors show you approaches to link your quality policy to quality objectivesand metrics.


��#��!Order ISOEDMRThis course interprets the ISO 15189 requirements for management review. The CAP 15189 assessors discuss how to structure thereview meeting, communicate results of quality assessments, and prompt strategic decisions from management—all in the contextof the overall health of your organization.


Make sure your laboratory team is ready to meet the challenges ahead. Sign up now for this comprehensive set of learning tools.

For more information, visit cap.org/QMEd or call 800-323-4040 or 847-832-7000 option 1.

B+��!��+T��

O ��N�� #��K�=��

J�~��

��

&��

��

��

��

��

��

��

%

/� ��4 � #�� 6��Q-PROBES™.....................................................................................................................................27Q-TRACKS®.....................................................................................................................................32

Clinical Pathology Monitors ...........................................................................................................33Anatomic Pathology Monitors ........................................................................................................38

Q-MONITORS™ ...............................................................................................................................40LMIP® .............................................................................................................................................42CAP LINKS™....................................................................................................................................44

@�] ��#� � New

Technical Staffing Ratios (QP141)......................................................................................................28Validating Laboratory Results in Electronic Health Records (QP142).......................................................29Physician Satisfaction with Clinical Laboratory Services (QP143) ..........................................................30Use and Effectiveness of Delta Checks (QP144) ..................................................................................31Mislabeled Cases, Specimens, Blocks, and Slides in Surgical Pathology (QT19) .....................................39

V�� #� �Reasons for Test Cancellation (QP131)Point-of-Care Glucose Critical Values (QP132)Microbiology Testing for Hospital Infection Control (QP133)Molecular Testing in Anatomic Pathology (QP134)

% _ /� ��4 � #��6��

`6��#��#� ��

�� # ��

��

��

��D��>+��+5�"5=�� /� ��

$' ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

/� ��4 � #��6��

&�� The CAP’s comprehensive collection of Quality Management Tools (QMT) strengthens yourknowledge of key laboratory processes, identifies quality improvement opportunities, andprovides the information you need for effective laboratory management.

&(��63�@™ In-Depth Quality Assessment Program

� &(��U@® Continuous Quality Monitoring Program

� &(�6��6�@™ Customized Quality Monitors Program

K��® Laboratory Management Index Program

��K��U@™ The Laboratory Integrated Knowledge Source

The CAP’s Quality Management Tools help you:

�� quality improvement opportunities and monitor progress over time

��+ realistic goals for your laboratory using a set of customizedexternal benchmarks

"�� the ability to meet accreditation requirements

Integrate QMT into your daily activities to support your quality improvement initiatives!

Q-PROBES, Q-TRACKS, and Q-MONITORS activities meet the American Board of Pathology MOC Part IV PracticePerformance Assessment requirements.

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $)

&��

��

��

��

��

��

��

%

/� ��4 � #��6��

&(��63�@5&(��U@5��&(�6��6�@�� {� �� #��#� ��

��/��<9=$��/�6<��>�� /�49@J69<��{� ��

��

��

��

��

��

��

��

��

��

��

��

��+

��

��

��

��

��

�+�

��

�

��

��

��

��

�

��

��@

��

��

��

��

��

��

��

��

��

��

�

��

�

�+�

��

��A

<�

��

��

��

��

��

��@

��

��

��

&(��63�@

Technical Staffing Ratios (QP141) ❚ ❚ ❚ ❚ ❚

Validating Laboratory Results in Electronic Health Records(QP142)

❚ ❚ ❚ ❚ ❚ ❚ ❚

Physician Satisfaction with Clinical Laboratory Services(QP143)

❚ ❚ ❚ ❚ ❚ ❚ ❚ ❚ ❚

Use and Effectiveness of Delta Checks (QP144) ❚ ❚ ❚ ❚

&(��U@

Patient Identification Accuracy (QT1) ❚ ❚ ❚ ❚

Blood Culture Contamination (QT2) ❚ ❚ ❚ ❚

Laboratory Specimen Acceptability (QT3) ❚ ❚ ❚

In-Date Blood Product Wastage (QT4) ❚ ❚ ❚

Gynecologic Cytology Outcomes:Biopsy Correlation Performance (QT5)

❚ ❚ ❚ ❚ ❚

Satisfaction With Outpatient Specimen Collection (QT7) ❚ ❚ ❚

Stat Test Turnaround Time Outliers (QT8) ❚ ❚ ❚ ❚ ❚

Critical Values Reporting (QT10) ❚ ❚ ❚ ❚

Turnaround Time of Troponin (QT15) ❚ ❚ ❚ ❚ ❚ ❚

Corrected Results (QT16) ❚ ❚ ❚ ❚ ❚ ❚ ❚

Outpatient Order Entry Errors (QT17) ❚ ❚ ❚

Mislabeled Cases, Specimens, Blocks, and Slides inSurgical Pathology (QT19)

❚ ❚ ❚

*The CAP requires accredited laboratories to have a quality management plan that covers all areas of the laboratory and includesbenchmarking key measures of laboratory performance (GEN.13806, .20316). The Joint Commission requires accredited hospitals toregularly collect and analyze performance data (PI.01.01.01, PI.02.01.01). CLIA requires laboratories to monitor, assess, and correctproblems identified in preanalytic, analytic, and postanalytic systems (§493.1249, §493.1289, §493.1299).

$, ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

/� ��4 � #��6��

��/��<9=$��/�6<��>�� /�49@J69<��{� ��

��

��

��

��

��

��

��

��

��

��

��

��+

��

��

��

��

��

�+�

��

�

��

��

��

��

�

��

��@

��

��

��

��

��

��

��

��

��

��

�

��

�

�+�

��

��A

<�

��

��

��

��

��

��@

��

��

��

&(�6��6�@

Monitoring of Troponin Metrics for Chest Pain Centers(QM1)

❚ ❚ ❚ ❚ ❚ ❚ ❚ ❚

*The CAP requires accredited laboratories to have a quality management plan that covers all areas of the laboratory and includesbenchmarking key measures of laboratory performance (GEN.13806, .20316). The Joint Commission requires accredited hospitals toregularly collect and analyze performance data (PI.01.01.01, PI.02.01.01). CLIA requires laboratories to monitor, assess, and correctproblems identified in preanalytic, analytic, and postanalytic systems (§493.1249, §493.1289, §493.1299).

B�N��+��Q

9��#�� ^�� 4�� #��\�� +�� 4��N�%� �4��6��6��#�� #� �� #��#�

� �� #��#��

� X� ��#��

� V��#�� {��

� J�� #��'(�)��4��

J��]�� 8::(%$%(':':�� 8'-(8%$(-:::�� V��D��

/��<9=$�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $-

&��

��

��

��

��

��

��

%

&(��63�@

��#� ��J��

�#��H��#��XWith today’s focus on reducingmedical errors, laboratories strive to achieve and maintain excellence. Using short-term studies,Q-PROBES provides a one-time comprehensive assessment of key processes in your laboratory.

@��XUse Q-PROBES to help build andimprove data collection and analysis processes that contribute to quality of care, patient safety,and outcomes.

��+��+��>��XImplementQ-PROBES, an external peer-comparison program, to address process-, outcome-, andstructure-oriented quality assurance issues. Establish benchmarks through external databasecomparisons and compare your performance to that of other organizations to establishlaboratory goals and improve performance.

Q-PROBES activities meet the American Board of Pathology MOC Part IV Practice PerformanceAssessment requirements.

�7��+��#��>��!��+ &(��63�@D

/��<9=$�

$8 ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

��+��@�� &��'�Staff accounts for two-thirds of direct clinical laboratory costs and management of staffing levels is central to managing overalllaboratory expenses. In this study, key staffing ratios are calculated for four different laboratory testing sections: anatomicpathology, chemistry/hematology/immunology, microbiology, and transfusion medicine. Your laboratory’s results will bebenchmarked against staffing levels from all participating institutions.

6�Y��#��Measure staffing in different areas of the laboratory, calculate key staffing ratios, and compare key staffing ratios with otherinstitutions.

"��Participants will use their laboratory or institution’s revenue and usage reports to obtain billable test counts and staffing figuresfor the mos t recently completed fiscal year for four key laboratory testing sections.

��

��+��Io Histology blocks/histology nonmanagement FTEo Cytology accessions/cytology nonmanagement FTEo Nonmanagement FTE/management FTE�+��A<��A��Io Total billable tests/nonmanagement FTEo Nonmanagement FTE/management FTE

��Io Total billable tests/nonmanagement FTEo Nonmanagement FTE/management FTE

��Io Crossmatches and/or type and screens/nonmanagement FTEo Transfused units/nonmanagement FTEo Nonmanagement FTE/management FTE

New

This is a one-time study conducted in the first quarter.

/��<9=$�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $9

&��

��

��

��

��

��

��

%

;��K�� <��+��&��'$Laboratories must ensure the accuracy, completeness, and ease of use of information that is transmitted from the laboratoryinformation system (LIS) to the patient’s electronic health record (EHR). This has become more important as health care providersincreasingly request laboratory tests using computerized order entry and review many test results within the EHR.

This Q-PROBES study will focus on the electronic reporting of laboratory results within the EHR. Historically, laboratories metregulatory requirements for verifying test result accuracy and completeness by reviewing test results within the LIS. Participationin this Q-PROBES study will take this one step further by verifying the integrity of laboratory results within the EHR. This study canhelp document that your laboratory meets information technology requirements set forth in the CAP’s Laboratory AccreditationProgram Laboratory General Checklist and the Code of Federal Regulations.

6�Y��#��Document the accuracy, completeness, and ease of use of laboratory test result information that is transmitted to the EHR.

"��Participants will retrospectively review multiple results from approximately 10-15 laboratory tests by directly viewing theresults within the EHR. Results from a variety of tests performed locally or at a reference laboratory (eg, INR, eGFR, HgA1c,quantitative HIV) that are within and outside the test reference range are included. Inpatient and outpatient testing are alsoincluded. Anatomic pathology reports (eg, biopsies, cytology) are included if the results are reported within the EHR.

��

��Io Percent of electronic test results that are accurately transmitted to the EHRo Percent of electronic test results that contain essential reporting elements

@��Io Percent of electronic test results that are transmitted in an appropriate and useable format

New

This is a one-time study conducted in the second quarter.

/��<9=$�

%: ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

�+��@��!��+ �� K��@��#��&��'%Accessing physician satisfaction with laboratory services provides valuable information for targeting quality improvementactivities. The CAP’s Laboratory Accreditation Program requires that institutions measure patients’ satisfaction with laboratoryservices (GEN.20335). This Q-PROBES study will assist your organization in meeting this requirement while helping to identifyareas for improvement and to ensure physician satisfaction with your services.

6�Y��#��Assess physician satisfaction with laboratory services and correlate this with the laboratory workload, performanceimprovement activities, and customer support services.

"��Clinicians will be asked to complete a standardized questionnaire regarding their perceptions across various laboratoryservice categories, including turnaround time, critical value notification, diagnostic accuracy, communication, accessibility,responsiveness, and courtesy. Data from the first 50 returned questionnaires will be submitted for analysis.

��

��Io Overall mean satisfaction score

@��Io Mean satisfaction score for laboratory service categories

New

This is a one-time study conducted in the third quarter.

/��<9=$�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # %�

&��

��

��

��

��

��

��

%

Z��#�� "��+��>�&��''Delta checks are routinely performed by laboratory information systems to automatically compare two successive test results onthe same patient to determine if the difference is outside the expected physiological range, which may indicate an analyticalerror or specimen mix-up. Delta checks are widely deployed during manual or autoverification as a check on reliability of testresults before release to the medical record. While delta checks have been in use for more than 30 years, selection of tests andcut-offs are highly variable among laboratories. As analytical test systems have improved and rates of specimen misidentificationdecline, delta checks have become less effective due to a high fraction of false alerts that increase the amount of effort requiredto identify infrequent errors. This study is designed to provide comparative benchmarking information to help assess use of deltachecks in laboratory practice.

6�Y��#��Evaluate laboratory practices relating to the use of delta checks including analytes and cut-offs used, actions taken, andoutcomes observed.

"��Information about consecutive delta checks will be evaluated for 60 days or until 100 records are identified. The analyte,amount of change, action taken and outcome will be reported. Participants will also complete a questionnaire about their deltacheck procedures.

��

New

This is a one-time study conducted in the fourth quarter.

/�6<��>�

%$ ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

&(��U@

��#� ��/� ��4��#Observe performance trends over time to identify and monitor opportunities for quality improvement through quantitativequality measures. Q-TRACKS offers continuous quality monitoring with longitudinal tracking of performance and keyindicators for clinical and anatomic pathology.

Step 1:Establish realistic benchmarks by comparing yourlaboratory to others like yours.

Step 2:Identify improvement opportunities.

Step 3:Monitor improvement over time toensure accurate results, patient safety,and quality patient care.

��

��

��

!"��

(most like you)

Q-TRACKS activities meet the American Board of Pathology MOC Part IV Practice PerformanceAssessment requirements.

/�6<��>�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # %%

&��

��

��

��

��

��

��

%��&��

In order to report accurate laboratory results and meet The Joint Commission National Patient Safety Goal #1: “Improve theaccuracy of patient identification,” institutions must properly identify patients. Since most laboratories perform testing awayfrom the patient, patient identification, and labeling of specimens and coordination with test requisitions must be performedaccurately and completely. By continuously monitoring for wristband errors, participants can promptly identify and correctproblems that may interfere with patient care services.

6�Y��#��Assess the incidence of wristband errors within individual institutions, compare performance between participating institutions,and identify improvement opportunities.

"��On six predetermined days per month, participants will monitor patient wristband identification for all phlebotomies performedat their institution. Phlebotomists will tally the total number of wristbands checked, the number of errors found, and the typesof wristband error. This monitor includes all routinely wristbanded patients. Include emergency department patients only if theemergency department routinely applies wristbands to these patients.

�� 3��>�!�

3�� &�$Despite advances in blood culture practices and technology, false-positive blood culture results due to contaminants continue tobe a critical problem. Blood culture contamination rate, the primary indicator of preanalytic performance in microbiology, isassociated with increased length of hospital stay, additional expense, and the administration of unnecessary antibiotics. TheCAP and other accrediting organizations require you to monitor and evaluate key indicators of quality for improvementopportunities. Use this monitor to help meet this requirement.

6�Y��#�Determine the rate of blood culture contamination using standardized criteria for classifying contaminants.

"��On a monthly basis, participants will tabulate the total number of blood cultures processed and the total number of contaminatedblood cultures. Blood cultures from neonatal patients are tabulated separately. For the purposes of this study, participants willconsider a blood culture to be contaminated if they find one or more of the following organisms in only one of a series of bloodculture specimens: Coagulase-negative Staphylococcus; Micrococcus; Alpha-hemolytic (viridans) Streptococci; Propionibacteriumacnes; Corynebacterium sp. (diptheroids); or Bacillus sp. Participants have the option to monitor institution-specific subgroups.

��

&(��U@ �� +��

Look for your input forms approximately three weeks prior to the quarter.

/�6<��>�

%' ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

K��@�� &�%A substantial amount of rework, diagnostic and therapeutic delay, and patient inconvenience can result from specimenrejection. Patient redraws may result from unlabeled, mislabeled, and incompletely labeled specimens; clotted and/orhemolyzed specimens; or insufficient specimen quantity. By continuously monitoring specimen acceptability, collection, andtransport, laboratories can promptly identify and correct problems.

6�Y��#�Identify and characterize unacceptable blood specimens that are submitted to the chemistry and hematology sections ofthe clinical laboratory for testing.

"��This monitor includes all blood specimens submitted for testing to the chemistry and hematology departments of the clinicallaboratory. On a weekly basis, participants will record the total number of specimens received, the number of rejectedspecimens, and the primary reason each specimen was rejected.

�� 3��>�!�

��("��3��B��&�'Blood for transfusion is a precious resource. At a minimum, wastage of blood that is not out-of-date represents a financial lossto the health care system. More ominously, systemic wastage of blood may reflect an environment of care that is out of controland could pose risks to patient safety.

6�Y��#�Compare the rates of blood product wastage (ie, units discarded in-date) in participating hospitals and track rates ofimprovement over time.

"��On a monthly basis, participants will use blood bank records to obtain information on the total number of units transfusedfor each type of blood component. Participants will track the number and type of blood units that are wasted in-date and thecircumstances of wastage. Include the following types of blood components: red blood cells (allogeneic), frozen plasma,platelet concentrates, single donor platelets, and cryoprecipitate.

�� 3��>�!�


/�6<��>�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # %)

&��

��

��

��

��

��

��

%

@�� B��+ 6�� @�� &�-Specimen collection is one of the few areas of laboratory medicine that involves direct outpatient contact. As a result, patientsatisfaction with this service is a vital indicator of quality laboratory performance. The CAP’s Laboratory AccreditationProgram requires measurement of patient satisfaction with laboratory services (GEN.20335). Use this monitor to help meet thisrequirement.

6�Y��#�Assess patient satisfaction with outpatient phlebotomy services by measuring patients’ assessment of waiting time, discomfortlevel, courteous treatment, and overall satisfaction.

"��On a monthly basis, participants will distribute copies of a questionnaire to a minimum of 25 outpatients (maximum of 99outpatients), using predetermined data collection criteria. This monitor includes any outpatient undergoing venipuncture. Thismonitor excludes patients seen in the emergency department, ambulatory surgery area, urgent care facility, chest pain center,23-hour short-stay facility, employee health department, outpatient health screening fair/promotion, dialysis center, nursinghome, or extended care facility.

��

@�� 6�� &�8The stat test turnaround time (TAT) outlier rate, expressed as a percentage of tests missing target reporting times, is a measureof outcomes that evaluates how well the laboratory meets patient and clinician needs. This monitor helps meet CAP Checklistrequirement GEN.20316, “The QM program includes monitoring key indicators of quality in the preanalytic, analytic, andpostanalytic phases.”

6�Y��#�Monitor the frequency with which stat test TAT intervals exceed institutional stat test TAT expectations.

"��Before beginning data collection, participants will establish a specimen receipt-to-report deadline for emergency department(ED) stat potassium tests. On six predetermined days per month, participants will monitor the TAT of up to 10 randomlyselected ED stat potassium tests on each of three, eight-hour shifts (up to 180 tests per month) and track the number of ED statpotassium results reported later than the established reporting deadline. This monitor includes stat potassium testsordered as part of a panel and excludes stat potassium levels that are requested on body fluids other than blood, as part oftimed or protocol studies, or after the specimen arrives in the laboratory.

�� 3��>�!��


/�6<��>�

%, ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

�� ;��&��:Laboratories commonly refer to critical values as results requiring immediate notification to the physician or caregiver fornecessary patient evaluation or treatment. Regulations from agencies and accreditors such as the CMS, The JointCommission, and the CAP (GEN.20316, COM.30000) mandate that laboratories develop and implement an alert systemfor critical values. Use this monitor to document compliance with your laboratory’s alert plan.

6�Y��#�Evaluate the documentation of successful critical values reporting in the general laboratory for inpatients (including dischargedinpatients) and outpatients.

"��On a monthly basis, participants will evaluate 120 inpatient and 120 outpatient critical values. Data collection will includegeneral chemistry, hematology, and coagulation analytes on the critical values list. Retrospectively, participants will record thetotal number of critical values monitored and the number with documentation of successful notification. This monitor willexclude critical values for cardiac markers, drugs of abuse, therapeutic drug levels, urinalysis, blood gases,point-of-care tests, and tests performed at reference laboratories.

��

�� &��)The swiftness with which physicians establish diagnoses of acute myocardial infarction (AMI) in patients presenting to theemergency department (ED) with chest pain may determine the type and predict the outcome of therapy those patients willreceive. Included in the total time consumed in establishing diagnoses of AMI are the component intervals required to measurebiochemical markers of myocardial injury. One of the most critical biochemical markers is troponin. Use this monitor to helpmeet CAP Checklist requirement GEN.20316 QM Indicators of Quality.

6�Y��#�Determine the median order-to-report turnaround time (TAT) of troponin (I or T) and the percent of troponin results reported byeach institution’s established deadline.

"��On six predetermined days per month, participants will record TATs (in minutes) for three randomly selected troponin specimensobtained from ED patients on each of three traditional shifts for a total of nine measurements. Participants will measure TATsfrom the time of test order to the time results are available to ED personnel.

��


/�6<��>�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # %-

&��

��

��

��

��

��

��

%

�� &��,The CAP developed this Q-TRACKS monitor in recognition of the importance of timely detection and correction of erroneouslaboratory results. Accuracy in laboratory results is critical to the effectiveness of a physician’s plan of care for a patient. Anerroneous result can delay or alter patient treatment; therefore, detection of erroneous results should be a priority in everylaboratory and should be monitored as a key quality indicator. Help measure your compliance with CLIA 493.1299,Postanalytic Systems Quality Assessment, with this monitor.

6�Y��#�Monitor the number of corrected test results within individual institutions and compare performance with that of all institutionsand those institutions similar to yours.

"��On a monthly basis, participants will monitor the number of corrected test results and the total number of billable tests for thatmonth. Include test results for all patients in all care settings with the following exclusions: anatomic pathology tests, narrativephysician-interpreted tests (eg, bone marrow biopsies and peripheral smear reports), and point-of-care tests.

��

6�� 6�� &��-Order accuracy bears an obvious relationship to the quality of laboratory testing. When the laboratory fails to complete arequested test, it delays the diagnostic evaluation, potentially extending a patient’s hospital stay and prolonging therapy. When the laboratory completes a test that was not requested, the cost of care increases, patients may be subjected tounnecessary phlebotomy, and laboratory efficiency declines.

6�Y��#�Measure the incidence of incorrectly interpreted and entered outpatient physician test orders into the laboratory informationsystem, compare performance across institutions, and track performance over time.

"��On six preselected weekdays per month, participants will compare eight outpatient requisitions or order sheets to the ordersentered into the laboratory’s information system to determine if any order entry errors occurred. Order entry error categoriesinclude requesting physician errors; incorrect, missing, and extra test errors; test priority errors; and nonroutine routing requesterrors. This monitor excludes tests performed in transfusion medicine or anatomic pathology. This monitor also excludes testsfrom the following patient care settings: inpatient, emergency department, ambulatory surgery, urgent care, chest pain center,23-hour short-stay facility, employee health department, outpatient screening fair/promotion, and dialysis center.

�� 3��>�!�


/�6<��>�

%8 ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%*��6��I3�� &�)

The correlation of cervicovaginal cytology (Pap test) findings with cervical biopsy results is a significant part of thecytopathology laboratory’s quality assurance program. By monitoring this correlation, the laboratory can identify potentialproblems requiring improvement, thereby ensuring better patient results.

6�Y��#�Quantify the correlation between the findings of cervicovaginal cytology and corresponding histologic material.

"��On a monthly basis, participants will record information on true-positive, false-positive, and false-negative cytology-biopsycorrelations. The false-negative correlations will be classified into four error categories: screening errors, interpretive errors,screening and interpretive errors, and adequacy determination errors. Participants will also record the biopsy diagnoses forPap tests with an interpretation of atypical squamous cells (ASC-US and ASC-H) or atypical glandular cells (AGC). This monitorincludes patients for whom a cervical biopsy specimen is submitted to the laboratory and for whom a satisfactory or satisfactorybut limited Pap test has been submitted within three months previous to the biopsy or at the time of the biopsy.

��

&(��U@ �� +��


/�6<��>�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # %9

&��

��

��

��

��

��

��

%

��5 @��53��>�5��@��@��+��&��9

Mislabeling of surgical pathology specimens has potential catastrophic consequences for patient care. By continuouslymonitoring the rate of mislabeled specimens, participants will be able to identify problems and variables associated withmislabeled specimens, blocks, and slides. This Q-TRACKS monitor will also help participating laboratories fulfill The JointCommission National Patient Safety Goal #1: “Improve the accuracy of patient identification” in the discipline of surgicalpathology.

6�Y��#��Determine the rates of mislabeled cases, specimens, blocks, and slides and the rate at which mislabeling errors led to acorrected report and compare performance to other institutions.

"��Prospectively track each time a specimen container, block or slide is relabeled or renumbered due to an identification error;and if, as a result, a corrected report is issued. Participants will also report the number of cases processed each month and thenumber of blocks and slides (including special stains) that are processed during the same time period. Data will be collectedmonthly.

This Q-TRACKS monitor is limited to routine histology processing.

��

New


/�49@J69<�

': ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

&(�6��6�@

��#� ��

�#��H�� #��

With today’s focus on reducing medical errors, achieving and maintaining excellence is key tosuccess. Using continuous monitoring, Q-MONITORS provide a comprehensive assessment ofkey processes in your institution and allow your institution to meet accreditation and regulatoryrequirements.

@��

Use Q-MONITORS to help build and improve data collection and analysis processes thatcontribute to quality of care, patient safety, and outcomes. Observe performance trends overtime to identify and monitor opportunities for quality improvement through quantitative qualitymeasures.

��+ �� +��>��

Q-MONITORS are customized programs that address process-, outcome-, and structure-orientedquality assurance issues. Establish benchmarks through external database comparisons andcompare your performance to establish goals for performance improvement.

/�49@J69<�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # '�

&��

��

��

��

��

��

��

%

&(�6��6�@ ��[� &��

�� +�� &��Patients presenting to the emergency department (ED) with chest pain must be evaluated quickly. Rapid serum troponinmeasurement is an important part of ED practice that can provide decisive information for patient management. Reducingdelays in troponin testing has been reported to result in shorter length of stay in the ED and more rapid initiation of anti-ischemictreatment. Chest pain centers should therefore have effective procedures for ensuring optimal turnaround time (TAT) for troponinand a process for ongoing monitoring to ensure that performance meets expectations. Participants will monitor two to eightmetrics required by the Society of Cardiovascular Patient Care (SCPC) (Cycle IV: Key Element 4.4.0.0).

Institutions do not need to be accredited by the SCPC to participate in this monitor.

6�Y��#�Help meet the SCPC quality performance requirements for monitoring ED troponin TAT and meeting timeliness goals.

"��Six days per month, collect data from nine patients presenting to the ED with chest pain and tested for troponin level. Dataincludes time of patient arrival, troponin test order, specimen collection, laboratory receipt, and result availability. It is notnecessary to provide data from each turnaround time (TAT) component. Participants select which TAT metrics to monitor, withthe option to monitor all metrics.

Participants will also complete a questionnaire about clinical and laboratory practices related to troponin testing.

@��Main Laboratory Troponin Testing

at least one of the following:

and at least one of the following:

Point-of-Care Troponin Testing

��

��Participants will receive benchmarking, as compared to all institutions, for specimen collection toresult availability and patient arrival to result availability TATs.

A report will be provided on a quarterly basis for compliance with SCPC Cycle IV:Key Element 4.4.0.0; ED Baseline Troponin Turn-Around-Time Metrics.


K4J�

'$ ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

K��

K �� 4 � #��J��}��#�

��#��!��+K��XThe Laboratory Management IndexProgram (LMIP), an effective fiscal management tool, offers a valuable peer comparison of yourlaboratory’s performance. LMIP can help you with the annual budget process, contractnegotiations, and daily operations management.

With more than 15 years of experience and the largest laboratory participant database, LMIP isthe best management resource for health care professionals charged with decision-makingresponsibilities. Using management ratios as performance indicators, LMIP extends beyondtraditional analysis of productivity and staffing to focus on the most important factors affectinglaboratory performance:

��#��XHow effectively are you using your laboratory personnel?

Z��[��XHow do your test-ordering patterns compare to those of your peers?

��(��#��XHow efficiently are you using your supplies, equipment, and labor?

With LMIP’s statistically valid method of peer grouping (fingerprint clustering), you receive the mostmeaningful comparisons. These comparisons allow you, your colleagues, and your administrationto make informed and realistic decisions about staffing, budgets, and other performance targets.

Achieving quality test results involves more than just ensuring properly conducted tests.Understanding financial factors that drive laboratory processes enhances your confidence in themanagement decisions you make. Ultimately, these decisions will guide your organization todeliver superior patient care.

K4J�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # '%

&��

��

��

��

��

��

��

%

K��7��K�3LMIP provides a report of your laboratory’s overall operation. Quarterly reports summarize relevant management ratios thatprovide analysis of the productivity of personnel, laboratory policies and procedures, salary and other expenses, physician testutilization, and organizational benefits.

The input items you will collect include:

Outpatient VisitsReferred SBTsReferred SBT ExpenseTesting Labor ExpenseTesting Paid HoursTotal Labor ExpenseTotal Laboratory Paid HoursTotal Laboratory Worked HoursTotal SBTs

LMIP uses the Standardized Billable Test (SBT) as the primary unit of measure. The SBT standardizes test counts and eliminatesbilling, accounting, and interpretation variations to ensure valid comparisons.

��KJ@>�

'' ��#�� #�� !"�� #��$�� #� �

&��

��

��

��

��

��

��

��

��

%

�� K��U@

6��J��#� ��>��]��#��5��5��H��#��[��D

The CAP designed CAP LINKS for multihospital systems, academic medical centers with numeroustesting locations, and national commercial reference laboratories. CAP LINKS provides a high-leveloverview useful in identifying improvement opportunities and demonstrating good QI performance.You can access CAP LINKS data directly from the CAP laboratory improvement database.Therefore, the CAP does not require additional data submission. Use CAP LINKS for your CAPlaboratory improvement programs, including:

Surveys and Anatomic Pathology Education Programs and EXCEL®

Laboratory Accreditation Program

LMIP—Laboratory Management Index Program

The enchanced CAP LINKS provides you the ability to do the following:

Download data and manipulate reports to accommodate your specific institution’s needs

Use email to forward one or all reports to appropriate individuals for viewing

Designate viewing options to select individuals directly via the CAP website

Receive CAP LINKS reports promptly via the Web—the CAP will continue to forwardyour printed reports via regular mail

Respond to exceptions in a more timely manner

The report package allows you to quickly see good performance and identify sites that may requirespecial attention, both at the laboratory level and at the system or corporate level.

The CAP generates reports on a quarterly basis and distributes them via the Internet and by mail toan individual whom you designate as your system’s primary contact. Annually, your primarycontact will receive an overview of the system’s full-year performance for proficiency testing. Thoseindividuals with granted viewing privileges may view these secure online reports.

��KJ@>�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ')

&��

��

��

��

��

��

��

%

Accreditation reports recap inspection findings for each laboratory.

Quarterly reports summarize PTsystemwide average results bydiscipline to allow for interlaboratorycomparisons.

��

��

��

College of American Pathologists325 Waukegan Road, Northfield, Illinois 60093-2750800-323-4040 ● www.cap.org

�� !�� "�#�$%

�� &�� #�'�

��()��)��*�� +�� "#�+%

��+��#��6��]�� !��*� +��,��-��!��/��0�� {� �� 6��]�� ^�� #�� ^�� ]�� ^�� #��}��

Y�� #Z� ��]�� ]�� '��%�%�"�"��'"+�'%��+��!��

��I��X=�!��*�� #��!%

PRESS

`6�� 6�� #�� ]�� ^�� #� �� {��6��^�]�� }��{��^�� ]��

U��5�"5=��+��

��7��!��5��

��

�(��(�

��

��

��

�

'

�� #� �

@�] ��#� � New

POC Blood Gases Competency (POC10) ...........................................................................................49POC Blood Gases, i-STAT Competency (POC11).................................................................................49POC Plasma Cardiac Markers Competency (POC12) ..........................................................................49POC H. pylori Antibody Competency (POC13) ...................................................................................49POC Medtronic ACT/ACT, i-STAT Competency (POC14) .....................................................................49POC Hemochron Jr IL GEM ACT-LR Competency (POC15)....................................................................49POC Hemochron Jr Signature IL GEM PCL ACT Competency (POC16) ..................................................49

V�� #� ��Anti-HIV-1, Waived (RHIVW)

See Survey AHIVW ....................................................................................................................202

' _ �� #� �

`��]��

�� 6��#��9�6��<��

��

�� #��#�]��9�� #��

"��+�D��5�"5=�� 6��#��

�� #� �

'8 ��#�� #�� !"�� #��$�� #� �

��

�(�

�(�

��

��

��

��

'

��(��(��

POC Competency Challenges are designed to improve waived test results. These programs will evaluateinstrument and method performance, troubleshoot, assess staff competency, and provide information totrain staff. Expected results will be provided. These programs are not proficiency testing programs andparticipants will not return results to the CAP.

POC Competency Challenges may have limited availability and stability.

�6� ��+��6��5 �6�$5 �6�%5 �6�'

�� +��A@+��

�6�� 6�$ �6�% �6�'

POC hCG Competency ❚ 10

POC Glucose Competency ❚ 10

POC Urine Dipstick Competency ❚ 10

POC Strep Screen Competency ❚ 10

�6��+��6�)5 �6�,5 �6�-5 �6�85 �6�9

�� +��A@+��

�6�) �6�, �6�- �6�8 �6�9

POC PT/INR, i-STATCompetency

❚ 10

POC PT/INR, CoaguChek XS PlusCompetency

❚ 10

POC Waived Chemistry, Glucoseand HgB Competency

❚ 10

POC Influenza A/B AntigenDetect Competency

❚ 10

POC Fecal Occult BloodCompetency

❚ 10

��

liquid urine specimen

specimen

liquid specimen

material to test up to 10 staff

request

��

lyophilized plasma specimens


whole blood specimen. Foruse with the HemoCue® B,

HemoPoint®

positive for Influenza A;

Influenza B

fecal specimen

material to test up to 10 staff

request

�� #� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # '9

��

�(��(�

��

��

��

�

'

�6��+��6��:5 �6��5 �6��$5 �6��%

�� +��A@+��

�6��: �6�� 6��$ �6��%

POC Blood Gases Competency ❚ 10

POC Blood Gases, i-STATCompetency

❚ 10

POC Plasma Cardiac MarkersCompetency

❚ 10

POC H. pylori AntibodyCompetency

❚ 10

�6��+��6��'5 �6��)5 �6��,

�� +��A@+��

�6��' �6��) �6��,

POC Medtronic ACT/ACT,i-STAT Competency

❚ 5

POC Hemochron Jr IL GEMACT-LR Competency

❚ 5

POC Hemochron Jr Signature ILGEM PCL ACT Competency

❚ 5

��

abnormal 2.5-mL aqueousblood gas specimens and tenduplicate 2.5-mL hematocrit/hemoglobin specimens

abnormal 2.5-mL aqueousspecimens for blood gasand hematocrit/hemoglobintesting

abnormal 1.0-mL plasma

plasma based tests, suchas Alere Triage and i-STATinstruments

liquid specimen

request

New

��

abnormal 1.7-mL lyophilized

and one calcium chloride

Medtronic HemoTec ACT/ACT, Medtronic Hepcon HMS,i-STAT Celite ACT, i-STATKaolin ACT

abnormal 0.5-mL unitized

IL GEM PCL Plus ACT-LR andITC Hemochron Jr./SignatureACT-LR

abnormal 0.5-mL unitized

IL GEM PCL Plus ACT andITC Hemochron Jr./SignatureACT+

request

New

�� #� �

): ��#�� #�� !"�� #��$�� #� �

��

�(�

�(�

��

��

��

��

'

In many hospitals today, laboratory testing has shifted from the central main laboratoryto inpatient rooms, emergency departments, and intensive care units. We have developedthis section in response to this shift and the increased use of point-of-care instrumentsin the hospital. This section will help you select the most appropriate proficiency testingprograms for staff members who work near patient and bedside testing in the hospitalsetting. For additional information about selecting the right programs for your institution,

Use the charts to select the proficiency testing programs that meet your testing needs.

�� H��3��*��67��@��#��

Critical Care Aqueous Blood Gas

Blood Oximetry SO

�+��@��#��

B-Type Natriuretic Peptides BNP

Hemoglobin A1c

Neonatal Bilirubin

Plasma Cardiac Markers PCARM

Whole Blood Glucose

��@��#��

Activated Clotting Time

Platelet Function PF1

Drug-Specific Platelet Aggregation PIA

Thromboelastogram TEG

Whole Blood D-Dimer WBDD

Whole Blood Prothrombin Time/INR

�� #� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # )�

��

�(��(�

��

��

��

�

'

<�� @��#��

Blood Cell Counts HE, HEP, FH series

Clinical Microscopy CMP, CMMP

Erythrocyte Sedimentation Rate ESR, ESR1

Gastric Occult Blood GOCB

Occult Blood OCB

Rapid Total White Blood Cell Count RWBC

Reticulocytes

Rupture of Fetal Membranes Testing ROM1

Waived Combination HCC

��@��#��

Anti-HCV, Waived RHCVW

AHIVW

Infectious Mononucleosis, Waived IMW

��@��#��

Group A Strep Antigen Detection

��7��@��#��

Urine Drug Screen

�� #� �

)$ ��#�� #�� !"�� #��$�� #� �

��

�(�

�(�

��

��

��

��

'

We created the following charts to help you select the most appropriate CAP Surveys to meet your testing needs. These charts arenot intended to be construed as approval or disapproval of any commercial product or instrument. Please contact a

compatibility questions. Select the compatible Survey for your instrument and cartridge from the charts.

��(��(��(@��\

��@��#��

�(@�� @��#��

Blood Gas+Critical Care Aqueous

Blood Gas

Chemistry+

G

Critical Care AqueousBlood Gas

Crea

Coagulation

Celite ACTActivated Clotting Time

Kaolin ACT

PT/INR Whole Blood Coagulation

Cardiac Markers

CKMB

Plasma Cardiac Markers

PCARM, PCARMX

BNP PCARM, PCARMX

cTnl PCARM, PCARMX

3��\5��D��@��#��

3�� @��#��

Triage® Cardiac Panel Plasma Cardiac Markers PCARM, PCARMX

Triage BNPB-Type Natriuretic Peptides,Plasma Cardiac Markers

BNP, PCARM, PCARMX

Triage CardioProfilER® BNP, PCARM, PCARMX

Triage Profiler Shortness of Breath BNP, PCARM, PCARMX

Triage TOX Drug ScreenUrine Drug Screen

Triage Drugs of Abuse Panel

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

O�� 6�� V��# 4��#General Chemistry and Therapeutic Drug Monitoring...........................................................................54Urine Chemistry ...............................................................................................................................63Special Chemistry ............................................................................................................................66

@�] ��#� � New

Accuracy-Based Thyroid (ABTH).........................................................................................................58

) O�� 6�� V��#�4��#

`6�� #� ��

!N�� #��]�� ]��

�� ]��#��!��

��#��K ��

�� #�� ]��

��#� �� 9��

�!�� |��

��

�� #��

��#�� ^��#��

��#��

*��KD<��!��[5�"5=�� <��

O�� 6�� V��#�4��#

)' ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

*��+�� +��"��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

*��+�� +��"��5 �%A�%]5�^A�^]A�^$A�^$]5 ^

�� +��A@+��

�� %A�%]�^A�^]A

�^$A�^$] ^

Alanine aminotransferase(ALT/SGPT) ❚ ❚ ❚ 5

Albumin ❚ ❚ ❚ 5

Alkaline phosphatase ❚ ❚ ❚ 5

Amylase ❚ ❚ ❚ 5

Aspartate aminotransferase(AST/SGOT) ❚ ❚ ❚ 5

Bilirubin, direct ❚ ❚ ❚ 5

Bilirubin, total ❚ ❚ ❚ 5

Calcium ❚ ❚ ❚ 5

Chloride ❚ ❚ ❚ 5

Cholesterol ❚ ❚ ❚ 5

Cortisol ❚ ❚ ❚ 5

Creatine kinase (CK) ❚ ❚ ❚ 5

Creatinine ❚ ❚ ❚ 5

Glucose ❚ ❚ ❚ 5

HDL cholesterol ❚ ❚ ❚ 5

Human chorionic gonadotropin(hCG), quantitative ❚ ❚ ❚ 5

Iron ❚ ❚ ❚ 5

Lactate dehydrogenase (LD) ❚ ❚ ❚ 5

LDL cholesterol ❚ ❚ ❚ 5

Lipoprotein (a) ❚ ❚ ❚ 5

Magnesium ❚ ❚ ❚ 5

Pancreatic amylase ❚ ❚ ❚ 5

Potassium ❚ ❚ ❚ 5

Protein, total ❚ ❚ ❚ 5

Sodium ❚ ❚ ❚ 5

T3, free (triiodothyronine, free) ❚ ❚ ❚ 5

T3, total (triiodothyronine, total) ❚ ❚ ❚ 5

T3, uptake and related tests ❚ ❚ ❚ 5

T4, free (thyroxine, free) ❚ ❚ ❚ 5

��+��7��

General Chemistry and Therapeutic Drugs Surveys do not fulfill the CAP accreditationrequirements for neonatal bilirubin proficiency testing. See Surveys NB, NB2 on page 61.

��

Units (SI) reporting offered

��#��

reporting

O�� 6�� V��#�4��#

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ))

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

*��+�� +��"��5 �%A�%]5�^A�^]A�^$A�^$]5 ^ ��

�� +��A@+��

�� %A�%]�^A�^]A

�^$A�^$] ^

T4, total (thyroxine, total) ❚ ❚ ❚ 5

Thyroid-stimulatinghormone (TSH) ❚ ❚ ❚ 5

Triglycerides ❚ ❚ ❚ 5

Urea nitrogen (BUN) ❚ ❚ ❚ 5

Uric acid ❚ ❚ ❚ 5

Acid phosphatase ❚ ❚ 5

❚ ❚ 5

Apolipoprotein A1 ❚ ❚ 5

Apolipoprotein B ❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

Iron binding capacity,❚ ❚ 5

Iron binding capacity, unsaturated❚ ❚ 5

Iron saturation (%) ❚ ❚ 5

Lactate ❚ ❚ 5

Lipase ❚ ❚ 5

❚ ❚ 5

Phosphorus (inorganic) ❚ ❚ 5

❚ ❚ 5

Transferrin ❚ ❚ 5

Lithium ❚ ❚ ❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

Carbamazepine ❚ ❚ 5

❚ ❚ 5

Digoxin ❚ ❚ 5

❚ ❚ 5

❚ ❚ 5

��+��7��


��


��#��

reporting

O�� 6�� V��#�4��#

), ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

*��+�� +��"��5 �%A�%]5�^A�^]A�^$A�^$]5 ^ ��

�� +��A@+��

�� %A�%]�^A�^]A

�^$A�^$] ^

Ethosuximide ❚ ❚ 5

Gentamicin ❚ ❚ 5

Lidocaine ❚ ❚ 5

❚ ❚ 5

N-acetylprocainamide (NAPA) ❚ ❚ 5

Phenobarbital ❚ ❚ 5

Phenytoin ❚ ❚ 5

Phenytoin, free ❚ ❚ 5

Primidone ❚ ❚ 5

Procainamide ❚ ❚ 5

Quinidine ❚ ❚ 5

Salicylate ❚ ❚ 5

Theophylline ❚ ❚ 5

Tobramycin ❚ ❚ 5

Valproic acid ❚ ❚ 5

Valproic acid, free ❚ ❚ 5

❚ ❚ 5


��A�� #�"��@�� +��A@+��

�@

❚ 3

❚ 3

❚ 3

��


��#��

reporting

��

AACC

O�� 6�� V��#�4��#

'��%�%�"�"� _�'"+�'%��+��9��! _�� # )-

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

�#�� ;�� +��A@+��

�;

❚ 3

��+�� +��A@+��

��

Mycophenolic acid ❚ 3

�+��"��5�7��^�

�� +��A@+��

^�

❚ 3

❚ 3

❚ 3

❚ 3

�+��"��5 @��^�5 ^^�� +��A@+��

^�5^^�

❚ 3

❚ 3

❚ 3

Nortriptyline ❚ 3

❚ 3

��

��

��

��

O�� 6�� V��#�4��#

)8 ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

��(3��K��3K�� +��A@+��

�3K

Apolipoprotein A1 ❚ 3

Apolipoprotein B ❚ 3

Cholesterol* ❚ 3

HDL cholesterol* ❚ 3

LDL cholesterol ❚ 3

Lipoprotein (a) ❚ 3

Triglycerides* ❚ 3

*This analyte will be evaluated against the Centers for Disease Control and Prevention (CDC)reference method.

3(�� 3�� +��A@+��

3��

BNP ❚ 2

NT-pro BNP ❚ 2

��(3��+��3�<�� +��A@+��

�3�<

T3, free (triiodothyronine, free) ❚ 3

T3, total (triiodothyronine, total) ❚ 3

T4, free (thyroxine, free) ❚ 3

T4, total (thyroxine, total) ❚ 3

Thyroid-stimulating hormone (TSH) ❚ 3

��

Standards Institute Guideline CLSI C37-A, Preparation and Validation ofCommutable Frozen Human Serum Pools as Secondary Reference Materials forCholesterol Measurement Procedures; Approved Guideline.

��

specimens

��

specimens

International System of Units (SI) reporting offered

reporting offered

New��

specimens

O�� 6�� V��#�4��#

'��%�%�"�"� _�'"+�'%��+��9��! _�� # )9

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

��>��5 ��5 �� +��A@+��

��

CK-MB, immunochemical ❚ ❚ 5

CK isoenzymes CK-MB,❚ 5

LD1electrophoretic

❚ 5

LD1/LD2 ratio, calculationand interpretation

❚ 5

Myoglobin ❚ ❚

Troponin I ❚ ❚

Troponin T ❚

��=��[��@��=@�� +��A@+��

�=@

❚ 1

Bilirubin ❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

Iron ❚ 1

❚ 1

Phosphorus ❚ 1

❚ 1

Protein, total ❚ 1

❚ 1

❚ 1

Urea nitrogen (BUN) ❚ 1

Uric acid ❚ 1

15 measurements have been assigned using reference measurement procedures.

��

��

and has been stored at

to establish traceability of

the first Monday of each

O�� 6�� V��#�4��#

,: ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

<��*<$�� +��A@+��

*<$

1c ❚ 3

(NGSP) reference method.

*��@�� *@�� +��A@+��

*@�

❚ 3

<��+(@��#��A�� (��#�� +�� +��A@+��

+��

protein❚ 3

<��<�@�� +��A@+��

<�@

❚ 3

U��U�� +��A@+��

U��

❚

❚

��

��

��

��

��

® and

the nitroprusside reaction for

O�� 6�� V��#�4��#

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ,�

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

K�� +��5 B��#�K�B�� +��A@+��

K�B

❚ 3

❚ 3

❚ 3

❚ 3

HDL cholesterol ❚ 3


Triglycerides ❚ 3

��3�� 35 �3$�� +��A@+��

��

�3 �3$

Bilirubin, direct

Bilirubin, total 5

One human-based serum specimen will be evaluated against the value assigned using thereference method procedure (Clin Chem.

��>��5 ��]�� +��A@+��

�� ]

BNP ❚ ❚

CK-MB ❚ ❚ 5

❚ ❚

Myoglobin ❚ ❚

Troponin I ❚ ❚

��

®

®

Instant Plus

not appropriate for use on

��

��

O�� 6�� V��#�4��#

,$ ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

B��#��<�� +��A@+��

<��

❚

❚

B+��3��*��B3*5 B3$�� +��A@+��

��

B3* B3$

5 3

��#��+��!��+��@��#��;��

*��+�� "�5;��;�� @��#��

��

® B,

®

��

ancillary testing sites or

��

X��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ,%

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

Z��+��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Z��+��5 *��Z�� +��A@+��

Z

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

Nitrogen, total ❚ 3

❚ 3

Phosphorus ❚ 3

❚ 3


❚ 3

Urea nitrogen ❚ 3

Uric acid ❚ 3

❚ 3

❚ 3

��(3��Z��3Z�� +��A@+��

�3Z

❚ 3

❚ 3

❚ 3

❚ 3

��

per year

��

X��

,' ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

U��@��>�� U@�� +��A@+��

U@�

❚ 3

❚ 3

❚ 3

Sulfate ❚ 3

Z��+��5 @��5 �]�� +��A@+��

�5�]

❚ 3

❚ 3❚ 3❚ 3

Aldosterone ❚ 3❚ 3❚ 3❚ 3

Epinephrine ❚ 3❚ 3

Metanephrine ❚ 3Norepinephrine ❚ 3

❚ 3Uroporphyrin ❚ 3

❚ 3

��5Z��M*�� +��A@+��

�M*

❚

��

��

��

X��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ,)

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

��#��+�� !��+ �� @��#��;��Use the same material that is sent in the Surveys program to:

Z��+��5 ;��

;�� @��#��

64

U 63

��

1�� #��#

� � �� ]�� 6��#�

� $�� #��6��

� <�� ]�� #�� #� ��

� <��6��^��

@��

K�� D��A�K��5 �� K��V��D��D

�� X��

��

,, ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

@��+��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

�5)(��+�� *�� +��A@+��

�*

❚ 3

�� "K�� +��A@+��

�"K

Aldolase ❚

��(��#�� [�� +��A@+��

��

❚

��

��

��

��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ,-

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

3��=�� +�� =K"�� +��A@+��

=K"

❚ 3

❚ 3

❚ 1

❚ 1

❚ 3

❚ 3

❚ 3

Lactate ❚ 3

Lactate dehydrogenase (LD) ❚ 3

pH ❚ 3


Triglycerides ❚ 3

Urea nitrogen ❚ 1 per year

3��=�� +�� $=K"$�� +��A@+��

=K"$

❚ 3

Bilirubin ❚ 3

❚ 3

❚ 3

Lipase ❚ 3

❚ 3

❚ 3

Uric acid ❚ 3

��

��

��

,8 ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

��"�� +��A@+��

�"

❚ 3

❚ 3

❚ 3

❚ 3

This Survey meets the Occupational Safety and Health Administration (OSHA) guidelines for

��=��+�� 6�� 3��5 6K�

�� +��A@+��

� 6K�

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

Lactate ❚ ❚ 3

Lactate dehydrogenase (LD) ❚ ❚ 3

Protein, total ❚ ❚ 3

Oligoclonal bands ❚ 3

�� M@�� +��A@+��

�M@

❚

��

reporting offered

��

��

��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ,9

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

=��=��=�=@�� +��A@+��

=�=@

❚

=��=�� +��A@+��

=�

❚

*��(,(�+��+��"�+�� *,�"@�� +��A@+��

*,�"@

❚

K��(�� +��+��$�K�� +��A@+��

�K�

)❚

��

of neutral fats (triglycerides)

fatty acids)

��

��

��

��

-: ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

K��+��K��5@��5Z3P�

�� +��A@+��

K�� @�� Z3P�

Lipoprotein electrophoresis ❚

❚

❚

❚

identification ❚

Protein, total ❚

Protein electrophoresis ❚

Protein electrophoresis patterninterpretation

❚

Urine Bence Jones proteins ❚

K�� 3��K3�� +��A@+��

K3�

❚ 3

K�� K�5 K��A�� +��A@+��

K� K��

Bilirubin (Δ ❚ 1

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

��

��

��

��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # -�

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

��<��<*�� +��A@+��

�<*

❚

�� +��A@+��

��

Procalcitonin ❚ 3

��+��-�� +��A@+��

�-

Pseudocholinesterase ❚ 1

@��#�� @�K�� +��A@+��

@�K�

❚ 3

��

��

��

��

��

-$ ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

�� @��#��3@�� +��A@+��

�3@

❚ 4

❚ 4

Estradiol ❚ 4

Testosterone ❚ 4

❚ 4

��

�� 3�� 3K�� +��A@+��

�3K�

Total bile acids ❚ 3

�� +��A@+��

�

❚ 3

❚ 3

❚ 3

Manganese ❚ 3

❚ 3

❚ 3

��

��

��

��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # -%

*�

��

��

+�

��

�

�+�

��

��

��"

��

��

��

)

��5 Z��Z�� +��A@+��

��Z

Arsenic ❚ 3

❚ 3

❚ 3

Lead ❚ 3

Mercury ❚ 3

❚ 3

❚ 3

❚ 3

@!�� @��@B�5 @B$5@B%5@B'�� +��A@+��

@B�5@B$5@B%5@B'

❚ 3

❚ 3

❚ 3

❚ 3

For method compatibility, see chart below.

�� 7 ��@!�� @��+�A��

@B� @B$ @B% @B'

Orion direct electrode ❚

™ &Nanoduct® ❚

needles

® ❚Polystyrene boats and

❚No additional

��

��

��

-' ��#�� #�� !"�� #��$�� #� �

*�

��

��

+�

��

��

��

�

+�

��

��

��"

��

��

��

��

)

;�� ;�� +��A@+��

;

Viscosity ❚

@�� @�=�� +��A@+��

@�=�

❚ 3

��#��+��!��+��@��#��;��

@��+��5 ;��;�� @��#��

MVM M

��

��

��

��

��

��

��

�

,

$��#�

@�] ��#� � New

Anti-Müllerian Hormone (AMH) .........................................................................................................77

, _ $��#�

`��#�� #��] ��

��#��{� ��

� ��

*��KD<��!��[5�"5=�� <��

$��#�

-, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

,

��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

K��5 *��U5UU�� +��A@+��

U5UU

Alpha-fetoprotein (AFP) ❚ 5

CEA ❚ 3

Cortisol ❚ 5

Ferritin ❚ 3

Folate, serum ❚ 3

hCG, quantitative ❚ 5

IgE ❚ 5

Prostate-specific antigen (PSA) ❚ 2

Prostate-specific antigen,complexed (cPSA)

❚ 2

Prostate-specific antigen, free ❚ 2

Prostatic acid phosphatase (PAP) ❚ 3

T3, free (triiodothyronine, free) ❚ 3


T3 uptake and related tests ❚ 5

T4, free (thyroxine, free) ❚ 5

T4, total (thyroxine, total) ❚ 5


Vitamin B12 ❚ 3

3(�� 3�� +��A@+��

3��

BNP ❚ 2

NT-pro BNP ❚ 2

��

lyophilized serum specimensfor PSA assays

in duplicate


��

specimens


reporting offered

$��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # --

��

��

��

��

�

,

K��5 @��M5MM5"M�� +��A@+��

M5MM "M

11-deoxycortisol ❚ 3

17-hydroxyprogesterone ❚ 3

Androstenedione ❚ 3

DHEA sulfate ❚ 3

Estradiol ❚ 3

Estriol, unconjugated (uE3) ❚ 3

Follicle-stimulating hormone (FSH) ❚ 3

Growth hormone (GH) ❚ 3

IGF-1 (somatomedin C) ❚ 3

❚ 3

Progesterone ❚ 3

Prolactin ❚ 3

Testosterone ❚ 3

❚ 3

Testosterone, free ❚ 3

Sex hormone-binding globulin (SHBG) ❚ 3

��(�_�� <��<�� +��A@+��

��<

Anti-Müllerian hormone (AMH) ❚ 3

��

specimens (two duplicate sets)

serum specimens (threeduplicate sets)


��

serum specimens

New

$��#�

-8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

,

��(3��;�� "�3;"�� +��A@+��

�3;"

❚ 3

��

Preparation and Validation ofCommutable Frozen Human Serum Pools as Secondary Reference Materialsfor Cholesterol Measurement Procedures; Approved Guideline.

3��*��!�+ 3*@�� +��A@+��

3*@

❚ 3

IGF-1 (somatomedin C) ❚ 3

Osteocalcin ❚ 3

3�� 5 Z��3Z�� +��A@+��

3Z

C-telopeptide (CTx) ❚ 2

Creatinine ❚ 2

Deoxypyridinoline (DPD) ❚ 2

N-telopeptide (NTx) ❚ 2

❚ 2

��

serum specimens

endogenous pools

��

specimens


��

human urine specimens


$��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # -9

��

��

��

��

�

,

3��>��;��3�;�53�;$53�;%53�;'53�;)53�;,

�� +��A@+��

3�;� 3�;$ 3�;% 3�;' 3�;) 3�;,

1,25 dihydroxy❚ 3

Bone specific alkalinephosphatase

❚ 3

Vitamin A ❚ 3

Vitamin E ❚ 3

C-telopeptide (CTx) ❚ 3

N-telopeptide (NTx) ❚ 3

��+�� 6�� +��A@+��

��6

Erythropoietin ❚ 2

=��=��==�� +��A@+��

==

Fetal fibronectin ❚ 2

�(��5 *��5��5 ��<�� *�� +��A@+��

��*

C-peptide ❚ 3

Gastrin ❚ 3

Insulin ❚ 3

Parathyroid hormone (PTH) ❚ 3

��

specimens for each program

for each program

��

��

��

serum specimens


$��#�

8: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

,

��@��=�5=�]�� +��A@+��

=�5=�]

Alpha-fetoprotein (AFP), amniotic fluid ❚ 2

Alpha-fetoprotein (AFP), serum ❚ 5

Dimeric inhibin A (DIA) ❚ 5

Estriol, unconjugated (uE3) ❚ 5

Human chorionic gonadotropin (hCG),quantitiative ❚ 5

The CAP designed this Survey for laboratories using AFP and hCG for prenatal screeningpurposes only. For all other applications, see Survey K or KK on page 76.

=�� @��=��5=��3

�� +��A@+��

=�� =��3

Total hCG ❚ 5

Free beta hCG ❚ 5

PAPP-A ❚ ❚ 5

The CAP designed these Surveys for laboratories using hCG for prenatal screening purposesonly. For all other applications, see Survey K or KK on page 76.

��

simulated amniotic fluid specimens

specimens in duplicate; two

fluid specimens

��

specimens

specimens

"�!��@+��[��+��+��

��#�� #��2�-��@��2�-��O�� #Z�K ��#��

SO L U T I

O

NS

. . . . . . . . . . .

..

..

..

..

..

..

...

-LAB TM

$��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 8�

��

��

��

��

�

,

�+��*75 �*7�5 �*7$

��A�� +��A@+��

�*7 �*7� �*7$

CYP2C19 ❚ 2

CYP2C9 ❚ 2

CYP2D6 ❚ 2

UGT1A1 ❚ 2

VKORC1 ❚ 2

❚ 3

❚ 3

��

�3�=��=6K�� +��A@+��

=6K

RBC folate ❚ 2

�� +��A@+��

��

Aldosterone ❚ 3

Renin ❚ 3

��

DNA specimens

extracted DNA specimens

��

specimens

��

plasma specimens


$��#�

8$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

,

��>��5 ��]�� +��A@+��

��5��]

Adrenocorticotropic hormone (ACTH) ❚ 3

Beta-2-microglobulin ❚ 3

CA 15-3 ❚ 3

CA 19-9 ❚ 3

❚ 3

❚ 3

CA 125 ❚ 3

Calcitonin ❚ 3

Thyroglobulin ❚ 3

��#��+��!��+��@��#��;��

��5;��;�� @��#��

77

��

serum specimens

specimens in duplicate

��

lyophilized serum specimensfor PSA assays; three shipments per year

serum specimens (twoduplicate sets); two shipmentsper year

3��

*

��5�

��

��

��5�

�

67��

��

-

- _ =��O �� 9}��

`��#��#��

�� ]��

��J�� ]��^�]��

��

*��KD<��!��[5�"5=�� <��

=��O �� 9}��

8' ��#�� #�� !"�� #��$�� #� �

3��

�

*�

�5�

��

��

��

5��

6

7��

��

�

-

3��*��5�� 5 ��67��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

�� H��3��*��&5 �&$5 �&%5 �&'

�� +��A@+��

�& �&$ �&% �&'

Calcium, ionized ❚ ❚ ❚ ❚ 2

Chloride ❚ ❚ ❚ ❚ 5

Hematocrit ❚ ❚ ❚ ❚ 5

Hemoglobin, estimated ❚ ❚ ❚ ❚ 5

Lactate ❚ ❚ ❚ ❚ 2

Magnesium, ionized ❚ ❚ 2

PCO2 ❚ ❚ ❚ ❚ 5

pH ❚ ❚ ❚ ❚ 5

PO2 ❚ ❚ ❚ ❚ 5

Potassium ❚ ❚ ❚ ❚ 5

Sodium ❚ ❚ ❚ ❚ 5

tCO2 ❚ ❚ ❚ ❚ 5

Creatinine ❚ ❚ 5

Glucose ❚ ❚ 5

Urea nitrogen (BUN) ❚ ❚ 5

��

aqueous specimens (twoduplicate sets) and ten

®


available

"��(@��

��T

M��

��6��@��#��&��&$

6��@��#��&%��&'

=��O �� 9}��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 8)

3��

*

��5�

��

��

��5�

�

67��

��

-

3��67�� @6�� +��A@+��

@6

Carboxyhemoglobin ❚ 5

Hematocrit, estimated ❚ 5

Hemoglobin, total ❚ 5

Methemoglobin ❚ 5

Oxyhemoglobin ❚ 5

This Survey is not compatible with Oxicom-2000, -2100, or -3000 whole blood oximeters.

��

human hemoglobin solution specimens

�+��>��+��#��+��+�(��@��R

�� \�� ]��6�� {�� ]�� ]��6�6��#�O��

�� !�"�� #��V��# ��#� ��6��}��6��~��6�$}��^�� 6�6��#�O�� 6�$}��J��# ��^��##��#��2�-��

K��(��@��D��A�K��@��>��A&��`��N��+��D

SO L U T I

O

NS

. . . . . . . . . . .

..

..

..

..

..

..

...

-LAB TM

�#��H��+��+�+��+��>��+��+��#��(��(��H��D� 4 �� #��

� ��#�� ^��#��^�� ]�� {��

� ��} ��

� $�� #�� {�� #��

� ��^��{��

� J��#��#��#��#��#�� #�� {��

�� ^��#��2�-��@�� ^��V�<94�

$ �� #�]�� {�� ^��#�� ^��# �� ^�� #�

��7��

��

��

86�}��#�

@�] ��#� � New

Vitreous Fluid, Postmortem (VF) ..........................................................................................................92Synthetic Cannabinoid/Designer Drugs (SCDD) ..................................................................................96

@�] �� Toxicology (T)..................................................................................................................................88

DesmethylclomipramineEcgonine ethyl esterMaprotilineZolpidem

Urine Toxicology (UT) .......................................................................................................................88DesmethylclomipramineEcgonine ethyl esterMaprotilineZolpidem

Oral Fluid for Drugs of Abuse (OFD) ..................................................................................................92MethadoneOxycodoneOxymorphone

Forensic Toxicology, Criminalistics (FTC).............................................................................................95Alpha-hydroxyalprazolamChlorpheniramine

8 _ 6�}��#�

`�� {��#�

�#�� #��#��#��

��+��*D 3��5 �"5�+"5��<5=�� 6�}��#��<��

6�}��#�

88 ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

��7��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��7�� +��A@+��

�

See drug listing on next page ❚ 5

Z��7��Z�� +��A@+��

Z�

See drug listing on next page ❚ 5

��

drug analysis with

��

��#��+��5��5#��5��5��T

��!��@��#��F;=G��#��!�#��D• ��]�� #��

�}�� {� �� ]��{� ��

• �� • 9�� ]��

�� #�� #

��;=��@��#��D

6�}��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 89

��7��

��

��

8Benzodiazepinegroup

Buprenorphine

Bupropion

Carisoprodol

Chlordiazepoxide

Clozapine

Codeine

Cotinine

Digoxin

Doxepin

Duloxetine

Ephedrine

Naproxen

Nordoxepin

Norpropoxyphene

Norsertraline

Nortriptyline

Quetiapine

Quinidine

Quinine

Ranitidine

Sertraline

�5 Z�"��K��

6�}��#�

9: ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

��A�� Z��"��5 @��Z"@5Z"@,

��

�+��A@+��

Z"@ Z"@,K��

5 3

5 3

5 3

5 3

Benzodiazepine group 5 3

5 3

Buprenorphine 5 3

5 3

Ethanol 5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

5 3

Z��"��A��"�� +��A@+��

"��

Creatinine ❚ 3

Glutaraldehyde ❚ 3

Nitrite ❚ 3

❚ 3

❚ 3

❚ 3

��

Clinical & ForensicToxicology News

AACC

��

6�}��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 9�

��7��

��

��

8

��A�� =��Z��"��5�� Z"�

�� +��A@+��

Z"�

❚

❚

❚

❚

Buprenorphine ❚

❚

Codeine ❚

❚

❚

❚

❚

❚

❚

❚

❚

❚

❚

❚

❚

❚

Norpropoxyphene ❚

❚

❚

❚

❚

❚

❚

❚

❚

Creatinine ❚

❚

❚

��

testing

Clinical & ForensicToxicology News

AACC

6�}��#�

9$ ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

6�� =�� "�� 6="�� +��A@+��

6="

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

Codeine ❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

❚ 5

;�� =��5 �� ;=�� +��A@+��

;=

Chloride ❚ %

Creatinine ❚ %

Ethanol ❚ %

❚ %

❚ %

❚ %

Vitreous urea nitrogen ❚ %

��

New��

6�}��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 9%

��7��

��

��

8

@��"��@��@"@�� +��A@+��

@"@

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

��A�� +��A��+��*��A;�� K�O5 �K$

�� +��A@+��

�K�OB+��3��

�K$@��

❚ ❚ 5

Ethanol ❚ ❚ 5

❚ ❚ 5

Isopropanol ❚ ❚ 5

❚ ❚ 5

*The American Society of Crime Laboratory Directors/Laboratory Accreditation Board ProficiencyReview Committee (ASCLD/LAB PRC) has approved Survey AL1.

��+��3��>��3�� +��A@+��

��3

❚ 3

❚ 3

��

��

AACC

��

6�}��#�

9' ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

��A�� 3��K��3K�� +��A@+��

3K

Lead ❚ 5

This Survey meets the Occupational Safety and Health Administration (OSHA) requirements forproficiency testing [OSHA lead standards-29 CFR 1910.1025(j)(2)(iii)].

��"�� +��A@+��

�"

❚ 3

❚ 3

❚ 3

❚ 3

This Survey meets the Occupational Safety and Health Administration (OSHA) guidelines forproficiency testing (OSHA standard-29 CFR 1910.1027AppF).

��5 Z��Z�� +��A@+��

��Z

❚ 3

❚ 3

Copper ❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

��

AACC

��

��

6�}��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 9)

��7��

��

��

8

=��7��5�� =�� +��A@+��

=��

See drug listing below ❚ 4

The American Society of Crime Laboratory Directors/Laboratory Accreditation Board ProficiencyReview Committee (ASCLD/LAB PRC) has approved Survey FTC.

��

Codeine

Nortriptyline

=�� "��K��

6�}��#�

9, ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

@��+��A"��"��@�""

�� +��A@+��

@�""

α ❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

��FZ@"G

New��

6�}��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 9-

��7��

��

��

8

"�� "��

�� +��A@+��

"��

❚ 3

❚ 3

❚ 3

Benzodiazepines ❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

��

6�}��#�

98 ��#�� #�� !"�� #��$�� #� �

��7�

��

��

�

8

��#��+��!��+��@��#��;��Use the same material that is sent in the Surveys program to:

��7��5;��;�� @��#��

AL2 93

BL 94

90

��

;��N��

K� ��}��#��9\V�� #��4[��N��#�� ]��

� V��#��#

� V��#��#Z��

� V��#��#Z�� Z{� ��

6��

� �� #�� ]�� #��

� ��

�6��=��"��F6="G��@��#��D

��

��

��

�(3��

��

��

��

9

�� = ��#� �Accuracy-Based Programs...............................................................................................................100Validated Materials........................................................................................................................104

@�] ��#� � New

Accuracy-Based Thyroid (ABTH).......................................................................................................102

9 _ �� = ��#� �

`6�� #� ��

!N�� #��]�� ]��

�� ]��#��!��

��#��K ��

�� #�� ]��

��#� �� 9��

�!�� |��

��

�� #��

��#�� ^��#��

��#��

*��KD<��!��[5�"5=�� <��

�� = ��#� �

�:: ��#�� #�� !"�� #��$�� #� �

��

��

��

�(3�

��

��

��

��

9

��(3��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��(3��K��3K�� +��A@+��

�3K

Apolipoprotein A1 ❚ 3

Apolipoprotein B ❚ 3

Cholesterol* ❚ 3

HDL cholesterol* ❚ 3


Lipoprotein (a) ❚ 3

Triglycerides* ❚ 3

*This analyte will be evaluated against the Centers for Disease Control and Prevention (CDC)reference method.

��(3��;�� "�3;"�� +��A@+��

�3;"

25-OH vitamin D (D2 and D3) ❚ 3

��

using isotope-dilution LC-MS/MS method.

Standards Institute Guideline CLSI C37-A, Preparation and Validation ofCommutable Frozen Human Serum Pools as Secondary Reference Materialsfor Cholesterol Measurement Procedures; Approved Guideline.

��3�� 35 �3$�� +��A@+��

��

�3 �3$

2 2

Bilirubin, total 5 2

One human-based serum specimen will be evaluated against the value assigned using thereference method procedure (Clin Chem. 1985;31:1779-1789).

��

specimens

��

serum specimens

endogenous pools

��

serum specimens; threeshipments per year

serum specimens; must

�� = ��#� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �:�

��

��

��

�(3��

��

��

��

9

�� @��#��3@�� +��A@+��

�3@

Calcium ❚ 4

Cortisol ❚ 4

Estradiol ❚ 4

Testosterone ❚ 4


��

��(3��Z��3Z�� +��A@+��

�3Z

Calcium ❚ 3

Creatinine ❚ 3

❚ 3

❚ 3

Analytes may be evaluated against the reference method or by using harmonization.

�� ;��AK�� K�$'

��

K�$' K�$'��

Creatinine ❚

Estimated glomerular❚

��

��

specimens

��

specimens

��

specimens

�� = ��#� �

�:$ ��#�� #�� !"�� #��$�� #� �

��

��

��

�(3�

��

��

��

��

9

��(3��+��3�<�� +��A@+��

�3�<

❚ 3


❚ 3

❚ 3


��FZ@"G

��

Standards Institute Guideline CLSI C37-A, Preparation and Validation ofCommutable Frozen Human Serum Pools as Secondary Reference Materials forCholesterol Measurement Procedures; Approved Guideline.

<�� ;��AK��

��

K��) K��)��

1c ❚

CAP-assigned target values derived from Hemoglobin A1c measurements assayed byNational Glycohemoglobin Standardization Program (NGSP) secondary reference laboratories.

LN Express service is available.

<��*<$�� +��A@+��

*<$

1c ❚ 3

This Survey will be evaluated against the National Glycohemoglobin Standardization Program(NGSP) reference method.

��

specimens

New

��

��

�� = ��#� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �:%

��

��

��

�(3��

��

��

��

9

��=��[��@��=@�� +��A@+��

�=@

❚ 1

❚ 1

Chloride ❚ 1

Cortisol ❚ 1

Creatinine ❚ 1

Glucose ❚ 1

Iron ❚ 1

Magnesium ❚ 1

❚ 1

❚ 1

❚ 1

Sodium ❚ 1

❚ 1

❚ 1

Uric acid ❚ 1

This material was prepared using a slightly modified CLSI C37-A preparation protocal. Values for15 measurements have been assigned using reference measurement procedures.

��

specimen

measurement procedures andassigned values is provided

analytical measurementsystems

month)

Y �� 4 ��

�:' ��#�� #�� !"�� #��$�� #� �

��

��

��

�(3�

��

��

��

��

9

;��#��+��!��+��@��#��;��

�+��5 ;��;�� ;�� @��#��

Chemistry/TDM VM CZVM CZ

MVM M

Urine Chemistry (Special) VM

Urine Chemistry (General) VM UVM U

��5;��;�� ;�� @��#��

Coagulation (Limited) VM CGM CGL

�� ;��AK��5 ;��;�� ;�� @��#��

LDM

LLM

LUM

Y �� 4 ��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �:)

��

��

��

�(3��

��

��

��

9

��5 ;��;�� ;�� @��#��

Cytogenetics VM CYM CY

��5;��;�� ;�� @��#��

Ligands (General) VM

Ligands (Special) VM YVM Y

��7��5;��;�� ;�� @��#��

Serum Alcohol/Ethylene Glycol/Volatiles VM AL2M AL2

Blood Lead VM BLM BL

Urine Drug Testing (Screening) VM UDSM UDS

@��!��>��!��

� �� #�� #� �

� ��

� �� ]� �� #� �

� V�� K �� J�� ]��

� 9�� #�� #�� !� ��

� 4�� 6Z$/� � �� ]��

� 4 � #�� ]��^�� ]�� #

��!�#��X�(��@��R5��+��X

� �� 6Z$/� ��# �� 2�-�� # ��

� <�� 6Z$/� �� ^� � ��

SO L U T I

O

NS

. . . . . . . . . . .

..

..

..

..

..

..

...

-LAB TM

� �� ]�� ]� �� Y�� ZK�� #� � ��#� ��2�- ��

K��7��@�

�7��#��#��

� �� ]�� # ��6�Z$/��#� � � ��

� ��]� �� ^ �� SM

��

��

��

��;

��

��

��

��

�:

J�� Y �� 6��Calibration Verification/Linearity .....................................................................................................108Instrumentation Quality Management Programs .................................................................................122

@�] ��#� � New

CMV Viral Load CVL (LN38) ...........................................................................................................120HIV Viral Load CVL (LN39) .............................................................................................................120Vitamin D CVL (LN40) ....................................................................................................................120Procalcitonin CVL (LN41) ................................................................................................................121D-Dimer CVL (LN42).......................................................................................................................121

��#� �� #��Interfering Substances (IFS)..............................................................................................................123

Lipid interferent

�: _ J�� Y �� 6��

`�� #��]�� {� ��

�� 6�� ]��

��#� �� ]��# �#��]�]��]��#��

��+��DU��5�"5=�� J�� <��

� �� Y�� ZK��

�:8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:

�+��;K��Our program will help you meet CLIA regulations and CAP Laboratory Accreditation Program requirements forcalibration verification and analytical measurement range (AMR) validation under 42 CFR493.1255(b)(3) for mostanalytes. In addition, you will receive a linearity assessment to help identify instrument/method performance issuesbefore they can affect your patient results.

With your enrollment in the CAP CVL program you will receive:

Testing Kit o Kit instructions—Contain important information to help you complete testing and accurately report your results o Result form o Specimens—The majority of CAP CVL programs offer human-based materials to closely mimic your patient results

Customized Report Package o Executive Summary—A quick overview of both your calibration verification and linearity results for all reported

analytes o Calibration Verification evaluation o Linearity evaluation

LN ExpressSM, our expedited delivery service, within two businessdays for select CVL programs by logging in to e-LAB Solutions™

o Linearity Troubleshooting Report o Participant Summary—A summary of laboratory performance that includes peer group statistics and enhanced

diagnostic information for early insight into potential problems

Additional Tools o Calibration Verification/Linearity Program User’s Guide—Get assistance in interpreting your evaluations and

reports as well as helpful troubleshooting information with suggested actions. Also available online by logging into e-LAB Solutions

o Calibration Verification Troubleshooting Guide—The guide provides suggested actions if you receive acalibration verification result of Different, or if your evaluation result is Verified over a range that does notinclude all of your reported results

o Calibration Verification/Linearity Surveys Investigation Checklist for Problematic Results—Interpretative checklistsare included to help with troubleshooting and documentation

�� ;��AK��

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �:9

��

��

��

��;

��

��

��

��

�:

M�� ;��AK�� F�;KG @��

�;K�� D

��@��#�� D ;��

��D

LN2 - Chemistry, Lipid, Enzyme CVL 110C1, C3/C3X,

CZ/CZX/CZ2/CZ2X54

LN2VM 104LN2BV - Chemistry, Lipid, Enzyme all Beckman(except AU), Vitros CVL

110 LN2VM1 104

LN3 - TDM CVL 111 CZ/CZX/CZ2/CZ2X/Z 54 LDM 104LN5 - Ligand Assay CVL 112

K/KK 76 LLM 104LN5S - Ligand Assay all Siemens ADVIA(Centaur, CP, and XP) CVL

112

LN6 - Urine Chemistry CVL 112 U 63 LUM 104LN7 - Immunology CVL 113 IG/IGX 182LN8 - Reproductive Endocrinology CVL 113 Y/YY 77LN9 - Hematology CVL 114 FH series, HE series 129, 128LN11 - Serum Ethanol CVL 114 AL2 93LN12 - C-Reactive Protein CVL 114 CRP 182LN13, LN13C - Blood Gas/Critical Care CVL 115 AQ, AQ2, AQ3, AQ4 84LN14 - Whole Blood Ethanol CVL 115 AL1 93LN15 - Hemoglobin A1c Accuracy CVL 115 GH2 102LN16 - Homocysteine CVL 116 HMS 60LN17 - Whole Blood Glucose CVL 116 WBG, WB2 62LN18 , LN19 Reticulocyte CVL 116 RT, RT2, RT3, RT4 131LN20 - Urine Albumin CVL 116 U 63LN21 - High-Sensitivity C-Reactive Protein CVL 117 hsCRP 186LN22 - Flow Cytometry CVL 117 FL 189LN23 - Prostate-Specific Antigen CVL 117 K/KK 76

LN24 - Creatinine Accuracy CVL 118C1, C3/C3X,

CZ/CZX/CZ2/CZ2X54

LN25, LN27 - Troponin I and T CVL 118 CRT, CRTI, TNT 59LN30 - B-Type Natriuretic Peptides CVL 118 BNP 76LN31 - Immunosuppressive Drugs CVL 119 CS 56

LN32 - Ammonia CVL 119C1, C3/C3X,

CZ/CZX/CZ2/CZ2X54

LN33 - Serum Myoglobin CVL 119 CRT, CRTI 59LN34 - Tumor Markers CVL 119 TM/TMX 82LN35 - Thrombophilia CVL 120 CGS2 147LN36 - Heparin CVL 120 CGS4 147LN37 - von Willebrand Factor Antigen CVL 120 CGS3 147LN38 - CMV Viral Load CVL 120 VLS, VLS2 175LN39 - HIV Viral Load CVL 120 HIV, HV2 175LN40 - Vitamin D CVL 120 BGS 78LN41 - Procalcitonin CVL 121 PCT 71LN42 - D-Dimer CVL 121 CGL, CGDF 146

All CVL Surveys provide individual evaluation reports by analytes, an Executive Summary, and graphical plots for linearity andcalibration verification.

� �� Y�� ZK��

��: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:

Please note that the ranges listed are an estimate of the values recovered. Some instruments may recover lower or higher valuesthan the ranges listed.

�+��5 K��5 ��[�� ;��AK�� K�$5 K�$3;

�� K�$ K�$3; Z��

K�$5K�$3;

F��G

��3��>��F�7��ZG ;��

Albumin ❚ 1.5–9.0 g/dL

Calcium ❚ 4.0–18.0 mg/dL

Chloride ❚ 60–180 mmol/L

CO2 ❚ 7–40 mmol/L

Creatinine ❚ 0.3–32.0 mg/dL

Glucose ❚ 20–780 mg/dL

Iron ❚ 10–950 μg/dL

Magnesium ❚ 0.3–10.0 mg/dL

Osmolality ❚ 200–600 mOsm/kg H2O

Phosphorus ❚ 0.5–20.0 mg/dL

Potassium ❚ 1.5–13.0 mmol/L

Protein ❚ 1.5–10.0 g/dL

Sodium ❚ 90–215 mmol/L

Urea nitrogen ❚ 3–190 mg/dL

Uric acid ❚ 1–25 mg/dL

Alkaline phosphatase ❚ 25–1,800 25–1,000 25–1,100 U/L

ALT (SGPT) ❚ 10–900 10–650 30–700 U/L

Amylase ❚ 30–1,800 30–900 30–800 U/L

AST (SGOT) ❚ 10–900 10–500 10–700 U/L

Creatine kinase ❚ 25–2,000 25–1,200 25–700 U/L

CK-2 (MB) Mass ❚ 1–250 1–300 1–200 ng/mL

Gamma glutamyltransferase

❚ 10–1,400 10–900 10–1,100 U/L

Lactatedehydrogenase

❚ 50–1,800 50–700 185–3,000 U/L

Lipase ❚ 20–1,400 20–190 150–2,500 U/L

Bilirubin, direct ❚ 0.1–10.0 mg/dL

Bilirubin, total ❚ 0.2–25.0 mg/dL

Cholesterol ❚ 35–625 mg/dL

HDL ❚ 7–120 mg/dL

Triglycerides ❚ 20–700 mg/dL


��

specimens for basic chemistry,six 5.0-mL liquid serumspecimens for direct and totalbilirubin, seven 5.0-mL liquidserum specimens for lipids,and seven 5.0-mL liquidserum specimens for enzymes

major instruments

Beckman (except AU) andVitros instruments only

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��

��

��

��

��;

��

��

��

��

�:


�+��"�� ;��AK�� K�%

��

K�% K�%��

Acetaminophen ❚ 20–450 μg/mL

Amikacin ❚ 1–45 μg/mL

Carbamazepine ❚ 2–18 μg/mL

Digoxin ❚ 0.5–4.4 μg/mL

Gentamicin ❚ 1–11 μg/mL

Lidocaine ❚ 1–10 μg/mL

Lithium ❚ 0.3–4.0 mmol/L

N-acetylprocainamide (NAPA) ❚ 2–25 μg/mL

Phenobarbital ❚ 8–70 μg/mL

Phenytoin ❚ 5–35 μg/mL

Primidone ❚ 1–22 μg/mL

Procainamide ❚ 2–18 μg/mL

Quinidine ❚ 0.4–7.0 μg/mL

Salicylates ❚ 7–90 mg/mL

Theophylline ❚ 5–35 μg/mL

Tobramycin ❚ 1–12 μg/mL

Valproic acid ❚ 15–140 μg/mL

Vancomycin ❚ 7–90 μg/mL


��

specimens

specimen for acetaminophenand vancomycin

� �� Y�� ZK��

��$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:


K��;��AK��K�)5K�)@��

K�)5K�)@O K�)�� K�)@��

AFP ❚ 0.5–900.0 ng/mL

CEA ❚ 0.5–750.0 ng/mL 0.5–90.0 ng/mL

Cortisol ❚ 1–65 μg/dL

Ferritin ❚ 2–1,200 ng/mL

Folate ❚ 1–20 ng/mL

Human chorionicgonadotropin (hCG)

❚ 5–14,000 mIU/mL

T3, total (triidothyronine) ❚ 0.5–7.0 ng/mL

T4, total (thyroxine) ❚ 1–24 ng/mL

Thyroid-stimulatinghormone (TSH)

❚ 0.01–100 μU/mL

Vitamin B12 ❚ 100–2,200 pg/mL

*The LN5S CVL will allow Siemens ADVIA Centaur users to report other major instruments if needed.


Z��+�� ;��AK��K�,

��

K�, K�,��

Amylase ❚ 40–1,500 U/L

Calcium ❚ 5–30 mg/dL


Creatinine ❚ 20–460 mg/dL


Osmolality ❚ 30–1,800 mOsm/kg H20

Phosphorus ❚ 15–200 mg/dL

Potassium ❚ 7–225 mmol/L

Protein, total ❚ 10–235 mg/dL


Urea nitrogen ❚ 20–2,000 mg/dL

Uric acid ❚ 6–150 mg/dL


��

serum specimens; appropriatefor most major instrumentsexcept Siemens ADVIACentaur

serum specimens; appropriatefor Siemens ADVIA Centaur,XP, and CP users

��

specimens

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��%

��

��

��

��;

��

��

��

��

�:


��;��AK�� K�-

��

K�- K�-��

Alpha-1-antitrypsin ❚ 25–616 mg/dL

Complement C3 ❚ 21–420 mg/dL

Complement C4 ❚ 5–100 mg/dL

IgA ❚ 32–650 mg/dL

IgG ❚ 150–3,000 mg/dL

IgM ❚ 25–450 mg/dL

Transferrin ❚ 38–950 mg/dL


��#�� ;��AK�� K�8

��

K�8 K�8��

Estradiol ❚ 25–2,500 pg/mL

Follicle-stimulating hormone (FSH) ❚ 3–190 mIU/mL

Human chorionic gonadotropin (hCG) ❚ 5–1,600 mIU/mL

Luteinizing hormone (LH) ❚ 2–190 mIU/mL

Progesterone ❚ 1–50 ng/mL

Prolactin ❚ 3–220 ng/mL

Testosterone ❚ 20–1,500 ng/dL


��

specimens

��

specimens

serum specimen for estradiol (4,500 pg/mL),hCG (8,000 mIU/mL), andprolactin (315 ng/mL)

� �� Y�� ZK��

��' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:


<��;��AK�� K�9

��

K�9 K�9��

Hemoglobin ❚ 1.5–24.0 g/dL

Platelet count ❚ 10–2,500 x 109/L

RBC count ❚ 0.5–8.00 x 1012/L

WBC count ❚ 0.5–350.0 x 109/L


@��+�� ;��AK��K��

��

K�� K��

Serum ethanol ❚ 15–550 mg/dL


�(��#�� ;��AK�� K��$

��

K��$ K��$��

C-reactive protein ❚ 5–280 mg/L


��

specimens

��

specimens

��

specimens

high-sensitivity C-reactiveprotein (hsCRP)

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��)

��

��

��

��;

��

��

��

��

�:


3��*��A�� ;��AK�� K��%5 K��%�

��

��

K��% K��%�� K��%� K��%�

��

PCO2 ❚ 12–91 mm Hg ❚ 12–91 mm Hg

pH ❚ 6.83–7.82 ❚ 6.83–7.82

PO2 ❚ 18–490 mm Hg ❚ 18–490 mm Hg

Calcium, ionized ❚ 0.15–3.3 mmol/L



Lactate ❚ 0.2–18 mmol/L

Magnesium, ionized ❚ 0.1–2.4 mmol/L

Potassium ❚ 0.5–10.7 mmol/L


B+��3��+�� ;��AK�� K��'

��

K��' K��'��

Ethanol ❚ 15–400 mg/dL


<�� ;��AK�� K��)

��

K��) K��)��

Hemoglobin A1c ❚ 5%–12%

CAP-assigned target values derived from Hemoglobin A1c measurements assayed byNational Glycohemoglobin Standardization Program (NGSP) secondary reference laboratories.


��

aqueous specimens

only

��

specimens

��

whole blood specimens

� �� Y�� ZK��

��, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:


<��;��AK�� K��,

��

K��, K��,��

Homocysteine ❚ 5–65 μmol/L


B+��3��*�� ;��AK�� K��-

��

K��- K��-��

Whole blood glucose ❚ 50–400 mg/dL

��;��AK��K��85 K��9

��A��+� ��

K��8 K��8��

K��9 K��9��

LH500, LH700 series,and Unicel DxH

❚ 0.5%–28.0%

All other instruments ❚ 0.4%–25.0%


Z�� ;��AK��K�$:

��

K�$: K�$:��

Urine albumin ❚ 10–350 mg/L

Urine creatinine ❚ 20–500 mg/dL

��

specimens

��

blood specimens

ancillary testing sites orinstruments

��

blood cell specimens

��

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��-

��

��

��

��;

��

��

��

��

�:


<��+(@��#�� (��#�� ;��AK�� K�$�

��

K�$� K�$��

High-sensitivity C-reactive protein ❚ 0.5–6.0 mg/L


=��! �� ;��AK��K�$$

��

K�$$ K�$$��

CD3+ ❚ 50%–70% positive

CD3+ T lymphocytes absolute ❚ 350–4,000 cells/μL

CD3+/CD4+ ❚ 1%–40% positive

CD3+/CD4+ T lymphocytes absolute ❚ 6–2,000 cells/μL

CD3+/CD8+ ❚ 25%–40% positive

CD3+/CD8+ T lymphocytes absolute ❚ 250–1,600 cells/μL

��(@�� ;��AK�� K�$%

��

K�$% K�$%��

Prostate-specific antigen ❚ 0.1–90.0 ng/mL

��

specimens

only

��

blood specimens

��

specimens

� �� Y�� ZK��

��8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:


�� ;��AK�� K�$'

��

K�$' K�$'��

Creatinine ❚ 0.6–4.0 mg/dL

Estimated glomerularfiltration rate (eGFR)

❚

��The College of American Pathologists (CAP) and the National Kidney Disease EducationProgram (NKDEP) have an initiative to harmonize clinically reported creatinine values.This initiative is analagous to what the federal health agencies and the clinical laboratorycommunity did to improve the accuracy of cholesterol and glycohemoglobin testing.

��;��AK��K�$)5 K�$-

��

K�$) K�$)�� K�$- K�$-��

Troponin I ❚ 0.05–60.00 ng/mL

Troponin T ❚ 0.1–22.00 ng/mL

3(�� ;��AK�� K�%:

��

K�%: K�%:��

BNP ❚ 30–3,500 pg/mL

NT-pro BNP ❚ 50–30,000 pg/mL


��

specimens

��

serum specimens

serum specimens

��

specimens for BNP and NT-pro BNP

plasma specimen for NT-proBNP only

� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # ��9

��

��

��

��;

��

��

��

��

�:


��#�"�� ;��AK�� K�%�

��

K�%� K�%��

Cyclosporine ❚ 60–1,200 ng/mL

Tacrolimus ❚ 1.5–30.0 ng/mL

�� ;��AK�� K�%$��

K�%$ K�%$��

Ammonia ❚ 13–900 μmol/L


@�� ;��AK��K�%%

��

K�%% K�%%��

Myoglobin ❚ 25–900 ng/mL


��>�� ;��AK�� K�%'

��

K�%' K�%'��

CA 125 ❚ 1–1,000 U/mL

CA 15-3 ❚ 2–190 U/mL

CA 19-9 ❚ 10–900 U/mL


��

blood hemolysate specimens

��

specimens

��

specimens

��

specimens

� �� Y�� ZK��

�$: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:

��;��AK��K�%)5 K�%,5 K�%-

��

K�%) K�%, K�%- ��

Antithrombin activity ❚ 10%–130%

Protein C activity ❚ 10%–120%

Heparin, low molecular weight ❚ 0.1–2.0 U/mL

Heparin, unfractionated ❚ 0.1–2.0 U/mL

von Willebrand factor antigen ❚ 5%–140%

The LN35, LN36, and LN37 CVL programs meet the CAP Accreditation requirementsHEM.38009, 38010, and 38011.


;�� K�� ;��AK��K�%85 K�%9

��

K�%8 K�%9 ��

CMV viral load ❚ 0–1M IU/L

HIV viral load ❚ 0–10M copies/L

;�� "�� ;��AK��K�':

��

K�': ��

25-OH vitamin D, total ❚ 2-120 ng/mL

��

specimens

on dry ice

New��

plasma specimens

plasma specimens

on dry ice

New��


� �� Y�� ZK��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �$�

��

��

��

��;

��

��

��

��

�:

��;��AK�� K�'�

��

K�'� ��

Procalcitonin ❚ 0.5-200 ng/mL

"("��;��AK�� K�'$

��

K�'$ ��

D-dimer ❚ 200-4,500 ng/mL FEU

New��

New��

K��+��>��!��N#��+��>

6�� ^��#��# �� ]��]�� #�� 6� �� ]�� +�%�� 6�� ^�� ] �� ~�� #�� #�� #� ��]��

6�� ^� �� ]��

��!��>5��(��@��R��5��+��V��D��D

J�� /� ��4 � #��#� �

�$$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:

�� &��

�� +��

�

�@+�� 3@+�� @+��

Adjustable micropipettecalibration verification/linearity

❚ ❚

Analytical balance check ❚ ❚

Gravimetric pipette calibration ❚ ❚

Microtiter plate linearity ❚ ❚

Refractometer calibration ❚ ❚

Spectrophotometer (stray light check) ❚ ❚

Absorbance check – UV wavelength ❚

Fluorescent intensity check –fluorescent microscopes

❚

Ocular micrometer calibration ❚

Osmometer study ❚

Peak absorbance measurement ❚

pH meter check ❚

Photometric calibration – visiblewavelength

❚

WARNING: The Instrumentation (I) Survey specimens may contain corrosive or toxic substances,environmental hazards, or irritants.

��

instruments not routinelychallenged during theproficiency testing process

materials to assess importantfunctional parameters,including accuracy andlinearity

J�� /� ��4 � #��#� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �$%

��

��

��

��;

��

��

��

��

�:

�� @��@��#��=@��

�=@

3��

<��

K��

Alanine aminotransferase (ALT/SGPT) ❚ ❚ ❚

Albumin ❚ ❚ ❚

Alkaline phosphatase ❚ ❚ ❚

Amylase ❚ ❚ ❚

Aspartate aminotransferase (AST/SGOT) ❚ ❚ ❚

Calcium ❚ ❚ ❚

Chloride ❚ ❚ ❚

CK2 (MB) mass ❚ ❚ ❚

Creatine kinase (CK) ❚ ❚ ❚

Creatinine ❚ ❚ ❚

Gamma glutamyl transferase (GGT) ❚ ❚ ❚

Glucose ❚ ❚ ❚

Iron ❚ ❚ ❚

Lactate dehydrogenase (LD) ❚ ❚ ❚

Lipase ❚ ❚ ❚

Magnesium ❚ ❚ ❚

Osmolality ❚ ❚ ❚

Phosphorus ❚ ❚ ❚

Potassium ❚ ❚ ❚

Protein, total ❚ ❚ ❚

Sodium ❚ ❚ ❚

Urea nitrogen (BUN) ❚ ❚ ❚

Uric acid ❚ ❚ ❚

The material expires December 1, 2014.

��

serum specimens

manufacturing interferencespecifications andinvestigating discrepantresults caused by interferingsubstances

the material's expiration date

J�� /� ��4 � #��#� �

�$' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�;

��

��

��

��

�:

@��#��@�6��

@�6

Creatinine ❚

hCG ❚

Lactate dehydrogenase (LD) ❚

Phenytoin ❚

The material expires May 1, 2015.

Z��7��#��Z��6��

Z��6

Benzoylecgonine ❚

Delta-9-THC-COOH ❚

Opiates ❚

Propoxyphene ❚

The material expires May 1, 2015.

��

specimen (low level) and one5.0-mL liquid serum specimen(high level)

instrument sample probecarryover

��

(low and high levels)

instrument sample probecarryover

J�� /� ��4 � #��#� �

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �$)

��

��

��

��;

��

��

��

��

�:

��#��+�� !��+ �� ;K;��Use the same material that is sent in the CVL program to:

Each laboratory receives a Participant Summary, which includes readily available results.

�� ;��AK��5 ;��;�� @��#��

Chemistry, Lipid,Enzyme CalibrationVerification/Linearity VM

LN2VM LN2 110

Chemistry, Lipid,Enzyme CalibrationVerification/Linearity;All Beckman (except AU)and Vitros VM

LN2VM1 LN2BV 110

TDM CalibrationVerification/Linearity VM

LDM LN3 111

Ligand Assay CalibrationVerification/Linearity VM

LLM LN5 112

Urine Chemistry CalibrationVerification/Linearity VM

LUM LN6 112

��

5.0-mL liquid serumspecimens for basic chemistry,six 5.0-mL liquid serumspecimens for direct and totalbilirubin, seven 5.0-mL liquidserum specimens for lipids,and seven 5.0-mL liquidserum specimens for enzymes

serum specimens

serum specimens; appropriatefor most major instrumentsexcept for Siemens ADVIACentaur

urine specimens

��5��5��

6�� #��

�{��^��

��

� X�� V��

;��!��D��A3��+��*��D

9��=<O

9��X�=<O

9��=\=<O

9��4=<O

9��[=<O

<�

��

��

��

�

��

��

��

��

��

�

��

[� ��#� � �� 4��Hematology ..................................................................................................................................128Clinical Microscopy .......................................................................................................................134

@�] ��#� � New

Erythrocyte Sedimentation Rate, ALCOR (ESR3) .................................................................................128Clinical Microscopy for iCHEM Instruments (CMP1) ...........................................................................134Rupture of Fetal Membranes Testing (ROM1) ....................................................................................138Urinalysis Benchtop Reference Guide (UABRG)..................................................................................139

V�� #� �Rupture of Fetal Membranes (ROM)

See Survey ROM1.......................................................................................................................138

�� _ [� ��#�� 4��

`9�� #��

�� #��

��#� ��

�� ]��#��

�� #��9��

��]��#�� V�#�� ?��

��

�� #��

P��[��5�"5=�� [� ��#�Z�� 4��<��

[� ��#�

�$8 ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

<��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

3��<��<�5<��A�� +��A@+��

<� <��

Blood cell identification ❚ 10

Hematocrit ❚ ❚ 5

Hemoglobin ❚ ❚ 5

MCV, MCH, and MCHC ❚ ❚ 5

Platelet count ❚ ❚ 5

Red blood cell count ❚ ❚ 5

White blood cell count ❚ ❚ 5

3�� 3�� +��A@+��

3��


��+��@��@�5�@��5�@�$5�@�%

�� +��A@+��

�@� �@�� @�$ �@�%

All methods except the Sedimat 15�,Alifax�, and ALCOR

❚ 3

Sedimat 15 ❚ 3

Alifax ❚ 3

ALCOR ❚ 3

��

specimens

��

��

[� ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �$9

<�

��

��

��

�

��

��

��

��

��

�

��

<��"�� =<@�� =<�(=<�:5=<��(=<�:�

��A�� +��A@+��

=<�(=<�: =<��(=<�:�


Hematocrit ❚ ❚ 5

Hemoglobin ❚ ❚ 5

❚ ❚

❚ ❚

MCV, MCH, and MCHC ❚ ❚ 5

❚ ❚

Platelet count ❚ ❚ 5

Red blood cell count ❚ ❚ 5

White blood cell count ❚ ❚ 5

WBC differential ❚ ❚ 5

For method compatibility, see instrument matrix below.

<��"��5 �� 7

�� =<@��

=<� =<$ =<% =<' =<, =<9 =<�:

❚

❚

® ❚

❚

® ❚

® ❚

❚

❚

❚

❚

® ❚

❚

❚

❚

❚

❚

❚

��

[� ��#�

�%: ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

3��3�� +��A@+��

3�

Thin/thick blood film sets* ❚ 5

*This Survey will include corresponding thick films when available.

3��! �� "�� 3�"�� +��A@+��

3�"

❚ 1

❚ 5

❚

��

=�� "��<3=�� +��A@+��

<3=

❚

❚

��

Plasmodium,Babesia, Trypanosoma, and

��

��

[� ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%�

<�

��

��

��

�

��

��

��

��

��

�

��

<��+� <*�� +��A@+��

<*

❚

❚

❚

❚ 1

❚

��5��$5��%5��'��A��+� �� +��A@+��

�� $ ��% ��'

❚ 3

❚ 3

❚ 3

❚ 3

❚ ❚ 3

@��>�� @��@�@�� +��A@+��

@�@

❚ 3

��

��

��

[� ��#�

�%$ ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

��(�� +��A@+��

��

❚ 5

❚

WBC counts must be performed using a Nageotte chamber or by flow cytometry.

B��#��<�� +��A@+��

<��

❚

❚

�� B+�� 3�� B3�� +��A@+��

�B3�

❚ 5

;�� +��3��@��;�3@�� +��A@+��

;�3@

❚

❚

❚

❚ 10

��

��

��

specimens®

®

��

specimens

��

[� ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%%

<�

��

��

��

�

��

��

��

��

��

�

��

�7�� ;��+��3��@��<��

�� +��A@+��

�<��

WBC differential ❚ 2

Platelet estimate ❚ 2

RBC morphology ❚ 2

WBC morphology ❚ 2


Interpretive questions ❚ 1-2

��

annotated cells for identification

interpretive questions

��

include 10 annotated cells foridentification

technology

<��3��+��*��F<3�*G� 4�� N�� #

��

� V�� #�

� ��}�� o $��o $��J��o O� ��4�� 4��o K��o �� 4�# ^ ��o 4��# ��

� �� ] �� N��}�;�!Z�� ]��

��<3�*��@��#��D

�� 4��

�%' ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

�� Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

�� 5 ��

��A��

��

�+��A@+��

��

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

pH ❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚ 3

❚ ❚

❚ ❚

�� +��A@+��

��

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

��

��

�� 4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%)

<�

��

��

��

�

��

��

��

��

��

�

��

;�� 3��=�� ;3=�� +��A@+��

;3=

Total nucleated cells differential ❚ 2

Body fluid cell identification ❚ 10

��

cells for identification.

�� =�� K��>��=K�� +��A@+��

�=K

❚ 3

��3��=�� 3=�5 �3=$5 �3=%�� +��A@+��

�3=� �3=$ �3=%

❚ ❚ ❚ 2

❚ ❚ ❚ 2


��3��=��5 �� 7

�� 3=@��

�3=� �3=$ �3=%

❚

❚

❚

® 200 ❚

��

10 annotated cells foridentification

��

�

��

�� 4��

�%, ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

��Z�� Z��5 Z�� +��A@+��

Z�� Z��

❚

❚ ❚

❚

❚

❚ ❚

❚ ❚

�� 3=�5 Z��53�� +��A@+��

3=� Z�� 3��

❚

❚

❚

"��>��"@��A�� +��A@+��

"@�

❚

❚

=��=��=�=@�� +��A@+��

=�=@

❚

��

��

specimens

specimens

��

specimens

��

fat specimens

�� 4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%-

<�

��

��

��

�

��

��

��

��

��

�

��

=��<�� +��A@+��

��

❚ 2

*�� 6��3��*6�3�� +��A@+��

*6�3

❚ 3

Gastric pH ❚ 3

*��(,(�+��+��"�+�� *,�"@�� +��A@+��

*,�"@

❚ 2

<��=��<=�� +��A@+��

<=�

Cytopreparation differential ❚ 3

❚ 3

❚ 3

K�� 3��K3�� +��A@+��

K3�

❚ 3

��

fluid specimens

��

gastric specimens

��

hemolysate samples

��

fluid specimens

��

amniotic fluid specimens

performed on all hematology

�� 4��

�%8 ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

6�� 3��6�3�� +��A@+��

6�3

❚ 3

��=��6�� +��A@+��

�6��

❚ 3

@�� @��5 @��$��A�� +��A@+��

@�� @��$

❚ 3

❚ 3

��>�5 ��5 ��6�+�� +��6�� +��A@+��

��6

❚ 3

Z�� F��GA��Z��A�� +��A@+��

Z��

❚

❚

❚

For quantitative reporting, refer to Survey U, page 63.

��

specimens

��New

��

��

��

specimens

�� 4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �%9

<�

��

��

��

�

��

��

��

��

��

�

��

B��B�"�� +��A@+��

B�"

Worm identification ❚ 3

��

��Z��3��+��*��FZ�3�*G

� 6�� #��

� V�� #�

� $�#�� o X�� o X�� o X��

� �� [� �� @�� [� �� @�� ^ �� [

o 9�# ��o 4�� Z$}�#��

� �� ] �� N��;�� ]��

��Z�3�*��@��#��D

�� 4��

�': ��#�� #�� !"�� #��$�� #� �

<�

��

��

��

��

�

��

��

��

��

��

��

3��=��3��+��*��F3=3�*G� 6��}�� #��#��

��

� V�� #�� #��

� @�� o $��o K��o 4��o 4�� #��o K��#��o 4�� o �� o 4��# ��o 4�� \��#�

� �� ] �� N��}�;�!Z�� ]��

��3=3�*��@��#��D

��

��

��#�

��

��

��

�$

<�� 4��Andrology and Embryology ............................................................................................................142

@�] ��#� � New

Anti-Müllerian Hormone (AMH) .......................................................................................................143

�$ _ <��4��

`�� }��]��^

]�� #��

� ��

��{� �� }�� #��

6�� #� ��

^��#��#�� ]��

"�#�KD3��>��5�"5=�� $��

��#�� $��#�

�'$ ��#�� #�� !"�� #��$�� #� �

��

��

��#

��

�

��

�

�$


@�� @�5@��5 �;5@�5 @;5�@�

�� +��A@+��

@� @�� ; @� @; �@�

Sperm count & presence/absence(manual methods and CASA systems)

❚ 2

Sperm count & presence/absence(automated methods)

❚ 2

Postvasectomy sperm count &presence/absence

❚ 2

Sperm morphology ❚ 2

Sperm viability ❚ 2

Antisperm antibody IgG ❚ 2

@��5 ��+��5��;�� @��"5 @��"5@�$�"

�� +��A@+��

@��" @��" @�$�"

Sperm count ❚ 2

Sperm motility/forwardprogression

❚ 2

Sperm morphology ❚ 2

Sperm viability ❚ 2

��

scan and adjust the magnification of the whole slide image.

��

human sperm specimens

human sperm specimens

human sperm specimenswith counts appropriate forpostvasectomy testing

for staining

stained slides

specimens

��

video clips

each available as images

whole slide images powered® technology

each available as images

whole slide images powered

��#�� $��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �'%

��

��

��#�

��

��

��

�$

��3�� +��A@+��

��3

Embryo transfer and quality assessment❚ 4

K��5 @��M5MM5"M�� +��A@+��

M5MM "M

❚

❚

Androstenedione ❚

❚

Estradiol ❚

❚

❚

❚

❚

❚

Progesterone ❚

Prolactin ❚

❚

❚

❚

❚

��(�_�� <��<�� +��A@+��

��<

❚

��

clips

��


serum specimens (threeduplicate sets)


New��

serum specimens

��+��>��H�� ] ��4 � #�� ]�� #�� ^��{��]��#� ��#��

��#��!��+X� ��X#��

�� {��#��^�

� ��X��

� 3��(��=��>A��>��X �� {��

� K��&�@�H��X�� ]��Z� ��

� "��@��=��+��X�� # �� #��

� K��&�@��K��X�� {� �� #��{��

� 3��(��X��#]�� Z{� �� #��

��@��+V��D��D

��

��

��

��

�%

�� #��

@�] ��#� � New

[�� J�� 6�� ^�� =��O�;��!"+V�V�� Y�� ZK�� K@"��!N�

�% _ �� #��

`�� #�� #

��#��#�� #��6�� #��

<�� }��

]�� ]��}��

��#��#� ��

��6��]��

�� }��

��

�� #�

�� 6��

�� # ��]��#

�� ^��

� �� #��

��<��5�"5=�� #�� <��

�� #��

�', ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�%


��K��50:50 mixing study, PT and APTT

Activated partial thromboplastin time

Activated protein C resistance

Alpha-2-antiplasmin

Anti-beta-2-glycoprotein (IgG and IgM)

Antiphospholipid antibody(IgG, IgM, and IgA)

Antithrombin activity/antigen

Dilute prothrombin time

Dilute Russell’s viper venom time

Euglobulin test

Factors II, V, VII, VIII, IX, X, XI,XII, and XIII

Factor VIII assay

Fibrin monomer

Fibrinogen activity

Fibrinogen antigen

Heparin-induced thrombocytopenia (HIT)

High molecular weight kininogen

Kaolin-activated APTT

Kaolin clotting time

Lupus anticoagulant

Plasminogen activator inhibitor

Plasminogen activity/antigen

Prekallikrein

Protein C

Protein S

Prothrombin fragment 1.2

Prothrombin time

Reptilase time

Thrombin-antithrombin

Thrombin time

Tissue plasminogen activator

von Willebrand factor activity:- Collagen binding- Glycoprotein Ib binding- Ristocetin cofactor

von Willebrand factor antigen

von Willebrand multimer analysis

��5K��*K5 �*"=�� +��A@+��

�*K �*"=

Activated partial thromboplastin time ❚ 5

Fibrinogen ❚ 5

International normalized ratio (INR)* ❚ 5

Prothrombin time ❚ 5

D-dimer ❚ ❚ 2 per year

Fibrin(ogen) degradation programs,plasma

❚ ❚ 2 per year

Fibrin(ogen) degradation programs,serum

❚ ❚ 2 per year

*Participants reporting INR results will receive a special evaluation to assess the INR calculation.

��5�7��*�5 �*�]�� +��A@+��

�*�5�*�]

See analyte listing below ❚ 2

��CGL - Five 1.0-mL lyophilizedplasma specimens; threeshipments per year; one 1.0-mL lyophilized plasmaspecimen; one 1.0-mL serum specimen; two shipments peryear

specimen; one 1.0-mLlyophilized plasma specimen;two shipments per year

��

lyophilized plasma specimens(three duplicate vials for eachchallenge)

lyophilized plasma specimens(five duplicate vials for each challenge)

�� #��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �'-

��

��

��

��

�%

��@�� @��*@�5 �*@$5 �*@%5 �*@'5 �*@)5 �*@,

��A�� +��A@+��

��

�*@� �*@$ �*@% �*@' �*@)�*@,

Activated partialthromboplastin time*

2 2 3

International normalizedratio (INR)

2 3

Prothrombin time* 2 3

Lupus Anticoagulant and Mixing Studies Module

Dilute Russell’s viper venom time 2

Lupus anticoagulant(confirmation and screen)

2

50:50 mixing studies, PT and APTT 2

Thrombophilia Module

Activated protein Cresistance

2

Antithrombin (activity,antigen)

2

Protein C (activity, antigen) 2

Protein S (activity, freeantigen, total antigen)

2

von Willebrand Factor Antigen Module

Factor VIII assay 2

von Willebrand factor(antigen, activity, multimers)

2

Heparin Module

Heparin activities usingmethodologies including Anti Xa(unfractionated low molecularweight, and hybrid curve)

3

Thrombin time 3

Heparin-Induced Thrombocytopenia Module

Appropriate with methods suchas Gen-Probe Lifecodes PF4 IgGand Gen-Probe Lifecodes PF4Enhanced® assays

2

Appropriate with the AkersBiosciences, Inc. PIFA® Heparin/Platelet Factor 4 Rapid Assay

3

*Not appropriate for meeting regulatory requirements, see page 146.

��

of 2.0-mL lyophilized plasmaspecimens


specimens

lyophilized serum specimens

�� #��

�'8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�%

"��5=��75��#��7��

"3*�5 =��]5 �;3�� +��A@+��

"3*� =��] �;3�

Activated partial thromboplastin time* ❚ ❚ ❚ 3

Prothrombin time* ❚ ❚ ❚ 3

Thrombin time ❚ 3

Dabigatran ❚ 3

Fondaparinux ❚ 3

Rivaroxaban ❚ 3

*Not appropriate for meeting regulatory requirements, see page 146.

��#�� @�� 5 ��5��$5 ��%5 ��)

��A�� +��A@+��

�� $ ��% ��)

Helena Actalyke® ❚ 3

❚ 3

IL Gem® PCL ACT ❚ 3

IL Gem PCL ACT-LR ❚ 3

IL GEM PCL Plus ACT ❚ 3

IL GEM PCL Plus ACT-LR ❚ 3

ITC Hemochron® CA510/FTCA510 ❚ 3

ITC Hemochron P214/P215 ❚ 3

ITC Hemochron FTK-ACT ❚ 3

ITC Hemochron Jr. Signature ACT+ ❚ 3

ITC Hemochron Jr. SignatureACT-LR

❚ 3

i-STAT® Celite® and Kaolin ACT ❚ 3

Medtronic HemoTecACT/ACTII/ACT Plus HR ACT

❚ 3

Medtronic HemoTecACT/ACTII/ACT Plus LR ACT

❚ 3

Medtronic HemoTecACT/ACTII/ACT Plus R ACT

❚ 3

Medtronic HemoTec Hepcon HMS,HMS Plus HR ACT

❚ 3

Sienco Sonoclot® ❚ 3

��

specimens

��



lyophilized whole bloodspecimens


�� #��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �'9

��

��

��

��

�%

�� =��O�=5�=��A��+� �� +��A@+��

�= �=�

Platelet aggregation ❚ 2

PFA-100 ❚ 2

Helena Plateletworks® ❚ 2

*This Survey requires the draw of a normal donor sample.

�+��*��A��+� �� +��A@+��

��*

Thromboelastogram ❚ 2

��;��AK��K�%)5 K�%,5 K�%-

��

K�%) K�%, K�%- ��

Antithrombin activity ❚ 10%–130%

Protein C activity ❚ 10%–120%

Heparin, low molecular weight ❚ 0.1–2.0 U/mL

Heparin, unfractionated ❚ 0.1–2.0 U/mL

von Willebrand factor antigen ❚ 5%–140%

The LN35, LN36, and LN37 CVL programs meet the CAP Accreditation requirementsHEM.38009, 38010, and 38011.


��

vacuum tubes; two 10.0-mL plastic tubes; two vials of specified agonists

citrate vacuum tubes; two 10.0-mL plastic tubes

reporting requires thepurchase of an additional kit

��

blood specimens ™

Thromboelastograph® andROTEM® delta hemostasis

��

specimens

on dry ice

�� #��

�): ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�%

"("��;��AK�� K�'$

��

K�'$ ��

D-dimer ❚ 200-4,500 ng/mL FEU

B+��3��B�%5B�'5 B�,5B�95B��:

�� +��A@+��

��

B�% B�' B�, B�9 B��:

International normalized ratio (INR) 5 5 5 5 3

Prothrombin time 5 5 5 5 –


B+��3��5�� 7 ��

B�% B�' B�, B�9 B��:

Abbott CoaguSense™ ❚

❚

❚

ITC Hemochron Jr. Signature/Signature +, SignatureElite and Jr. II – Citrated cuvette

❚

ITC Hemochron Jr. Signature/Signature +, SignatureElite and Jr. II – Noncitrated cuvette

❚

IL GEM PCL, PCL Plus – Citrated ❚

IL GEM PCL, PCL Plus – Noncitrated ❚

i-STAT ❚

Roche CoaguChek XS Plus and XS Pro ❚

Roche CoaguCheck XS System ❚

New��

��

plasma specimens

lyophilized whole bloodspecimens

plasma specimens

lyophilized plasma specimens;two shipments per year

�� #��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �)�

��

��

��

��

�%

��

specimens

For use with the SimpliRED®

and Clearview® SimplifyD-dimer methods

��

with diluents

VerifyNow® System

to perform one assay; multipleassay reporting requires thepurchase of additional kits

��

urine specimens

��

two heparin vacuum tubes; two 3.5-mL plastic tubes;one vial of 0.2M CaCl2

Platelet Mapping® assay

B+��3��"("��B3""�� +��A@+��

B3""

D-dimer, qualitative ❚ 2

"��(@�� +��A@+��

��

Aspirin assay ❚ 3

PRU test ❚ 3

llb/llla assay ❚ 3

��("�+��+��7�� 3$�3]�� +��A@+��

�3]

11-dehydrothromboxane B2 ❚ 3

�� O�K�� +��A@+��

�K��

AA % aggregation/inhibition ❚ 2

ADP % aggregation/inhibition ❚ 2

*This Survey requires the draw of a normal donor sample.

�� #��

�)$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�%


��5;��;�� @��#��

146

��

shipments per year

��+��@��

3��>��!��+��+��#��

�� ]�� {�� ]��]�� }��]�� $ ��#� �� } �� {�� ]��9�� #� ]�� $��\�� #Z �� ^��#�� 4 ��

�!�!��I� Y��#�� 4 ��|�� #��

� � �� '��%�%�"�"��'"+�'%��+��!�

�� ^��

�$��#�$�� 6��#� �� }��!��#�� ]��}��

��@��@��@

��

��

��

��

�'

4��#�Bacteriology ..................................................................................................................................154Mycobacteriology ..........................................................................................................................165Mycology......................................................................................................................................166Parasitology ..................................................................................................................................169Virology........................................................................................................................................172Molecular Microbiology..................................................................................................................175Infectious Disease Serology .............................................................................................................180

@�] ��#� � New

Gram-Positive Blood Culture Panel for Molecular Multiplex Testing (GPBC) ...........................................160Candida Culture (F3) .....................................................................................................................167Parasitology Benchtop Reference Guide (PBRG) ................................................................................170Gastrointestinal Panel for Molecular Multiplex Testing (GIP) ................................................................179

V�� #� �C. trachomatis and N. gonorrhoeae by DNA Probe (HC5)

See Surveys HC6/HC6X .............................................................................................................176

�' _ 4��#�

`6��4��#��<��

�� #

� �� }��6��

��

�� J�� ]��

�}��]��]�� #��#��#��

�� #� ��]��

�� #��

*��BD��5�"5=�� 4��#� <��

= ��#�

�)' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

3��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

*��6��3��@��#��

" "' "$ "- "% "�

Bacterial identification ❚ ❚ ❚ ❚ ❚ ❚

Gram stain ❚ ❚ ❚ ❚ ❚

Antimicrobial susceptibility testing ❚ ❚ ❚ ❚

Bacterial antigen detection ❚ ❚

Participants must report five specimens for each mailing to meet CLIA requirements for thesubspecialty of bacteriology. See the following pages for more detailed information abouteach Survey.

3��"�� +��A@+��

"

Antimicrobial susceptibility testing ❚ 1 graded, 1 ungraded

Bacterial antigen detection ❚ 2

Bacterial identification ❚ 5

Gram stain ❚ 1

��Antigen detection challenges will be included in the following shipments:

C. difficile antigen/toxin and spinal fluid meningitis panelStreptococcus

C. difficile Streptococcus

��

culture

antigen detection from thefollowing:

Streptococcus

One 1.0-mL lyophilizedspecimen for spinal fluidmeningitis testing

One 0.5-mL lyophilizedspecimen for Clostridiumdifficile, for use with rapidor molecular testing methods

Refer to the Ordering Information provided for information regarding additional dangerous goods and related fees.

= ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �))

��

��

��

��

�'

3��>��3�� +��A@+��

3��

Antimicrobial susceptibility testing ❚ 31

��

program and participants will not return results to the CAP.

�7�� 3��"�]�� +��A@+��

"�]

Live organisms ❚ 2

��

perform complete identification and susceptibility of bacterial isolates including lesscommon or problematic bacteria

patterns

anaerobic bacteria in cultures containing multiple organisms

��

the year

��

to perform bacterialidentification and


= ��#�

�), ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

��3��+��3�

�� +��A@+��

�3�

❚ 6


��

competency assessment and an educational resource for microbiology laboratories.

bench, including direct observation, monitoring, recording, and reporting of testresults

*�5 �+��5��Z�� "�5"$5"%5"-

�� +��A@+��

"� "$ "% "-

Antimicrobialsusceptibilitytesting

❚ ❚ 1

Bacterialidentification ❚ ❚ ❚ ❚ 5

Gram stain ❚ ❚ ❚ 1

Culture source: Urine Cervical

level:

Presence orabsence of

Streptococ-cus deter-mination

Organismsidentified tothe extentof your

laboratory’sprotocol

Presence orabsence ofNeisseriagonor-rhoeae

determina-tion

Combinationof two throat

and threeurine culturespecimens

��

competency

��


= ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �)-

��

��

��

��

�'

K�� 3��"'�� +��A@+��

"'


Bacterial antigen detection ❚ 1

Bacterial identification ❚ 5

Gram stain ❚ 1

Culture source:

Presence or absence ofNeisseria gonorrhoeae

determination

Presence or absence ofStreptococcus

determination

Urine cultureOrganisms identifiedto the extent of yourlaboratory’s protocol

*�� @��")�� +��A@+��

")

Gram stain ❚ 5

��

specimen

two urine culture specimens,one susceptibility specimen,

and one bacterial antigen

A Streptococcus

��

unstained glass slides


= ��#�

�)8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

;�� *��@�� ;*@�5;*@$�� +��A@+��

;*@� ;*@$

❚ 3

❚ 3

��

technologists/technicians. Participants will assess the quality of specimens and stainsand will report artifacts and detailed gram-positive and gram-negative morphology.

technologists/technicians and microbiologists. Participants will receive challengingimages of sputum, body fluids, and other specimens to assess the quality, quantity, andtypical morphology of both gram-positive and gram-negative organisms appropriatefor the site.

scan and adjust magnification of the whole slide image.

16.

��@�� "��",�� +��A@+��

",

Group A Streptococcus antigen detection ❚ 5

��@�� "��5B��#�"9�� +��A@+��

"9

Streptococcus antigen detection ❚ 2

��

assess personnel competency

technology

��

��

= ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �)9

��

��

��

��

�'

*��3@��"��"8�� +��A@+��

"8

Group B Streptococcus detection ❚ 5

3��"��K3�@5@3�@�� +��A@+��

K3�@ @3�@

Legionella pneumophilaantigen detection

❚ 2

Streptococcus pneumoniaeantigen detection

❚ 2

3�� 3�@�� +��A@+��

3�@

❚ 2

3��5$ �� 3�@�

�� +��A@+��

3�@�

Staphylococcus aureus ❚ 3

��

molecular methods

��

specimens

��

of blood culture bottles

��

inoculation of blood culturebottles

rapid detection of S. aureus/

blood culture bottles


= ��#�

�,: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

*��(��#� 3�� 7��*�3�

�� +��A@+��

*�3�

Identification of gram-positive organismssuch as Staphylococcus, Streptococcus,Enterococcus, Listeria, and commonresistance mechanisms isolated frompositive blood culture bottles

❚ 3

Survey GPBC is not for the inoculation of blood culture bottles.

�� =�@<��5 ��$5 ��%5 ��'�� +��A@+��

�� $ ��% ��'

Staphylococcus ❚ 3

Yeast ❚ 3

Enterococcus ❚ 3

❚ 3

�% �� +��A@+��

��

Campylobacter ❚ 2

New��

positive blood culture fluidspecimens

molecular multiplex panels

��

of blood culture bottles

��

culture-based testing, andmolecular methods


= ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �,�

��

��

��

��

�'

��%�� %��<��5<�%�� +��A@+��

<�� <�%

Antigen detection (DFA) ❚ 5

Antigen detection (EIA) ❚ 5

=��K�� =K�� +��A@+��

=K��

❚ 3

&�� '@��<�@�� +��A@+��

<�@

Helicobacter pylori antigen detection ❚ 2

K��7��K�]�� +��A@+��

K�]

Live organisms ❚ 3

��

the College of American Pathologists, the Centers for Disease Control and Prevention

live organisms that either exhibit characteristics of bioterrorism agents or demonstrateepidemiologic importance and will be expected to respond following Laboratory Response

Bacillus anthracis, Yersinia pestis, Francisella tularensis, and Brucella abortus that have been

��

specimens; for the detection ofchlamydial elementary bodies

specimens

��

specimens

��

��

customers due to UnitedStates export law restrictions


= ��#�

�,$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

��+��(�� $ �� @��@

�� +��A@+��

��@

❚ 2

��+��(�� $ �� @��@)

�� +��A@+��

��@)

MRSA detection ❚ 5

��Z��Z�� +��A@+��

�Z�

Urease ❚ 3

@��+��@�5@��A�� +��A@+��

@� @��

Adenovirus 40/41 ❚ 2

C. difficile ❚ 2

Rotavirus ❚ 2

Shiga toxin ❚ 2

Norovirus ❚ 1

��

and culture-based testing

��

and culture-based testing

��

biopsy specimens

®

��

specimens; for use with rapidor molecular testing methods;not available to internationalcustomers due to UnitedStates export law restrictions

specimen


= ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �,%

��

��

��

��

�'

@+��7��@�� +��A@+��

@�

Shiga toxin ❚ 2

3��;��3;�� +��A@+��

3;

❚ 3

;�� @��;@5;@�� +��A@+��

;@ ;@�

Candida sp. ❚ 5

Gardnerella vaginalis ❚ 5

Trichomonas vaginalis ❚ ❚ 5

��

testing only; not compatiblewith culture methods,cytotoxicity assays, or PCR

customers due to UnitedStates export law restrictions

��

®

��

technology™ VP III probe

detection method; threeshipments per year

Trichomonas®

Trichomonas vaginalismethods; two shipments per year


= ��#�

�,' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

;�� @��5;�� *�� @��;@$�� +��A@+��

;@$

smears❚ 3

��


16.

;��(�� ;�� +��A@+��

;��

Vancomycin-resistant Enterococcus❚ 2

��

technology

��

methods and culture-basedtesting


4�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �,)

��

��

��

��

�'


�� +��A@+��

�

Acid-fast smear ❚ 1

Antimycobacterial susceptibility testing ❚ 1 graded, 1 ungraded

Mycobacterial identification* ❚ 5

*This procedure requires identification of Mycobacterium tuberculosis.

K�� +��A@+��

��

Acid-fast smear ❚ 5

Mycobacterial culture ❚ 5

��

isolates and one specimenfor performing an acid-fastbacillus smear

performed by culture ormolecular methods

��

for acid-fast smears and/orfor the determination of thepresence or absence of acid-fast bacillus by culture


4��#�

�,, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'


��=�� +��A@+��

=

Antifungal susceptibility testing ❚ 1

Cryptococcal antigen detection ❚ 2 per year

Mold and yeast identification ❚ 5

M��=�� +��A@+��

=�

Antifungal susceptibility testing ❚ 1

Cryptococcal antigen detection ❚ 2 per year

Yeast identification ❚ 5

��

simulated cerebrospinal

mold may be performed byculture or molecular methods

��

simulated cerebrospinal

be performed by culture ormolecular methods


4��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �,-

��

��

��

��

�'

�� =%�� +��A@+��

=%

Yeast identification ❚ 5

*��=*�K�� +��A@+��

=*�K

Galactomannan ❚ 3

=��@��=@�� +��A@+��

=@��

Serological detection of specificfungal antibodies

❚ 3

=��@��=@�� +��A@+��

=@�

KOH preparation/calcofluor white ❚ 3

��

duplicate)

Candida speciesonly

Candidaspecies may be performed byculture, molecular, and rapidmethods

��

Bio-Rad Platelia™

��

methods

of antibodies to Aspergillus,Blastomyces, Coccidiodes,and Histoplasma

��

New

4��#�

�,8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

��>��"�� +��A@+��

��"

India Ink ❚ 2

��% ��(�� "��5 ��$5 ��%5 ��'

�� +��A@+��

�� $ ��% ��'

PCP – Calcofluor white stain ❚ 3

PCP – DFA stain ❚ 3

PCP – Giemsa stain ❚ 3

PCP – GMS stain ❚ 3

��

��

��

��3��+��*��F�3�*G� 4�� +��# ��

��

� V�� #�� #��#�� #��

� �� #�� #��

� ��}�� o �� K�^��\��#�o 4��|��@ ��]��[� ��[�� o V��\��#�o V�� o ��#��o V� �� 4��

� �� ] �� ;��}�+�� ]��

��3�*��@��#��D

� � ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �,9

��

��

��

��

�'


��5�%5�'5�)��

� �% �' �)

Fecal suspension (wet mount) ❚ ❚ ❚

Fecal suspension (Giardia and/orCryptosporidium immunoassay and ❚ ❚ ❚ ❚

Giemsa-stained blood smear ❚

Preserved slide (for permanent stain) ❚ ❚

��

as a preservative.

��

blood and tissue parasiteidentification; preserved slidesfor permanent stain; 0.75-mLfecal suspensions for directwet mount examination,photographs, and/or onlineimages; two 0.75-mL fecalsuspensions for Giardiaand/or Cryptosporidiumimmunoassay testing andmodified acid-fast stain

suspensions for directwet mount examination,photographs, and/or onlineimages; one 0.75-mL fecalsuspension for Giardiaand/or Crytosporidiumimmunoassay testing andmodified acid-fast stain

of 0.75-mL fecal suspensionsfor direct wet mountexamination, preservedslides for permanent stain,photographs, and/or onlineimages; one 0.75-mL fecalsuspension for Giardiaand/or Crytosporidiumimmunoassay testing andmodified acid-fast stain

suspensions for Giardiaand/or Cryptosporidiumimmunoassay testing andmodified acid-fast stain

� � ��#�

�-: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

3��3�� +��A@+��

3�

Thin/thick blood film sets* ❚ 5

*This Survey will include corresponding thick films when available.

�� K�� +��A@+��

��K

Rapid malaria detection ❚ 3

��

Plasmodium,Babesia, Trypanosoma, and

��

��3��+��*��F�3�*G� 4�� +��

��

� V�� #��#�� #��

� �� #��#��#�� #��

� �� #�� ]��

� \�� o =�� o J�� o J�� [��o 4�� o 4 ��|��

�� ] �� ;��+�� ]��

��3�*��@��#��D

� � ��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �-�

��

��

��

��

�'

��>�5 ��5 ��6�+�� +��6�� +��A@+��

��6

Tick, mite, and arthropod identification ❚ 3

B��B�"�� +��A@+��

B�"

Worm identification ❚ 3

��

��

�+��>��+��!��+��)��@�

9��'(�)�� ^��#��#� �#�� 6�^��

� �� ^��

� ��]� �� ^ �� #� ��^

� <�� ]��

��#��)��5��5��5��V��D��D

SM

Y��#�� 4�� 4��#��6��#

�-$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

Do youperformmoleculartesting onChlamydiaor GC only?

Do youperformnucleic acidamplificationother thanGC?

Do youperformviral loadtestingonly?

Do youperformmolecularmultiplexing?

Do you perform any of the followingvirology testing?■ virology culture■ virology antigen testing

Select fromthefollowingSurveys:

■ HC6,HC6XChlamydia/GCNucleic AcidAmplification

Select fromthefollowingSurveys:■ IDO, ID1,

ID1T, ID2Nucleic AcidAmplification

■ BSTS,BSTEBacterialStrain Typing

Select fromthefollowingSurveys:■ HIV,

HV2HIV Viral Load

■ HCVN,HCV2,HBVL,HBVL5HepatitisViral Load

■ VLS,VLS2Viral Load

Select fromthefollowingSurveys:■ IDR

InfectiousDiseaseRespiratoryPanel

■ GIPGastro -intestinalPanel

SelectVR1

SelectVR2

SelectVR4

SelectHC2

SelectHC4

For Comprehensive VirologyCulture Testing

For Virology AntigenTesting by Immunofluorescence

For Virology Antigen by EIA orLatex Agglutination

For Herpes Simplex VirusAntigen Detection by DFA

For Herpes Simplex VirusCulture Testing

YesYes Yes Yes Yes

;��

;��

the Customer Contact Center at 800-323-4040 or 847-832-7000 option 1.

Y��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �-%

��

��

��

��

�'

;��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

;�� ;�� +��A@+��

;��

Chlamydia trachomatis culture ❚ 1

Viral isolation/identification ❚ 5

Educational challenge ❚ 1 per year

;�� "��F"=�G ;�$��A�� +��A@+��

;�$ � 3 �

Adenovirus antigen ❚ 1 1

Cytomegalovirus antigen ❚ 1 1

Herpes simplex virus (HSV) antigen ❚ 1 1

Influenza A antigen ❚ 1 1

Influenza B antigen ❚ 1

Parainfluenza antigen ❚ 1 1

Respiratory syncytial virus (RSV)antigen ❚ 1 1

Varicella-zoster antigen ❚ 1 1

Educational challenge ❚ 1

��

viral culture and one 0.5-mL specimen for Chlamydiatrachomatis culture

��


�-' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

Y��#�

;�� "��F��(�=G ;�'�� +��A@+��

;�'

Adenovirus (Not 40/41) antigen ❚ 5

Influenza A antigen ❚ 5

Influenza B antigen ❚ 5

Respiratory syncytial virus (RSV)antigen ❚ 5

Rotavirus antigen ❚ 5

<��@��7;��<�$5<�'�� +��A@+��

<�$ <�'O

Antigen detection (DFA) ❚ 5Culture ❚ 5

* The biohazard warning applies to Survey HC4.

��

immunoassay and/or latexagglutination methods

��

specimens

suspension specimens


4�� 4��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �-)

��

��

��

��

�'


<�� ;�� K��<�;�5 <�;$5<3;K5<3;K)

��A�� +��A@+��

��

<�;�5<�;$ <3;K <3;K)

1

1

5

2 5

<�;;�� K��<�;5<;$5<�;*�� +��A@+��

<�;5<;$ <�;*

❚ 5

❚ 1

;�� K��;K@5;K@$��A�� +��A@+��

;K@ ;K@$

❚ ❚ 2

❚ ❚ 2

❚ ❚ 2

Adenovirus viral load ❚ 2

❚ 2

��

plasma specimens

plasma specimens

specimens

specimens

��

specimens

specimens

specimen

��

plasma specimens; twoshipments per year

plasma specimens; three shipments per year

4�� 4��#�

�-, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

�* �� %�� +* � � �� <�,5 <�,]�� +��A@+��

<�,5<�,]

Nucleic acid amplification (NAA) ❚ 5

<��#�� <�;�� +��A@+��

<�;

❚ 2

240.

3��@�� 3@��53@�@�� +��A@+��

3@�� 3@�@

Enterococcus ❚ 2Staphylococcus ❚ 2

��

and two 1.0-mL simulatedurine specimens

specimens; two simulated

use each swab to performboth C. trachomatis and N.gonorrhoeae testing

��

specimens contained inDigene transport media

only

��


4�� 4��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �--

��

��

��

��

�'

�� 5 6��"6��A�� +��A@+��

�"6

Bordetella pertussis/parapertussis ❚ 1

Legionella pneumophila/Chlamydophila pneumoniae

❚ 1

Staphylococcus aureus❚ 1

❚ 1

Mycobacterium tuberculosis ❚ 1

Mycoplasma pneumoniae ❚ 1

Vancomycin-resistant Enterococcus ❚ 1

�� 5 ;��"�5�"�� +��A@+��

�"� �"��

Cytomegalovirus ❚ 1

Enterovirus ❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

Varicella-zoster virus ❚ 1

❚ 1

JC virus ❚ 1

��

simulated clinical isolatespecimens

��

specimens

specimens


4�� 4��#�

�-8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

�� 5 ��"$�� +��A@+��

�"$

Adenovirus ❚ 1

Coronavirus/Rhinovirus* ❚ 1

❚ 1

Influenza virus* ❚ 1

Parainfluenza virus ❚ 1

Respiratory syncytial virus ❚ 1

*Coronavirus/Rhinovirus and influenza virus will be included in the following shipments:

�� "�� 7 ��"�

�� +��A@+��

�"�

Adenovirus ❚ 5

❚ 5

Influenza A ❚ 5

❚ 5

Parainfluenza ❚ 5

Respiratory syncytial virus ❚ 5

Rhinovirus/Enterovirus ❚ 5

❚ 1

��

��

multiplex panel users

4�� 4��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �-9

��

��

��

��

�'

*�� 7 �� *��

�� +��A@+��

*��

Campylobacter ❚ 3

Clostridium difficile, toxin A/B ❚ 3

Cryptosporidium ❚ 3

Enterotoxigenic E. coli (ETEC) LT/ST ❚ 3

Escherichia coli 0157 ❚ 3

Giardia ❚ 3

Norovirus GI/GII ❚ 3

Rotavirus A ❚ 3

Salmonella ❚ 3

Shiga-like toxin producingE. coli (STEC) stx1/stx2

❚ 3

Shigella ❚ 3

��

export law restrictions

New

��@��7�+��#��#��#��

��!��D

6��#�� #��~�� $}�� #�<�#�� ]�� 6��J�� #��#��]�� #�� K �� #�� |�� #�� ]�� }�� #��V � �]�� ]��]�� #�]��

;��D��A@��7�+��D

J��V�� #�

�8: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�'

�� "��@��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

�� "��@��;�%5;�%�� +��A@+��

;�% ;�%�

total antibodies❚ 1

❚ 1

Helicobacter pyloritotal antibodies

❚ 1

❚ 1

Mycoplasma pneumoniaetotal antibodies

❚ 1

❚ 1

antibody❚ 1

Toxoplasma gondiitotal antibodies

❚ 1

total antibodies❚ 1

��>(�� "��"�� +��A@+��

��"

organisms❚ 3

��


lyophilized plasma specimen

��

of antibodies to Borreliaburgdorferi, Babesiamicroti, and Anaplasmaphagocytophilum

��

��

��

��

�

=��!

��

��

��

�)

J��#� ��\��] ��Immunology...................................................................................................................................182Flow Cytometry..............................................................................................................................189

@�] ��#� � New

Antifilamentous Actin IgG Antibody (FCN) ........................................................................................184

�) _ J��#�� \��]��

`6��

�� #��6Z$/��#��

�� ]��^��}�� #��]��

�� #��

�� 6�� #��

�� 6Z$/��

#� ��

]�� ]��#� ��

� �� #�

�� #��

��]�� ~�

�� #��6�� #�

�� #��

��

�� #��

@��PD*��5�"5=�� V� #�� J��#� <��

J��#�

�8$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

��

=

��!

��

��

��

�

�)


��5 �@65 ��5 <�*5 ��5 �=A�=]5�Z3A�Z3]5�K

�� +��A@+��

�� @6 �� <�* �� =A�=]

�Z3A�Z3] �K

Antinuclear antibody(ANA)* ❚ ❚ 5

Antistreptolysin O (ASO)* ❚ ❚ 5

C-reactive protein(qualitative/quantitative)

❚ ❚ 2

hCG, serum (qualitative/quantitative) ❚ ❚ 5

Infectious mononucleosis ❚ ❚ 5

Rheumatoid factor* ❚ ❚ 5

Rubella (IgG)* ❚ ❚ 5

*Antinuclear antibody, Antistreptolysin O, Rheumatoid factor, and Rubella are regulatedanalytes and are graded for both qualitative and quantitative methods. Semiquantitativeand/or titer results for these analytes are ungraded/educational in this Survey and do notmeet regulatory requirements.

��5*�� *A�*]�� +��A@+��

�*A�*]

Alpha1-antitrypsin ❚ 5

Complement C3 ❚ 5

Complement C4 ❚ 5

Haptoglobin ❚ 5

IgA ❚ 5

IgE ❚ 5

IgG ❚ 5

IgM ❚ 5

Total kappa/lambda ratio ❚ 5

��

liquid serum specimens

specimens

serum specimens; not appropriate for high-

methods

specimens

in duplicate

specimens in duplicate

��

specimens

in duplicate

J��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �8%

��

��

��

��

�

=��!

��

��

��

�)

��5@��`��@��5K��`�� &* �� * ��@$5@'5@)

�� +��A@+��

@$ @' @) � 3 �

❚ 1 1

❚ ❚ 1 1 1

❚ 1 1

❚ 1 1 1

❚ 1 1

❚ 1 1 1

❚ 1 1 1

❚ 1 1 1

❚ 1 1 1

❚ 1 1

❚ 1 1

❚ 1 1

❚ ❚ 1 1 1

❚ ❚ 1 1 1

❚ ❚ 1 1 1

Ceruloplasmin ❚ ❚ 1 1

Haptoglobin ❚ ❚ 1 1

Helicobacter pylori, ❚ ❚

❚

12

12

❚ ❚ 1 1 1

❚ ❚ 1 1

❚ ❚ 1 1

❚ ❚ 1 1

Total kappa/lambda ratio ❚ ❚ 1 1

Transferrin ❚ ❚ 1 1

�� 5 B��#��B�� +��A@+��

��B

❚

��

serum specimens

specimens

per year

��

specimens

J��#�

�8' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

��

=

��!

��

��

��

�

�)

��*��=��

�� +��A@+��

=��

❚

��+�� <�� +��A@+��

�<�

❚

��+�� $��<�� +��A@+��

<

❚ 2

�� +��A@+��

��

❚ 2

��+��+�� K�� +��A@+��

��K

❚

❚

New��

specimens

��

specimens

��

��

��

serum specimens

J��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �8)

��

��

��

��

�

=��!

��

��

��

�)

��+��+��@�� +��A@+��

��@

❚

❚

❚

��($�� %�� "��@�� +��A@+��

�@�

Saccharomyces cerevisiae❚ 2

�� @��@�� +��A@+��

��@ � 3

❚ 2

❚ 2

❚ 2

❚ 2

❚ 2

❚ 2

❚ 2

��

serum specimens

��

��

appropriate number of

J��#�

�8, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

��

=

��!

��

��

��

�

�)

��(�� F��(��G��

�� +��A@+��

��

❚ 2

��>��U�� +��A@+��

��U�

❚

❚

❚

❚

❚

❚

❚

❚

"�� @��A�� +��A@+��

@�

❚ 5

IgE, total ❚ 5

❚ 5

❚ 25

❚ 2 per year

<��+(@��#��A�� (��#�� +�� +��A@+��

+��

High-sensitivity/Cardiac C-reactiveprotein

❚

��

��

��

as less frequently tested allergens

®

testing

��

specimens

J��#�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �8-

��

��

��

��

�

=��!

��

��

��

�)

K�#��(U��F��(KU�G KU�� +��A@+��

KU�

❚ 2

�* �� (@��"��&=�� +��A@+��

&=

M. tuberculosis ❚ 2

�+��"��@��@��"@�� +��A@+��

�"@

❚ 1

❚ 1

@��+�� @��*�� +��A@+��

*

Syphilis ❚ 5

Use with VDRL, RPR, MHA-TP/TP-PA/PK-TP, EIA, CMIA, multiplex flow immunoassay,FTA-ABS, and USR methods. Laboratories performing syphilis serology on CSF specimensmay also use this Survey.

��

��

specimens and one

?

only

��

��

J��#�

�88 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

��

=

��!

��

��

��

�

�)

�� <��<):�� +��A@+��

�<):

❚ 2

❚ 2

;�� ;�� +��A@+��

;

Viscosity ❚ 2

@��=��K��+� �+��@=K�� +��A@+��

@=K�

❚

❚

chain ratio and ratio interpretation❚

��

serum specimens

��

specimens

��

specimens

\��]��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �89

��

��

��

��

�

=��!

��

��

��

�)

=��! ��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

=��! �� =K5=K�5 =K$�� +��A@+��

=K =K� =K$

❚ ❚

❚ ❚

This Survey is not appropriate for hematology analyzers with monoclonal antibody analysis.

=��! ��X��+��+��[�� K��>��AK��+��

=K%5 =K%�"�� +��A@+��

=K% =K%�"

❚ 2

❚ 2

��™

��

blood specimens

specimens and one

and cell cycle analysis

specimens

��

blood specimens and/or celllines simulating leukemia/lymphoma; images of tissue

or peripheral blood smears

and ungated list mode files;

gating strategies and interpretantibody staining patterns;

�

�

�

\��]��

�9: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

��

=

��!

��

��

��

�

�)

=��! ��5 �"%'d=K'�� +��A@+��

=K'

❚ 2

=��! ��5 �� 6��=K)�� +��A@+��

=K)

❚ 2

Survey FL5 is for laboratories that receive flow cytometry analyses from referring laboratories toperform the interpretation of patient results.

=��! �� f��+��+��[�� 7��

<��<��A�� +��A@+��

��<

❚ 2

❚ 2

��Guidelines for the

Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and RelatedDisorders by Flow Cytometry

=�� "��<3=�� +��A@+��

<3=

❚ 2

❚ 2

��

��

or peripheral blood smears

��

��

blood specimens

quantitation

\��]��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �9�

��

��

��

��

�

=��!

��

��

��

�)

��=��! �� ;��5 �"��=�;�� +��A@+��

�=�;�

CD1a ❚ 1

Survey RFAV1 does not meet the regulatory requirements for proficiency testing.

��This Survey meets the CAP Accreditation Checklist item FLO.23737, which requiressemiannual testing of antigens.

^��(-:�� =��! �� ^��-:�� +��A@+��

^��-:

Zeta chain-associated protein kinase 70 ❚ 3

��This Survey tests for intracellular ZAP-70 staining of cell lines co-stained with panT- and B-cell markers. It allows for assessment of the laboratory’s staining techniques andthe antibody clone used for ZAP-70 detection.

��

specimen

��

specimens

RFVA2 has beendiscontinued as ofOctober 1, 2013

��T6�� <� ��<�?�� #� �� #��#�� <��

� \ �� #� �� #��{��

� [��#�� #�� ]�� {��

� V��#�� ]��~��

6��#��<�� %;��#��]�� ~�� {� �� #� ��]�� #��^��{�� <�� {�� #��}�� #��}��]��~�� #��# ��

��D^��>D ��"�� ,��$

��(��V��D��H��Y��D

`6��<� ��<�� 9��]��^��^]��^��

K��"��

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

6� �� 4�� Y�� 4 �^�� #� 6��#Transfusion Medicine......................................................................................................................194Viral Markers ................................................................................................................................201Parentage Testing ..........................................................................................................................204

@�] ��#� � New

Transfusion Medicine Automated, Educational Challenges (JATE1) ………………………..…………………195Transfusion Medicine Automated, Electronic Crossmatch (EXM2)………………………..……………………197Bacterial Detection in Platelets, Rapid (BDPV, BDPV5) .............. ………………………..……………………198Red Cell Antigen Genotyping (RAG) ...................................... ………………………..……………………200

V�� #� �Anti-HIV-1, Rapid Methods (RHIV and RHIVW)

See Survey AHIV and AHIVW............................................. ………………………..……………………202

�, 6� ��4��Y�� 4 �^�� #��6��#

`6��6� ��4��<��

��}��

��|�� #��

]��#��#��#� ��

��

��

P��K��*��+��5�"5=�� 6� ��4��<��

6� ��4��

�9' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

�� Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��5��+��#�AK��P5P�� +��A@+��

P P�

ABO grouping ❚ ❚ 5

Rh typing ❚ ❚ 5

Antibody detection ❚ 5

Antibody identification ❚ 5

Compatibility testing ❚ 5

Red blood cell antigen detection ❚ 1

�� P�� +��A@+��

P��

ABO grouping ❚ 5

Antibody detection ❚ 5

Antibody identification ❚ 5

Compatibility testing ❚ 5

Rh typing ❚ 5

�� +��P��A�� +��A@+��

P��


��

��

��

6� ��4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �9)

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

�� 5��+��P��

��A�� +��A@+��

P��

Eduational challenge ❚ 1

�7�� 7��

�� +��A@+��

��

Expanded challenges ❚

��

��New

��

challenge and one wetchallenge consisting of a

6� ��4��

�9, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

�� X��+��#��

�� +��A@+��

��

❚

❚

❚

❚

❚

Survey TMCA does not meet the regulatory requirements for proficiency testing.

�� X"�� "

�� +��A@+��

��"

❚

Survey TMCAD does not meet the regulatory requirements for proficiency testing.

�� X=�� &�� =

�� +��A@+��

��=

❚

❚

Survey TMCAF does not meet the regulatory requirements for proficiency testing.

��

suspensions

blood cell suspension

��

blood cell suspensions

��

6� ��4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �9-

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

�� 5��+�]�� +��A@+��

�]�

❚

��

�� 5��+�]�$

�� +��A@+��

�]�$

❚

��

�� 3�5 �3��5 �3�$��A�� +��A@+��

�3� �3�� 3�$

❚ ❚ 1

❚ ❚ 1

��


��


New

��

6� ��4��

�98 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

3��"�� 3"�53"�)�� +��A@+��

��

3"� 3"�)

Bacterial culture and detection systems 5

��

3��"��5 ��3"�;53"�;)

�� +��A@+��

��

3"�; 3"�;)

Rapid immunoassay 5

��

��

��New

6� ��4��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # �99

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

��3��@�� 3�5 @�� +��A@+��

�3� @��

❚

❚ ❚

❚

❚ ❚

❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

❚ ❚

��

"�� "�� +��A@+��

"��

❚

��

��

cell suspensions

6� ��4��

$:: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

��@��#��KZ�� +��A@+��

�KZ

❚

=�� "��<3=�� +��A@+��

<3=

❚

❚

�� @��@�� +��A@+��

�@

❚

❚

A low concentration of sodium azide may be present in the specimens and may affectlymphocytotoxicity methods.

��3�� *��*

�� +��A@+��

��*

❚

��(�� +��A@+��

��

❚ 5

❚

WBC counts must be performed using a Nageotte chamber or by flow cytometry.

��

cell suspensions

��

��

New��

��

Y�� 4 �^��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $:�

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

;�� >��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

;�� >��X@��;�� +��A@+��

;��

❚ 5

Anti-HBc, total ❚ 5

❚ 5

❚ 5

Anti-HIV-1 ❚ 5

Anti-HIV-1/2 ❚ 5

❚ 5

HBsAg ❚ 5

Do not use Survey VM1 with rapid anti-HCV, anti-HIV-1, or anti-HIV-1/2 kits. See page 202 forSurveys appropriate for rapid methods.

;�� >��X@��$;�$�� +��A@+��

;�$

❚ 5

HBeAg ❚ 5

;�� >��X@��%;�%�� +��A@+��

;�%

❚

❚

❚

��

��

��

Y�� 4 �^��

$:$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

;�� >��X@��';�'�� +��A@+��

;�'

Trypanosoma cruzi ❚

;�� >��X@��);�)�� +��A@+��

;�)

❚ 5

Anti-HBc, IgM ❚ 5

;�� >��X@��,;�,�� +��A@+��

;�,

Anti-HIV-1/2, ❚ 5

��(<�; �<�;5�<�;B��A�� +��A@+��

�<�; �<�;B

Anti-HIV-1, Anti-HIV-2, Anti-HIV-1/2 ❚ 5

❚

��(<�;5 ��+��<�;B��A�� +��A@+��

�<�;B

❚

��

��

��

��

��

Y�� 4 �^��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $:%

��

��

�

��

�5;

��

��>�

��5��

��

��

��

��

��

�,

�� +��A@+��

��

HBV ❚ 5

HCV ❚ 5

HIV ❚ 5

West Nile virus ❚ 5

��

��&��R��X��>�H��#��#��

�� ]�� ~�{� �� #��$��#�� ^�� ]�� ]�� ]��

&��I�D !N!'*�| �^��#�

$D /4��J�� <� �

%D <��

'D J�� #

)D V��

,D /� ��4 �� V��

-D 4 � #��<��]

@��D��A&��D

� �� #��6��#

$:' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�

��

�5;

��

��>

��

5��

�

��

��

��

��

��

�

�,

��

��A��+��A��=��A�� +��A@+��

��A��=

❚ 1

❚

��

challenge

challenge

<��

��

��

��

��

�-

�- _ [��

`� ��#��]��

��#�]��^�]�� #��

��#�� ~��

��#��#� ��

$��#��#��#��

��#� ��

��

��+��3DF3��G��5�"5�+"5=�� [�� ZJ��6��#<��

[��

$:, ��#�� #�� !"�� #��$�� #� �

<��

��

��

��

��

��

�-

<��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

For laboratories conducting BOTH Class I and Class II HLA testing, see next page.

<K��+��5��@��5��F��G�]�35�]��5�]��

�� +��A@+��

�]�3 �]�� ]��

Crossmatching ❚ ❚ 8

Antibody screen ❚ ❚ ❚ 4

Antibody identification ❚ ❚ ❚ 4

<K��+��5��@��5��F��G�]$35�]$�5�]$�

�� +��A@+��

�]$3 �]$� �]$�

Crossmatching ❚ ❚ 4

Antibody screen ❚ ❚ ❚ 2

Antibody identification ❚ ❚ ❚ 2

��

plasma specimens; two6

blood lymphocyte specimens



��





[��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $:-

<��

��

��

��

��

�-

<K��+��5��@��5��F��A��G��]35�]�

�� @��#��

�]3 �]�

Crossmatching, antibody screen, andantibody identification, Class I

❚

Crossmatching, antibody screen, andantibody identification, Class II

❚

Crossmatching, antibody screen, andantibody identification, Class I

❚

Crossmatching, antibody screen, andantibody identification, Class II

❚

*See page 206 for specimen and analyte information.

<K��K5 "K5"�K�� +��A@+��

�K "K "�K

❚ ❚

(Class II)❚ ❚

<K�@��F�� A��G �365 <K�@5 <K�@�

�� +��A@+��

�36 <K�@ <K�@�

ABO grouping (includes A subtyping) ❚

❚

❚

��

plasma specimens, two

lymphocyte specimens; Class

peripheral blood lymphocytespecimens

plasma specimens, two

lymphocyte specimens; Class

peripheral blood lymphocytespecimens

��

��

peripheral blood lymphocytes

peripheral blood lymphocytes

[��

$:8 ��#�� #�� !"�� #��$�� #� �

<��

��

��

��

��

��

�-

<K�(3$-��3$-�� +��A@+��

3$-

❚

�� 3�5 �3��5 �3�$��A�� +��A@+��

�3� �3�� 3�$

❚ ❚

❚ ❚

�� +��A@+��

��

❚

��

��

one corresponding titer cell

titer with one corresponding



��

specimens

and laboratories monitoringchimerism after organtransplantation

*�

��

��

�

��

��

��

��+

��

��

�8

O�� 4�� #�Cytogenetics..................................................................................................................................210Biochemical and Molecular Genetics................................................................................................213Molecular Oncology – Solid Tumors.................................................................................................219Molecular Oncology – Hematologic.................................................................................................222

@�] ��#� � New

CAP/ACMG Alpha-1 Antitrypsin (SERPINA1) Genotyping (AAT).........................................................214CAP/ACMG Apolipoprotein E Genotyping (APOE) ...........................................................................214CAP/ACMG Hemoglobinopathies, Molecular Methods (HGM)...........................................................214Pharmacogenetics, IL28B (PGx1) .....................................................................................................217Pharmacogenetics, HLA-B*5701 (PGx2)...........................................................................................217CAP/ACMG Rett Syndrome (MECP2) Genotyping (RETT) ...................................................................217CAP/ACMG Thrombophilia Mutations (TPM) ....................................................................................217Red Blood Cell Antigen Genotyping (RAG) .......................................................................................218Neoplastic Cellularity (NEO) ...........................................................................................................220Multigene Tumor Panel (MTP) ..........................................................................................................221

@�] �� CAP/ACMG Molecular Genetics (MGL1) .........................................................................................215

Plasminogen Activator Inhibitor (PAI)-1

�8 _ O�� 4�� #�

`6��Z��4O��#��<��

��{� ��#��#��#

�� #��

�� ^��{��

�� ]�� #��#��

�� #��

U��"D��+��5�"5=�� Z��4O��#��<��

��#��

$�: ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8


��A��* ��M5 �M3U��A�� +��A@+��

�M �M3U

Chromosome abnormality ❚ ❚ 5

Karyotype ❚ ❚ 5

Educational challenge, ungraded ❚ ❚ 1 per year

��Each challenge includes a case history and images of at least three metaphase cells thatare representative of each case. Challenges will vary and may include a constitutionalchromosome disorder or a neoplastic disorder.

��A��* =��@�� <��[��M=5 �M�

"��A�� +��A@+��

�M= �M� � 3

Constitutional and HematologicDisorders

FISH for neoplastic disorder ❚ 1 2

FISH for constitutional abnormality ❚ 2 1

Urothelial Carcinoma

FISH for urothelial carcinoma ❚ 2 2

��

Hematologic disorder – RUNX1T1/RUNX1(ETO/AML1) (8q21.3/21q22) (two slides)Constitutional abnormality – ELN (7q11.23) (two slides)Constitutional abnormality – (photograph)

Hematologic disorder – MLL (11q23) (two slides)

(17p11.2) (two slides)Neoplastic disorder – (photograph)

see page 211.

��

metaphase cells

metaphase cells

��

photograph

suspended in ethanol fromtwo different specimens;participants use FISH to detectchromosome abnormalitiesusing probes for thecentromeres for chromosomes

probe for 9p21

��#��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $��

*�

��

��

�

��

��

��

��+

��

��

�8

��A��* =��@�� <��[�� (�� M<5�MP5 �MU5�MK

"��A�� +��A@+��

�M< �MP �MU �MK � 3

HER2 gene amplification ❚

1p/19q ❚ 1 1

EWSR1 (22q12) gene rearrangement ❚ 1

DDIT3 (CHOP) (12q13) gene rearrangement ❚ 1

BCL6 (3q27) gene rearrangement ❚ 1

MALT1 (18q21) gene rearrangement ❚ 1

��A��* ��M�*<

�� +��A@+��

�M�*<

Cytogenomic microarray analysisfor constitutional abnormality

❚ 2

Educational paper challengefor constitutional or neoplasticabnormality

❚ 1

��Participants will identify and characterize gains or losses and the cytogenetic location ofany abnormalities detected.

��

core tissue microarray slides

embedded breast tissuespecimens; a duplicate set ofH&E stained tissue microarrayslides will also be provided

one H&E stained slide

slides; one H&E stained slide

mounted on positivelycharged glass slides

��

one educational paperchallenge

��#��

$�$ ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8


��5 ;��;�� @��#��

210

��

��+��>��H��!��+�+��

4 � #� �� ^��{��]��#� ��#�� J�� ]�� 4 � #�� ] ��#�� ]�� 6��[� ��

� ��#�� {��#��^�

� ��

� 3��(��=��>A��>�� {��

� K��&�@�H�� ]��Z� ��

� "��@��=��+�� # �� #��

� K��&�@��K�� {� �� #��{��

� 3��(��#�]�� Z{� �� #��

��@��+V��D��D

=�� 4�� O��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $�%

*�

��

��

�

��

��

��

��+

��

��

�8

3��+��*��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��A��* 3��+�� *��3*K5 3*K��A�� +��A@+��

3*K 3*K�

quantitative❚ 1

quantitative❚ 1

Carnitine, qualitative and quantitative ❚ 3

(mucopolysaccharides), qualitativeand quantitative

❚ 1

Organic acids, qualitative andquantitative

❚ 1


��

plasma specimen

specimen

urine specimen

consist of any one of the

specimens

=�� 4�� O��

$�' ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8

��A��* ��+�(��(SERPINA1)*��

��A�� +��A@+��

��

❚ 3

��A��* ��*��6�

��A�� +��A@+��

��6�

APOE) genotyping ❚ 3

APOE testing for cardiovascular andAPOE e2, APOE e3, and APOE

��A��* <��+��5��+��<*�

��A�� +��A@+��

<*�

❚ 3

❚ 3

Hemoglobin S/C ❚ 3

��New

New��

��New

=�� 4�� O��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $�)

*�

��

��

�

��

��

��

��+

��

��

�8

��A��* ��*��*K�5 �*K$5 �*K%5 �*K'5 �*K)

"��A*�� +��A

@+��*K� �*K$ �*K% �*K' �*K)

❚ 3

BRCA1/2 ❚ 3

Canavan ❚ 3

❚ 3

Cystic fibrosis ❚ ❚

❚ 3

❚ 3

Familial dysautonomia ❚ 3

Fanconi anemia complementationgroup C

❚ 3

Fragile X ❚ 3

❚ 3

❚ 3

❚ 3

Hemochromatosis ❚ 3

Hemoglobin S/C ❚ 3

Huntington ❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

❚ 3

Plasminogen activator inhibitor❚ 3

❚ 3

Prothrombin ❚ 3

❚ 3

Spinal muscular atrophy ❚ 3

❚ 3

❚ 3

��

=�� 4�� O��

$�, ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8

��A��* ��+��"��"�5 ��"$5��"%

��A�� +��A@+��

��"� ��"$ ��"%

Mitochondrial DNA deletion syndromes* ❚ 3

MCAD ❚ 3

Mitochondrial cytopathies** ❚ 3

*Includes disorders/diseases such as Leigh syndrome, Pearson syndrome, and Kearns-Sayresyndrome.**Includes disorders/diseases such as Leber hereditary optic neuropathy and myoclonus epilepsywith ragged red fibers (MERRF).

��A��* ��*��@�H��@��5 @��

�� +��A@+��

@�� @��

DNA sequencing interpretation challenge ❚ 3

DNA sequencing ❚ 3

��

disease using standard nomenclature.

points about genes/disorders represented.

��

each specimen contains

product that encompasses theentire mitochondrial genome

��

containing three DNAsequence electropherogram

calling and analysis using

and nomenclature/mutation

=�� 4�� O��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $�-

*�

��

��

�

��

��

��

��+

��

��

�8

�+��*75 �*7�5 �*7$

��A�� +��A@+��

�*7 �*7� �*7$

CYP2C19 ❚ 2

CYP2C9 ❚ 2

CYP2D6 ❚ 2

UGT1A1 ❚ 2

VKORC1 ❚ 2

❚ 3

❚ 3

��

��A��* ��@�� (MECP2)*��

��A�� +��A@+��

��

MECP2 genotyping ❚ 3

��A��* �+��+��

��A�� +��A@+��

��

Factor II ❚ 3

Factor V ❚ 3

��

��

(genotyping) and/orinterpretive challenges

New��

specimens

New��

specimens

=�� 4�� O��

$�8 ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8

��3�� *��*

�� +��A@+��

��*

❚ 3

New��

��@��7�+��#��#��#��

��!��D

6��#�� #��~�� $}�� #�<�#�� ]�� 6��J�� #��#��]�� #�� K �� #�� |�� #�� ]�� }�� #��V � �]�� ]��]�� #�]��

;��D��A@��7�+��D

4�� 9��#��&��6��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $�9

*�

��

��

�

��

��

��

��+

��

��

�8

��6��f@��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

"��#�"�� + ��A<��F<��G

�@�� +��A@+��

�@�

❚ 3

Laboratories performing DNA mismatch repair assessment by immunohistochemistry methodsshould see Survey MMR on page 232.

��@��<��[�� @<5 �@<$��A�� +��A@+��

�@< �@<$

❚

Human papillomavirus (HPV) ❚

❚

HER2 (ERBB2) gene amplification(brightfield)

❚

Laboratories performing FISH for interphase chromosomal targets in paraffin sections refer to theCytogenetics Surveys, page 211.

��

paraffin section slidesand one H&E slide; twophotograph challenges

��

microarray slides, and oneH&E slide (each)

microarray slides and one H&E slide

tissue microarray slides

4�� 9��#��&��6��

$$: ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8

�� 6�� +��A@+��

��6

Online assessment of percentneoplastic cellularity

❚

@��@��*�� +��A@+��

@��

❚ 1

*See translocation listing below.Laboratories performing FISH for sarcoma translocation refer to the Cytogenetics Surveys, page 211.

@��K��

COL1A1/PDGFB, t(17;22) EWSR1/WT1, t(11;22) PAX3/FOXO1 or PAX7/FOXO1

EWSR1/ATF1, t(12;22) FUS/DDIT3, SS18/SSX1, t(X;18)

EWSR1/ERG, t(21;22) PAX3/FOXO1, t(2;13) SS18/SSX2, t(X;18)

EWSR1/FLI1, t(11;22) PAX7/FOXO1, t(1;13) SS18/SSX1 or SS18/SSX2

EWSR1/FLI1 or EWSR1/ERG

New��

slide images

Survey to assess competencyfor determining percentneoplastic cellularity

technology

��

4�� 9��#��&��6��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $$�

*�

��

��

�

��

��

��

��+

��

��

�8

@��f6�+��3��=5�*=�5U��@5U�� +��A@+��

3��= �*=� U��@ U��

BRAF ❚ 3

EGFR ❚ 3

KRAS ❚ 3

KIT ❚ 1

PDGFRA ❚ 1

�� +��A@+��

��

BRAF ❚ 3

EGFR ❚ 3

KRAS ❚ 3

*�� *K�� +��A@+��

*K�

MGMT ❚ 1

IDH1, IDH2 ❚ 1

(PTEN) deletion ❚ 1

��

sections or shavings

paraffin section slides andone H&E slide

New��

performing molecular testingon multiple targets

��

paraffin section slides andone H&E slide

4�� 9��#��&�[� ��#��

$$$ ��#�� #�� !"�� #��$�� #� �

*�

��

��

��

�

��

��

��

��+

��

��

�8

��6��f<��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��<��6��<65 �<6�5 �<6$5 �<6%5�<6)

��A*�� +��A@+��

�<65�<6� �<6$5�<6% �<6)

IGH ❚ 3

IGH/BCL2 major ❚ 3

IGH/BCL2 minor ❚ 3

IGH/CCND1 ❚ 3

IGK ❚ 3

TRB ❚ 3

TRG ❚ 3

CBFB/MYH11 ❚ 1

FLT3 ITD ❚ 1

FLT3 TKD ❚ 1

JAK2 ❚ 1

NPM1 ❚ 1

PML/RARA ❚ 1

RUNX1/RUNX1T1 ❚ 1

(FFPE) tissue

❚ 1

�� "��"5��"�5��"$�� +��A@+��

��" ��"� ��"$

BCR/ABL1 p190 ❚ 3

BCR/ABL1 p210 ❚ 3

PML/RARA ❚ 3

��

specimen

testing

and amplification from FFPEtissue will be assessed by a

ships on dry ice (dry ice

international shipments)

��

water

tumor burden by measuringthe quantity of BCR/ABL1 orPML/RARA fusion transcripts

ships on dry ice

��

��

��

��+

��

��

�9

�� #�Surgical Pathology .........................................................................................................................224General Immunohistochemistry ........................................................................................................232Predictive Markers .........................................................................................................................234Specialty Anatomic Pathology .........................................................................................................235Cytopathology...............................................................................................................................236

@�] ��#� � New

CAP/NSH HistoQIP - IHC (HQIHC) .................................................................................................231Glass Slide Gynecologic Cytopathology PAP PT Program with Online PAP Education (PTGD).................236Glass Slide Gynecologic Cytopathology PAP PT Program with Glass Slide PAP Education,SurePathTM and ThinPrep� combination, Series 1 and 2 (PAPLPT, APAPLPT) ..........................................237Cytopathology Education Program, SurePath and ThinPrep combination,Series 1 and 2 (PAPLE, APAPLE) ......................................................................................................239

�9 _ �� #�

`6�� #��

��#��

��}��

]��^�� #� �

��6��

��#� ��

��#�� #��

�� }��

�+��3��5�"5=�� #�� #� <��

��#�� #�

$$' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9


��#��@��+��A��

�� +��A@+��

��A��

Surgical pathology case review ❚ 10

��PIP educates pathologists in general surgical pathology. This program:

performance with that of their peers

o A variety of neoplastic and nonneoplastic lesions o Inflammatory and infectious disease o Various sites, encompassing a variety of organ systems

��

challenges/H&E stained glassslides with clinical history;one individual response form

with CME credit for eachadditional pathologist (withinthe same institution); mustorder in conjunction withSurvey PIP

credits (AMA PRA Category 1 Credits™) per pathologist forcompletion of an entire year


��#�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $$)

��

��

��

��+

��

��

�9

6��#��@��+��BA��B�

�� +��A@+��

��BA��B�

Surgical pathology case review ❚ 10

��

educational program include:


that of their peers.

o A variety of neoplastic and nonneoplastic lesions o Inflammatory and infectious disease o Various sites, encompassing a variety of organ systems

��

challenges/whole slideH&E images with clinicalhistory; for each additionalpathologist, purchase PIPW1

CME credit for each additionalpathologist (within the sameinstitution); must order inconjunction with Survey PIPW

credits (AMA PRA Category 1 Credits™) per pathologist forcompletion of an entire year


technology

��#�� #�

$$, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

6�� ;�� 3��;3�A;3�� +��A@+��

;3�A;3��

❚ 5

��


smears). Activities with their corresponding topics are: o

o

o

o

��

challenges/whole slideimages with clinical history;for each additional pathologist, purchase VBP1

with CME credit for eachadditional pathologist (withinthe same institution); mustorder in conjunction withSurvey VBP

23 CME/SAM credits (AMA PRA Category 1Credits™) per pathologist forcompletion of an entire year


technology

��#�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $$-

��

��

��

��+

��

��

�9

6�� "�� @��"��+��"��<A"��<�

�� +��A@+��

"��<A"��<�

Online dermatopathology case review ❚ 6

��DPATH educates pathologists, dermatopathologists, and dermatologists to assessand improve their diagnostic skills in dermatopathology. Features of this onlineeducational program include:


��

challenges/whole slideimages with clinicalhistory; for each additional

additional pathologist (withinthe same institution); mustorder in conjunction with

(AMA PRA Category 1Credits™) per pathologist forcompletion of an entire year

Performance Assessment

technology

K��>��@��#��#��

|�� ~��#� ��!"�]��]�� #�� #�� ]�� ]�� #� ��#��2�-��~��K� ��#��

6�� ]�� #�� }� ��#�� #�� #��

��#�� #�

$$8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

��@��+��@�A��@��

�� +��A@+��

��@�A��@��

Online surgical pathology cancercase review

❚

��


o

o

o

o

��

containing four diagnosticchallenges/whole slide

history; for each additional

pathologist (within the sameinstitution); must order in

AMAPRA Category 1 Credits™) perpathologist for completion ofan entire year

technology

Performance Assessment

full calendar year

�7��!��#��+��!��+��@�� 9�� #� ��#��#�� #��

� ��]�� ]�� }��

� [�#�� ]�� ^

;��D��A��D

��#�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $$9

��

��

��

��+

��

��

�9

��A�@< <��&�� <&��@��A�� +��A@+��

<&�� 3

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

��HistoQIP improves the preparation of histologic slides in all anatomic pathology

slides for histologic technique using uniform grading criteria.

��A�@< <��&�� 3��@��<&��3]@��A�� +��A@+��

<&��3] � 3

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

��The HistoQIP Biopsy Series is an additional program to improve the preparation of

histologic technique using uniform grading criteria.

��

coverslipped glass slides (onefrom each category) per mailing

online learning assessmentquestions

��

and coverslipped glass slides(one from each category) permailing

��#�� #�

$%: ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

��A�@< <��&�� @��@��<&3]�5<&3]$5<&3]%

@��A�� +��A@+��

<&3]� <&3]$ <&3]% � 3

❚ 1 1

❚ 1 1

❚ 1 1

❚ 1 1

❚ 1 1

❚ 1 1

❚ 1 1

❚ 1 1

Urogenital Tract Biopsy Module

❚ 1 1

❚ 1 1

(nonneoplastic)❚ 1 1

(with carcinoma)❚ 1 1

��The HistoQIP Specialty Series includes modules to improve the preparation of histologic

technique using uniform grading criteria.

��

to four H&E stained andcoverslipped glass slides (one from each category) per mailing

��#�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $%�

��

��

��

��+

��

��

�9

��A�@<<��&��(�<�<&�<�@��A�� +��A@+��

<&�<� � 3

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

❚ 1

��

grading criteria.

New��

up to four IHC stained andcoverslipped glass slides(one from each category) permailing

O�� J��

$%$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

*��+��+��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

��+��+�� U�� +��A@+��

�U

Immunohistochemistry ❚

��

"�� + �� +��A@+��

��

immunohistochemistry❚ 1

If your laboratory performs DNA mismatch repair by molecular methods, see the MSI programon page 219.

�"��-5�"$:��+��+�� 5 ��%

�� +��A@+��

�� %

❚ 10

❚ 10

For ER/PgR testing, see the PM2 program on page 234.

��

tissue sections from four separate cases; additionalslides provided for an H&Estain and negative control

��

paraffin section slidesand one H&E slide for theimmunohistochemical analysis

and PMS2

��

microarray slide per

O�� J��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $%%

��

��

��

��+

��

��

�9

��+��+�� @�� )

�� +��A@+��

��)

Chromogranin ❚ 10

❚ 10

This newly designed program will allow immunohistochemistry laboratories to evaluateappropriate assay performance on a wide array of tissues and/or tumor types.

Each year, the PM5 program will offer different immunohistochemistry markers to evaluate assayperformance on a wide variety of tissues and/or tumor types. See list below.

CDX2CD30D2-40K 20Ki-67PAX 2PAX 8p63

��

slides, one for Chromogranin

��4 �^��

$%' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

��#��>��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

<��$��+��+�� <��$�� +��A@+��

<��$

❚ 28

��

provide notification prior to the originally scheduled shipping date.

*�� <��$*<��$�� +��A@+��

*<��$

❚ 10

��

��A��+��+�� $

�� +��A@+��

��$

❚ 20

❚ 20

��The PM2 program fulfills the proficiency testing requirement stated in the

the CAP will provide notification prior to the originally scheduled shipping date.

��

��

microarray slide

��

�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $%)

��

��

��

��+

��

��

�9


��+��Z�"A�Z�"�� +��A@+��

�Z�"A�Z�"�

Autopsy case analysis ❚

��

��+��A�� +��A@+��

��A��

❚ 8

��

in neuropathology. Each shipment of this educational program includes eight casesthat cover the spectrum of neoplastic and nonneoplastic disorders affecting the centraland peripheral nervous systems, including infectious, degenerative, developmental,

area in neuropathology, which relates to four of the eight cases.

��

autopsy cases

with CME credit for eachadditional pathologist (withinthe same institution); mustorder in conjunction with

credits (AMA PRA Category 1Credits™) per pathologist


��

with CME credit for eachadditional pathologist (withinthe same institution); mustorder in conjunction with

CME/SAM credits (AMAPRA Category 1 Credits™)per pathologist


�� #�

$%, ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

��+��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

*�� @��*��+��

!��+ 6��*"�� +��M��

��*"UA��*"U

��*"�A��*"�

��*"KA��*"K

��

��

SurePath™ ❚ ❚10 glass

slides

10 wholeslide

images

)��#��

��ThinPrep® ❚ ❚

6��

and Series 1 or 2 for PAP Education. The CAP will schedule PT according to slideset

gynecologic cytology where all personnel are testing at another location

��

Accreditation Program requirement for participation in a peer educational program.

summary of aggregate response data.


questions.

��

for proficiency testing; tenonline whole slide imagesfor education; five onlineadvanced education cases

section for program codedetails

credits (AMA PRA Category1 Credits™ ) per pathologist

credits per cytotechnologistfor completing all challenges


testing (10 slides) and threeonline education activities peryear

New

�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $%-

��

��

��

��+

��

��

�9

*��@��*��+��!��+*��@��

�� +��M��

��A��

��U��A��U��

��A��

��K��A��K��

��P��A��P��

��

��

Conventional ❚ ❚10 glass

slides

10glassslides

5 onlineadvancededucation

cases

SurePath™ ❚ ❚ ❚

ThinPrep® ❚ ❚ ❚

6��

��

��

online advanced educationcases

details

AMA PRA Category1 Credits™

�� #�

$%8 ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

6�� *��+��"

�� +��M��

��"UA��"U

��"�A��"�

��"KA��"K 10 whole

slideimages


casesSurePath ❚ ❚

ThinPrep ❚ ❚

6��

ThinPrep

��

��

education cases

details

credits (AMA PRA Category1 Credits™

credits per cytotechnologist

requirements

technology

year

��!#��!!+��+��

�+�6��*��+��F��"G��+��N�"��@��\��+��D� <�� #�#� ��

��]��#��

� ��]�� ]��]��#��#�� ]�� #��

� �� #��]��#��~��^��# �^�� ]�� #��

� $� �� ^ ��]�� #� ��]��

�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $%9

��

��

��

��+

��

��

�9

��+��5 ��P�5 ��U�5��K�5 ��@��$�� +��M��

��A��@��$

��U�A��U�@��$

��A��

@��$

��K�A��K�@��$

��P�A��P�@��$

��

❚ ❚

10 glassslides


cases

❚ ❚ ❚

❚ ❚ ❚

6��

��

��

advanced education cases

details

AMA PRA Category1 Credits™

�� #�

$': ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

*�� +�� f =��;��!=6;UA=6;U�5=6;�A=6;��

�� +��A@+��

=6;UA=6;U� =6;�A=6;��

Online review of SurePath slides ❚ 5

Online review of ThinPrep slides ❚ 5

��

<��#�� F<��+��>G �� <�;"5�<�;�5�<�;U5�<�;P

��A�� +��A@+��

�<�;" �<�;� �<�;U �<�;P

HPV ❚ ❚ ❚ ❚ 5

genotyping (optional)❚ ❚ 5

��

opportunity to report specific HPV genotypes.

��

challenges/whole slideimages for SurePath users

challenges/whole slide images for ThinPrep users

option for each additionalpathologist/cytotechnologist(within the same institution);must order in conjunction with


credits per cytotechnologist

��

specimens ® Specimen

Transport Medium™ (STM)

PreservCyt® TransportMedium

Medium

PreservCyt, and SurePathtransport mediums

�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $'�

��

��

��

��+

��

��

�9

��+��f��#��+��A��+��A��

�� +��A@+��

��A��

Online slide and image program in rapidassessment case review

❚ 5

��

slide images of varying stains, as well as ancillary studies, flow cytometry charts,and/or radiographic images where appropriate.


��

challenges with clinical history

CME/SAM/CE credit foreach additional pathologist/technologist (within the sameinstitution); must order inconjunction with Survey TICP


technology

�� #�

$'$ ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

��+��*�A�*��

�� +��A@+��

�*�A�*��

❚ 5

❚ 5 per year

��

their educational value. Cases may incorporate static online images that incorporateradiology and multiple aspects of pathology to enhance the interpretation.

comparison, and additional review time.


questions.

��

online advanced education

response form and two individual response forms

with CME/CE credit foreach additional pathologist/cytotechnologist (within thesame institution); must orderin conjunction with Survey

25 CME credits (AMA PRA Category 1 Credits™)per pathologist and a

per cytotechnologist forcompleting the glass slidesand online cases


�� #�

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $'%

��

��

��

��+

��

��

�9

6�� "�� @��=��(�� =��A=��

�� +��A@+��

=��A=��

aspiration case review❚ 5

��

questions.


��

challenges

with CME/CE credit foreach additional pathologist/cytotechnologist (within thesame institution); must orderin conjuction with Survey

credits (AMA PRA Category 1 Credits™) per pathologist and

per cytotechnologist

MOC Part IV PracticePerformance Assessmentrequirements

technology

�� #�

$'' ��#�� #�� !"�� #��$�� #� �

��

��

��

��

�+�

��

�

�9

=��(�� *�� @��=��*A=��*�

�� +��A@+��

=��*A=��*�

slide case review❚ 5

��

aspects of pathology to support the interpretation.

comparison, and additional review time.

��

of glass slides and selectedonline images, representing avariety of conditions; one

two individual response forms

with CME/CE credit foreach additional pathologist/cytotechnologist (within thesame institution); must order in

credits (AMA PRA Category1 Credits™) per pathologist/

CE credits per cytotechnologist

MOC Part IV PracticePerformance Assessmentrequirements

=��

��

@��

��

��

$:

$: _ \��

`6��\�� #��<��

��#��

�� #��

�� #��6��

��}��

#�� #��

��+��*��+��5�"5=�� \�� #� <��

@�] ��#� � New

Vitreous Fluid, Postmortem (VF) ........................................................................................................247

\��

$', ��#�� #�� !"�� #��$�� #� �

=��

��

�@

��

��

��

$:

=��@��Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

"�� "��"��5 "��=�� +��A@+��

"�� "��=

Database analysis (whole blood) ❚ 3

Database analysis (filter paper) ❚ 3

Mitochondrial DNA database analysis ❚ ❚ 3

The American Society of Crime Laboratory Directors/Laboratory Accreditation Board ProficiencyReview Committee (ASCLD/LAB PRC) has approved Surveys DNA and DNAF.

=��X��+��"�� =�"5 =�"�

�� +��A@+��

=�" =�"�

Forensic nuclear DNA analysis ❚ 3

Forensic mitochondrial DNA analysis ❚ 2

The American Society of Crime Laboratory Directors/Laboratory Accreditation Board ProficiencyReview Committee (ASCLD/LAB PRC) has approved Surveys FID and FIDM.

��

blood specimens

filter paper challenges

DNA results

��

work includes reference standards for all suspects andvictims along with evidentiarymaterial such as vaginal

crime scene blood stains

challenge (blood stain) and one challenge formitochondrial DNA analysis(hair or nails)

��J=��+��+��F�=�G

�+��"(�6��+��$5:::��+��N��99$f$:�:��+��F�Z�"G��+��99:f$:�:=��+��F=�G��D� Y��]�� #��

o K�� #� �� #�� #��o =��]��J #�� #��#��

�@��}�� } �� Z�� #��#��#��[�$��o �� #�� #�^��

]��]�� #��

� �� #�� #��]�� #�� #��

��+��#��N��+��D��=��@��#��D

\��

'��%�%�"�"� _�'"+�'%��+��9��! _�� # $'-

=��

��

@��

��

��

$:

=��+��=�A=�� +��A@+��

=�A=��

Forensic pathology cases ❚ 6

��

��

slides and questions related tomedicolegal decision making

investigator (within the sameinstitution) reporting option with

Pathologists can earn a

(AMA PRA Category 1 Credits™)for completion of an entire year

Performance Assessmentrequirements

Board of Medicolegal Death

technologists can earn a

completion of an entire year

;�� =��5 �� ;=�� +��A@+��

;=

❚ %

❚ %

❚ %

Glucose ❚ %

Potassium ❚ %

❚ %

❚ %

New��

vitreous fluid specimens

\��

$'8 ��#�� #�� !"�� #��$�� #� �

=��

��

�@

��

��

��

$:

Refer to Section 8, Toxicology, for a more comprehensive selection of toxicology offerings.

6-acetylmorphine (6-AM)

7-aminoclonazepam

7-aminoflunitrazepam

Acetaminophen

Alpha-hydroxyalprazolam

Alprazolam

Amitriptyline

Amphetamine

Benzoylecgonine

Butalbital

Carisoprodol

Chlorpheniramine

Clonazepam

Cocaethylene

Cocaine

Codeine

Cyclobenzaprine*

Delta-9-THC

Delta-9-THC-COOH

Desipramine

Desmethylcyclobenzaprine

Diazepam

Diphenhydramine

Doxepin

Ecgonine ethyl ester

Ecgonine methyl ester

Ephedrine

Fentanyl*

Fluoxetine

Flurazepam*

Gamma-hydroxybutyrate (GHB)

Hydrocodone

Hydromorphone

Imipramine

Ketamine

Lorazepam

Lysergic acid diethylamide (LSD)

Meperidine*

Meprobamate

Methadone

Methadone metabolite (EDDP)

Methamphetamine

Methylenedioxyamphetamine (MDA)

Methylenedioxymethamphetamine(MDMA)

Morphine*

Nordiazepam

Nordoxepin

Norfluoxetine

Norpropoxyphene

Nortriptyline

Oxazepam

Oxycodone

Oxymorphone

Paroxetine

Phencyclidine

Phenethylamine

Phenobarbital

Phentermine

Phenytoin

Propoxyphene

Pseudoephedrine

Secobarbital

Sertraline

Temazepam

Tramadol*

Trazodone

Zolpidem

*and/or metabolite(s)

=�� "��K��Challenges will include a mix of drugs from the list below:

=��7��5�� =�� +��A@+��

=��

See drug listing below ❚ 4

The American Society of Crime Laboratory Directors/Laboratory Accreditation Board ProficiencyReview Committee (ASCLD/LAB PRC) has approved Survey FTC.

��

synthetic urine specimen

Analyte/Procedure Index

$�

$� _ �� Z��J��}

�� Z��J��}

250 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

Analyte/Procedure IndexThe following Analyte/Procedure Index is a comprehensive listing of analytes and corresponding CAP program options.

Analytes/procedures in bold type whose corresponding program codes are bold are regulated for proficiency testing by theCenters for Medicare & Medicaid Services (CMS).

Laboratories must perform five challenges three times per year (as noted by boldface) for analytes that are regulated by the CMS.

The X in the LAP ENR column denotes the CAP programs that can be used to fulfill the proficiency testing enrollmentrequirements for CAP-accredited laboratories. Refer to the program description in this catalog to determine compatibilitywith your specific methodologies.

�� Z�� K��

$@<

��#�

��

V�� #

1,5-anhydroglucitol AG 1,5-Anhydroglucitol 661,25 dihydroxyVitamin D

BMV1 Bone Markers andVitamins

79

3-methoxytyramines N/NX Urine Chemistry,Special

64

5-hydroxyindoleaceticacid, qualitative

N/NX Urine Chemistry,Special

64

5-hydroxyindoleaceticacid, quantitative

X N/NX Urine Chemistry,Special

64

6-acetylmorphine(6-AM)

DMPM Drug Monitoring forPain Management

97

FTC Forensic Toxicology,Criminalistics

95

OFD Oral Fluid for Drugs ofAbuse

92

T Toxicology 88UDC Forensic Urine Drug

Testing, Confirmatory91

UT Urine Toxicology 887-aminoclonazepam FTC Forensic Toxicology,

Criminalistics95

T Toxicology 88UT Urine Toxicology 88

7-aminoflunitrazepam FTC Forensic Toxicology,Criminalistics

95


10q (PTEN) deletion GLI Glioma 22111-dehydrothromboxaneB2

TBX 11-Dehydro-thromboxane B2

151

11-deoxycortisol Y/YY Ligand Assay, Special 7717-hydroxycorticosteroids N/NX Urine Chemistry,

Special64

17-hydroxyprogesterone X Y/YY Ligand Assay, Special 7717-ketosteroids N/NX Urine Chemistry,

Special64

25-OH vitamin D X ABVD Accuracy-BasedVitamin D

78

�� Z�� K��

$@<

��#�

��

V�� #

25-OH vitamin D (cont.) X BGS Bone and Growth 78LN40 Vitamin D Cal Ver/Lin 120

50:50 mixing study,APTT

CGE/CGEX Coagulation, Extended 146

CGS1 Coag Special, Series 1 14750:50 mixing study, PT CGE/CGEX Coagulation, Extended 146

CGS1 Coag Special, Series 1 147ABO grouping X ABO HLA Serologic Typing 207

X J, J1 Transfusion Medicine 194X JAT Transfusion Medicine,

Automated194

JATE1 Transfusion Medicine,Automated, Educational

195

TMCA Transfusion Medicine,Competency Assessment

196

Acetaminophen X CZ, CZ2,CZ2X, CZX,Z

Chemistry and TDM 54-56


95

LN3 TDM Cal Ver/Lin 111X SDS Serum Drug Screen 93

T Toxicology 88UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88

Acetone X AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93

X AL2 Serum Alcohol/EthyleneGlycol/Volatiles

93

SDS Serum Drug Screen 93Acid-fast smear X E Mycobacteriology 165

X E1 Mycobacteriology, Ltd 165Acid phosphatase X C3, C3X,

CZ, CZ2,CZ2X, CZX


�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 251


$�

�� Z�� K��

$@<

��#�

��

V�� #

Activated clotting time X CT, CT1,CT2, CT3,CT5

ACT 148

POC14,POC15,POC16

Competency ActivatedClotting Time

49

Activated partialthromboplastin time


X CGL Coagulation, Ltd 146CGS1 Coag Special, Series 1 147CGS3 Coag Special, Series 3 147CGS4 Coag Special, Series 4 147DBGN Anticoagulant

Monitoring, Dabigatran148

FNPX AnticoagulantMonitoring,Fondaparinux

148

RVBN AnticoagulantMonitoring,Rivaroxaban

148

Activated protein Cresistance


CGS2 Coag Special, Series 2 147Acylcarnitine BGL Biochemical Genetics 213Adenovirus ID2 Nucleic Acid Amp,

Respiratory178

IDR Infectious DiseaseRespiratory Panel

178

VLS2 Viral Load 175X VR1 Virology Culture 173X VR2 Viral Antigen by DFA 173X VR4 Viral Antigen by EIA

and Latex174

Adenovirus 40/41 SP Stool Pathogen 162Adjustable micropipetteCal V/L

I Instrumentation 122

Adrenocorticotropichormone (ACTH)

X TM/TMX Tumor Markers 82

Alanine aminotrans-ferase (ALT/SGPT)

X C1, C3, C3X,CZ, CZ2,CZ2X, CZX


IFS Interfering Substances 123X LCW Ltd Chem, Waived 61

LN2 Chemistry, Lipid,Enzyme Cal Ver/Lin

110

LN2BV Chemistry, Lipid, Enzymeall Beckman except AU,Vitros Cal Ver/Lin

110

Albumin X C1, C3, C3X,CZ, CZ2,CZ2X, CZX


�� Z�� K��

$@<

��#�

��

V�� #

Albumin (cont.) CFS Commutable FrozenSerum

59

FLD Body Fluid 67IFS Interfering Substances 123LN2 Chemistry, Lipid,

Enzyme Cal Ver/Lin110


110

SPE Protein Electrophoresis 70Albumin, CSF X M, OLI CSF Chemistry and

Oligoclonal Bands68

Albumin, urine ABU Accuracy-Based Urine 101LN20 Urine Albumin 116

X U Urine Chemistry,General

63

Albumin: creatinine ratio ABU Accuracy-Based Urine 101LN20 Urine Albumin Cal

Ver/Lin116

U Urine Chemistry,General

63

UMC Urine AlbuminCreatinine

138

Alcohol, serum X AL2 Serum Alcohol/EthyleneGlycol/Volatiles

93

LN11 Serum Ethanol CalVer/Lin

114

Alcohol, whole blood X AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93

LN14 Whole Blood EthanolCal Ver/Lin

115

Aldolase ADL Aldolase 66Aldosterone, serum X RAP Renin and Aldosterone 81Aldosterone, urine X N/NX Urine Chemistry,

Special64

Alkaline phosphatase(ALP)



FLD2 Body Fluid Chemistry 2 67IFS Interfering Substances 123LN2 Chemistry, Lipid,



110

Allele detection PGX, PGX1,PGX2

Pharmacogenetics 217

Allergens (specific) SE Diagnostic Allergy 186Alpha-1 antitrypsin X IG/IGX Immunology, General 182

LN7 Immunology Cal Ver/Lin 113

�� Z��J��}

252 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Alpha-1 antitrypsingenotyping

AAT Alpha-1 antitrypsingenotyping

214

Alpha1 globulin SPE Protein electrophoresis 70Alpha2 globulin SPE Protein electrophoresis 70Alpha-2-antiplasmin CGE/CGEX Coagulation, Extended 146Alpha-fetoprotein (AFP),amniotic fluid

X FP/FPX Maternal Screen 80

Alpha-fetoprotein (AFP),serum


X K/KK Ligand Assay, General 76LN5 Ligand Assay Cal

Ver/Lin112

LN5S Ligand Assay, SiemensCal Ver/Lin

112

Alpha-hydroxyalprazolam


95

T Toxicology 88UT Urine Toxicology 88UDC Forensic Urine Drug


Alpha-PVP (a-Pyrrolidino-pentiophenone)

SCDD Synthetic Cannabinoid/Designer Drug

96

Alpha-thalassemia HGM Hemoglobinopathies,Molecular Methods

214

Alprazolam FTC Forensic Toxicology,Criminalistics

95


Aluminum X R Trace Metals 72AM-2201 N-(4-hydroxypentyl) metabolite

SCDD Synthetic Cannabinoid/Designer Drug

96

Amikacin X CZ, CZ2,CZ2X, CZX,Z


LN3 TDM Cal Ver/Lin 111Amino acids, qualitative X BGL Biochemical Genetics 213Amino acids,quantitative

BGL Biochemical Genetics 213

Amitriptyline FTC Forensic Toxicology,Criminalistics

95


X ZT, ZZT TDM, Special 57Ammonia C3, C3X,

CZ, CZ2,CZ2X, CZX


LN32 Ammonia Cal Ver/Lin 119Amniotic fluid leakage(nitrazine)

AFL Amniotic Fluid Leakage 135

Amphetamine DMPM Drug Monitoring forPain Management

97

�� Z�� K��

$@<

��#�

��

V�� #

Amphetamine (cont.) FTC Forensic Toxicology,Criminalistics

95


92



UT Urine Toxicology 88UDS, UDS6 Urine Drug Screen 90

Amphetamine group DMPM Drug Monitoring forPain Management

97


92


Amylase X C1, C3, C3X,CZ, CZ2,CZ2X, CZX





110

Amylase, pancreatic X C1, C3, C3X,CZ, CZ2,CZ2X, CZX


Amylase, urine LN6 Urine Chemistry CalVer/Lin

112


63

Analytical balance I Instrumentation 122Anaplasmaphagocytophilum

TTD Antibody Detection-Tick-Transmitted Diseases

180

Androstenedione X Y/YY Ligand Assay, Special 77Angiotensin convertingenzyme

ACE Angiotensin ConvertingEnzyme

66

Anti-A titer ABT, ABT1 Antibody Titer 197Anti-beta-2-glycoprotein CGE/CGEX Coagulation, Extended 146Antibody detection X J, JAT Transfusion Medicine 194


195

X PS Platelet Serology 200TMCA Transfusion Medicine,

Competency Assessment196

Antibody detection/identification (HLA)

X MX1B,MX1C,MX1E, MXB,MXC

HLA Analysis, Class I 206-207

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 253


$�

�� Z�� K��

$@<

��#�

��

V�� #

Antibody detection/identification (HLA)(cont.)


HLA Analysis, Class II 206-207

Antibody identification ETME1 Expanded TransfusionMedicine Exercises

195

X J, JAT Transfusion Medicine 194JATE1 Transfusion Medicine,

Automated, Educational195


196

Antibody screen (HLA) MX1B,MX1C,MX1E, MXB,MXC


MX2B,MX2C,MX2E, MXB,MXC


Anticardiolipin IgA,qualitative

ACL, APS AntiphospholipidAntibody

184-185

Anticardiolipin IgA,quantitative


184-185

Anticardiolipin IgG,IgM, polyclonal;qualitative

X ACL, APS AntiphospholipidAntibody

184-185

Anticardiolipin IgG,IgM, polyclonal;quantitative


184-185

Anti-CCP CCP Cyclic CitrullinatedPeptide Antibody

186

Anticentromere antibody S2 Immunology Special 183Anti-CMV, total X VM3 Viral Markers-Series 3 201

X VR3 Infectious DiseaseSerology

180

Anti-CMV, IgG, IgM X VR3 Infectious DiseaseSerology

180

Anti-D titer ABT, ABT2 Antibody Titer 197Anti-DNA (ds) antibody,qualitative

X S2, S4 Immunology, Special 183

Anti-DNA (ds) antibody,quantitative

S2, S4 Immunology, Special 183

Anti-DNA topoisom-erase (Scl-70)

RDS Rheumatic DiseaseSpecial Serologies

187

Antiendomysial antibodyIgA, qualitative

X CES Celiac Serology 185

Antiendomysial antibodyIgA, quantitative

CES Celiac Serology 185

Antiendomysial antibodyIgG, qualitative


Antiendomysial antibodyIgG, quantitative


�� Z�� K��

$@<

��#�

��

V�� #

Antifungal susceptibilitytesting

X F Mycology 166

X F1 Yeast 166Antigen detection,bacterial

X D Bacteriology 154

X D4 Bacteriology, Ltd 157X D6 Rapid Group A Strep 158X D8 Group B Strep 159X D9 Rapid Group A Strep,

Waived158

X HC1 C. trachomatis by DFA 161X HC3 C. trachomatis by EIA 161X LBAS Legionella pneumophila 159X SBAS Streptococcus

pneumoniae159

X VS Vaginitis Screen 163Antigen detection, viral X HC2 HSV by DFA 174

X VR2 Viral Antigen Detectionby DFA

173

X VR4 Viral Antigen Detectionby EIA and Latex

174

Antigliadin antibodyIgA, IgG, qualitative


Antigliadin antibodyIgA, IgG, quantitative


Antideamidated gliadinpeptide antibody, IgA,IgG, qual


Antideamidated gliadinpeptide antibody, IgA,IgG, quant


Antideamidated gliadinpeptide antibody screen,IgA, IgG


Antideamidatedgliadin peptide/tissuetransglutaminaseantibody screen, IgA, IgG


Antifilamentous actinIgG Antibody

FCN Antifilamentous ActinAntibody

184

Antiglomerular basementmembrane, qualitative

X S2 Immunology, Special 183

Antiglomerular basementmembrane, quantitative

S2 Immunology, Special 183

Anti-HAV, IgM X VM5 Viral Markers-Series 5 202Anti-HAV, total X VM1 Viral Markers-Series 1 201Anti-HBc, IgM X VM5 Viral Markers-Series 5 202Anti-HBc, total X VM1 Viral Markers-Series 1 201Anti-HBe X VM2 Viral Markers-Series 2 201Anti-HBs X VM1 Viral Markers-Series 1 201

�� Z��J��}

254 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Anti-HCV RHCVW Anti-HCV, RapidMethods, Wavied

202

X VM1 Viral Markers-Series 1 201Antihistidyl t-RNAsynthetase (Jo-1)


187

Antihistone antibody AHT Antihistone Antibody 184Anti-HIV-1 X AHIV Anti-HIV Rapid

Methods202

X AHIVW Anti-HIV RapidMethods

202

X VM1 Viral Markers-Series 1 201Anti-HIV-2 X VM1 Viral Markers-Series 1 201

X AHIV Anti-HIV RapidMethods

202

Anti-HIV-1/2 X AHIV Anti-HIV RapidMethods

202

X AHIVW Anti-HIV RapidMethods

202

X VM1 Viral Markers-Series 1 201Anti-HIV 1/2, HIV-1p24 antigen

X VM6 Viral Markers-Series 6 202

Anti-HTLV-I/II X VM3 Viral Markers-Series 3 201Anti-Jo-1(antihistidylt-RNA synthetase)


187

Anti-LKM LKM Liver-KidneyMicrosomal Antibody

187

Antimicrobialsusceptibility testing

BIT BreakpointImplementation Tool

155

X D Bacteriology 154X D2 Urine Cultures 156X D4 Bacteriology, Ltd 157X D7 Throat, Urine Cultures 156

MBT Microbiology BenchTools Competency

156

Antimitochondrialantibody, qualitative


Antimitochondrial M2antibody

H Antimitochondrial M2Antibody

184

Anti-MPO S2 Immunology, Special 183Anti-Müllerian Hormone AMH Anti-Müllerian

Hormone77

Antimycobacterialsusceptibility testing

X E Mycobacteriology 165

Antineutrophilcytoplasmic antibody(ANCA)


Antinuclear antibody(ANA)

X ANA, IL Immunology 182

Antiparietal cellantibody

APC Antiparietal CellAntibody

184

�� Z�� K��

$@<

��#�

��

V�� #

Antiphospholipidantibody

ACL AntiphospholipidAntibody

184

CGE/CGEX Coagulation, Extended 146Antiphosphatidylserineantibodies (IgG, IgMand IgA)

APS AntiphosphatidylserineAntibodies

185

Anti-PR3 S2 Immunology, Special 183Anti-RNP antibody,qualitative


Anti-RNP antibody,quantitative


Anti-Saccharomycescerevisiae antibody

ASC Anti-Saccharomycescerevisiae Antibody

185

Anti-Scl-70 (anti-DNAtopoisomerase)


187

Anti-Sm antibody,qualitative


Anti-Sm antibody,quantitative


Anti-Sm/RNP antibody,qualitative


Anti-Sm/RNP antibody,quantitative


Antismooth muscleantibody


Antisperm antibody IgG X ASA Semen Analysis 142Anti-SSA antibody,qualitative


Anti-SSA antibody,quantitative


Anti-SSB antibody,qualitative


Anti-SSB antibody,quantitative


Anti-SSA/SSB antibody,qualitative


Anti-SSA/SSB antibody,quantitative


Antistreptolysin O (ASO) X ASO, IL Immunology 182Antithrombin (Activity, Ag) CGE/CGEX Coagulation, Extended 146

CGS2 Coag Special, Series 2 147LN35 Thrombophilia Cal

Ver/Lin120

Antithyroglobulinantibody, qualitative


Antithyroglobulinantibody, quantitative


Antithyroid microsomal,qualitative


Antithyroid microsomal,quantitative


�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 255


$�

�� Z�� K��

$@<

��#�

��

V�� #

Antithyroid peroxidase,qualitative


Antithyroid peroxidase,quantitative


Antitissue transgluta-minase antibody IgA,qualitative


Antitissue transgluta-minase antibody IgA,quantitative


Antitissue transgluta-minase antibody IgGqualitative


Antitissue transgluta-minase antibody IgGquantitative


Anti-Trypanosoma cruzi VM4 Viral Markers-Series 4 202Apolipoprotein A1 ABL Accuracy-Based Lipids 100

X C3, C3X,CZ, CZ2,CZ2X, CZX


Apolipoprotein B ABL Accuracy-Based Lipids 100X C3, C3X,

CZ, CZ2,CZ2X, CZX


Apolipoprotein E(APOE) genotyping

APOE Apolipoprotein E(APOE) genotyping

214

Arsenic, urine TMU Trace Metals, Urine 94Arthropod identification TMO Ticks, Mites, and Other

Arthropods171

Aspartate aminotrans-ferase (AST/SGOT)



IFS Interfering Substances 123X LCW Ltd Chem, Waived 61


110


110

Atenolol T Toxicology 88UT Urine Toxicology 88

Atropine T Toxicology 88UT Urine Toxicology 88

Automated WBCdifferential

X FH1-FH4,FH6, FH9,FH10, FH1P-FH4P, FH6P,FH9P, FH10P

Hematology, Auto Diff 129

Autopsy pathology AUCD/AUCD1

Autopsy Pathology,CD-ROM

235

�� Z�� K��

$@<

��#�

��

V�� #

B-type natriuretic peptides X BNP B-Type NatriureticPeptides

58

LN30 B-Type NatriureticPeptides Cal Ver/Lin

118

X PCARM,PCARMX

Plasma CardiacMarkers

61

POC12 Competency PlasmaCardiac Markers

49

Babesia microti TTD Antibody Detectionof Tick-TransmittedDiseases

180

Bacteria, urine UAA1 Automated Urinalysis 136Bacterial antigendetection


X D4 Bacteriology, Ltd 157X D6 Rapid Group A Strep 158X HC1 C. trachomatis by DFA 161X HC3 C. trachomatis by EIA 161X LBAS Legionella Antigen

Detection159

POC4 POC Strep ScreenCompetency

48

X SBAS S. pneumoniae AntigenDetection

159

X VS Vaginitis Screen 163Bacterial detection inplatelets

X BDP5,BDPV5

Bacterial detection,platelets

198

BDP, BDPV Bacterial detection,platelets

198

Bacterial identification X D Bacteriology 154X D1, D2, D3,

D7Throat, Urine, GCCultures

156

X D4 Bacteriology, Ltd 157DEX Expanded Bacteriology 155MBT Microbiology Bench

Tools Competency156

MRS Methicillin-ResistantStaphylococcus aureusScreen

162

X MRS5 Methicillin-ResistantStaphylococcus aureusScreen

162

Bacterial strain typing BSTE Bacterial Strain Typing-Enterococcus

176

BSTS Bacterial Strain Typing-Staphylococcus

176

Bacterial vaginosisscreen

BV Bacterial Vaginosis 163

Barbiturate group DMPM Drug Monitoring forPain Management

97

SDS Serum Drug Screen 93

�� Z��J��}

256 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Barbiturate group (cont.) T Toxicology 88UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88

BCR/ABL1 p190 MRD1 Minimal ResidualDisease

222

BCR/ABL1 p210 MRD Minimal ResidualDisease

222

Bence Jones protein UBJP Urinary Bence JonesProtein

70

Benzodiazepine group DMPM Drug Monitoring forPain Management

97

SDS Serum Drug Screen 93T Toxicology 88UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88

Benzoylecgonine DMPM Drug Monitoring forPain Management

97


95


92



UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88UTCO Urine Toxicology

Carryover124

Beta-2-glycoprotein I ACL, APS AntiphospholipidAntibody

184-185

Beta-2-microglobulin,serum

X TM/TMX Tumor Markers 82

Beta-2-microglobulin,urine

CD Cadmium 94

Beta-hydroxybutyrate X KET Ketones 60Beta globulin SPE Serum Electrophoresis 70Beta-thalassemia HGM Hemoglobinopathies,

Molecular Methods214

Bile crystal identification BCR Bile Crystals 136Bilirubin, confirmatoryurine

DSC Dipstick Confirmatory 136

Bilirubin, direct X C1, C3,C3X, CZ,CZ2, CZ2X,CZX



110


110

X NB, NB2 Neonatal Bilirubin 61

�� Z�� K��

$@<

��#�

��

V�� #

Bilirubin, total X C1, C3, C3X,CZ, CZ2,CZ2X, CZX


CFS Commutable FrozenSerum

59

FLD2 Body Fluid Chemistry 2 67IFS Interfering Substances 123LM1 Lung Maturity 70LN2 Chemistry, Lipid,



110

X NB, NB2 Neonatal Bilirubin 61Bilirubin, urine X CMP, CMP1 Clinical Microscopy 134

DSC Dipstick Confirmatory 136POC3 POC Urine Dipstick

Competency48

Bioavailable testosterone DY Ligand Assay, Special 77Biochemical genetics BGL, BGL1 Biochemical Genetics 213Bioterrorism agents LPX Laboratory

Preparedness Exercise161

BK virus ID1T Nucleic Acid Amp, JCand BK

177

VLS, VSL2 Viral Load 175Blood cell identification X BCP Blood Cell Identification 128

EHE1 Expanded VirtualPeripheral Blood Smear

133

X FH1P-FH4P,FH6P, FH9P,FH10P


X HEP Basic Hematology 128Blood cell identification-body fluid

VBF Virtual Body Fluid 135

Blood culture X BCS Blood Culture 159GPBC Gram Positive Blood

Culture Panel160

Blood cultureStaphylococcus aureus

BCS1 Blood CultureStaphylococcus aureus

159

Blood parasite X BP Blood Parasite 170X P Parasitology 169

Blood parasite, rapid RMAL Rapid Malaria 170Bloom syndrome MGL4 Molecular Genetics 215Bocavirus IDR Infectious Disease

Respiratory Panel178

Body fluid (cell count) ABF1, ABF2,ABF3

Automated Body Fluid 135

X HFC HemocytometerFluid Count

137

Body fluid (chemistry) FLD, FLD2 Body Fluid 67Body fluid (crystals) BFC Crystals 136

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 257


$�

�� Z�� K��

$@<

��#�

��

V�� #

Body fluid photographs CMP, CMP1 Clinical Microscopy 134Bone marrow celldifferential

BMD Bone Marrow CellDifferential

130

Bone specific alkalinephosphatase


79

Bordetella parapertussis IDO Nucleic Acid Amp,Organisms

177

Bordetella pertussis IDO Nucleic Acid Amp,Organisms

177

Borrelia burgdorferi TTD Antibody Detectionof Tick-TransmittedDiseases

180

BRAF BRAF Mutation testing 221MTP Multigene Tumor Panel 221

BRCA1/2 X MGL3 Molecular Genetics 215Brain tissue by FISH CYJ Fluorescence In Situ

Hybrid, Brain/GliomaTissue

211

Brightfield in situhybridization

ISH, ISH2 In Situ Hybridization 219

Brompheniramine FTC Forensic Toxicology,Criminalistics

95


Buprenorphine DMPM Drug Monitoring forPain Management

97



UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88

Bupropion T Toxicology 88UT Urine Toxicology 88

Butalbital DMPM Drug Monitoring forPain Management

97


95



UT Urine Toxicology 88C. difficile X D Bacteriology-Antigen

Detection154

GIP Gastrointestinal Panel 179SP Stool Pathogens- Rapid

and Molecular162

CA 15-3 X TM/TMX Tumor Markers 82CA 19-9 FLD Body Fluid 67

X TM/TMX Tumor Markers 82CA 27.29 X TM/TMX Tumor Markers 82CA 72-4 X TM/TMX Tumor Markers 82

�� Z�� K��

$@<

��#�

��

V�� #

CA 125 LN34 Tumor Markers 119X TM/TMX Tumor Markers 82

Cadmium, urine X CD Cadmium 94Cadmium, whole blood X CD Cadmium 94Caffeine X CZ2, CZ2X,

CZX, ZChemistry and TDM—Not included in C3

54-56

Calcitonin X TM/TMX Tumor Markers 82Calcium ABS Accuracy-Based 101






110

Calcium, urine ABU Accuracy-Based Urine 101LN6 Urine Chemistry Cal

Ver/Lin112


63

Calcium, ionized X AQ, AQ2,AQ3, AQ4

Aqueous Blood Gas 84



LN13C Blood Gas Cal Ver/Lin 115POC10,POC11

POC Competency BloodGases

49

Calcofluor white FSM Fungal Smear 167Campylobacter CAMP Campylobacter 160

GIP Gastrointestinal Panel 179Canavan MGL4 Molecular Genetics 215Candida culture X F3 Candida culture 167Candida sp., DNA probe X VS Vaginitis Screen 163Cannabinoids See Delta-9-THC-

COOH and Delta-9-THC

Carbamazepine X CZ, CZ2,CZ2X, CZX,Z


LN3 TDM Cal Ver/Lin 111T Toxicology 88UT Urine Toxicology 88

Carbamazepine-10,11-epoxide

T Toxicology 88

UT Urine Toxicology 88

�� Z��J��}

258 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Carbamazepine, free X CZ, CZ2,CZ2X, CZX,Z


Carboxyhemoglobin X SO Blood Oximetry 85Carisoprodol DMPM Drug Monitoring for

Pain Management97


95


Carnitine BGL1 Biochemical Genetics 213Casts, urine UAA, UAA1 Automated Urinalysis 136CD1a RFAV1 Rare Flow Antigen

Validation CD1a191

CD3 X FL, FL1 Lymphocyte subsetimmunophenotyping

189

LN22 Flow Cytometry CalVer/Lin

117

SCP Stem Cell Processing 199CD4 X FL, FL1 Lymphocyte subset

immunophenotyping189


117

CD8 X FL, FL1 Lymphocyte subsetimmunophenotyping

189


117

CD20 PM3 Immunohistochemistry 232CD30 PM5 Immunohistochemistry

TMA233

CD34 CBT Cord Blood Testing 199X FL4 Flow Cytometry CD34+ 190

SCP Stem Cell Processing 199CD45 CBT Cord Blood Testing 199

X FL, FL1 Lymphocyte subsetimmunophenotyping

189

FL4 Flow Cytometry CD34+ 190SCP Stem Cell Processing 199

CD117 (c-kit) PM1 Immunohistochemistry 232CEA FLD Body Fluid 67


Ver/Lin112


112

Ceruloplasmin X S2, S4 Immunology, Special 183CFU-GM SCP Stem Cell Processing 199CH50 CH50 Total Hemolytic

complement188

�� Z�� K��

$@<

��#�

��

V�� #

CH100 CH50 CH100 188Chlamydia trachomatis X HC1 C. trachomatis by DFA 161

X HC3 C. trachomatis by EIA 161X HC6, HC6X C. trachomatis/GC by

Nucleic Acid Amp176

VR1 Virology Culture 173Chlamydiophilapneumoniae

IDO Nucleic Acid Amp,Organisms

177

Chlordiazepoxide T Toxicology 88UT Urine Toxicology 88

Chloride X AQ, AQ2,AQ3, AQ4





59




110



49

Chloride, sweat X SW1, SW2,SW3, SW4

Sweat Analysis Series 73

Chloride, urine LN6 Urine Chemistry CalVer/Lin

112


63

Chloride, vitreous fluid VF Vitreous Fluid, Post-mortem

92

Chlorpheniramine FTC Forensic Toxicology,Criminalistics

95


Chlorpromazine T Toxicology 88UT Urine Toxicology 88

Cholesterol ABL Accuracy-Based Lipids 100X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX


FLD Body Fluid 67X LCW Ltd Chem, Waived 61


110

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 259


$�

�� Z�� K��

$@<

��#�

��

V�� #

Cholesterol (cont.) LN2BV Chemistry, Lipid, Enzymeall Beckman except AU,Vitros Cal Ver/Lin

110

Chromium X R Trace Metals 72Chromium, urine TMU Trace Metals, Urine 94Chromosomalabnormalities

X CY, CYBK Cytogenetics 210

Cimetidine T Toxicology 88UT Urine Toxicology 88

Citalopram T Toxicology 88UT Urine Toxicology 88

CK isoenzymes X CRTI Cardiac Markers 59CK-MB(immunochemical)

X CRT, CRTI Cardiac Markers 59

IFS Interfering Substances 123LN2 Chemistry, Lipid,



110

X PCARM,PCARMX


61


49

CK2 (MB) IFS Interfering Substances 123LN2 Chemistry, Lipid,



110

Clinical PathologyImprovement Program

CPIP/CPIP1 Quality Management(Education)

15

Clomipramine T Toxicology 88UT Urine Toxicology 88

Clonazepam FTC Forensic Toxicology,Criminalistics

95


Clostridium difficile X D Bacteriology-AntigenDetection

154

GIP Gastrointestinal Panel 179SP Stool Pathogens- Rapid

and Molecular162

Clozapine T Toxicology 88UT Urine Toxicology 88ZE Therapeutic Drug

Monitoring, Extended57

CMV ID1 Nucleic Acid Amp,Viruses

177

LN38 CMV Viral Load CalVer/Lin

120

�� Z�� K��

$@<

��#�

��

V�� #

CMV (cont.) VLS, VLS2 Viral Load 175X VM3 Viral Markers-Series 3 201X VR1 Virology Culture 173X VR2 Viral Antigen Detection

by DFA173

X VR3 Infectious DiseaseSerology

180

CO2 X C3, C3X,CZ, CZ2,CZ2X, CZX





110

Cocaethylene FTC Forensic Toxicology,Criminalistics

95


Cocaine DMPM Drug Monitoring forPain Management

97


95


92


Codeine DMPM Drug Monitoring forPain Management

97


95


92



UT Urine Toxicology 88Compatibility testing X J, JAT Transfusion Medicine 194

JATE1 Transfusion MedicineAutomated, Educational

195


196

Complement C3 X IG/IGX Immunology, General 182LN7 Immunology Cal Ver/Lin 113

Complement C4 X IG/IGX Immunology, General 182LN7 Immunology Cal Ver/Lin 113

Complexed PSA X K/KK Ligand Assay, General 76Conductivity, sweat X SW1, SW2,

SW3, SW4Sweat Analysis Series 73

�� Z��J��}

260 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Connexin-26 X MGL3 Molecular Genetics 215Copper X R Trace Metals 72Copper, urine TMU Trace Metals, Urine 94Coproporphyrins X N/NX Urine Chemistry, Special 64Coronavirus ID2 Nucleic Acid Amp,

Respiratory178

IDR Infectious Disease,Respiratory Panel

178

Cortisol ABS Accuracy-Based 101X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX



59


Ver/Lin112


112

Cortisol, salivary SALC Salivary Cortisol 71Cortisol, urinary free X N/NX Urine Chemistry,

Special64

Cotinine T Toxicology 88UT Urine Toxicology 88

C-peptide X ING Insulin, Gastrin,C-Peptide, PTH

79

C-reactive protein (CRP) X CRP, IL Immunology 182LN12 C-Reactive Protein Cal

Ver/Lin114

C-reactive protein, high-sensitivity (hsCRP)

X hsCRP High-Sensitivity C-Reactive Protein

60

LN21 High-SensitivityC-Reactive Protein CalVer/Lin

117

Creatine kinase (CK) X C1, C3, C3X,CZ, CZ2X,CZ2, CZX





110

Creatinine X AQ2, AQ4 Aqueous Blood Gas 84X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX



59

FLD Body Fluid 67IFS Interfering Substances 123

�� Z�� K��

$@<

��#�

��

V�� #

Creatinine (cont.) LN2 Chemistry, Lipid,Enzyme Cal Ver/Lin

110


110

LN24 Creatinine AccuracyCal Ver/Lin

118

SCO Serum Carryover 124Creatinine, urine ABU Accuracy-Based Urine 101

X BU Bone and Mineral,Urine

78

X CD Cadmium 94DAI Urine Drug Adulterant/

Integrity Testing90

LN6 Urine Chemistry CalVer/Lin

112

LN20 Urine Albumin CalVer/Lin

116


63

UDC Forensic Urine DrugTesting, Confirmatory

91

X UMC Urine Albumin/Creatinine

138

Creatinine, vitreous fluid VF Vitreous Fluid, Post-mortem

92

Crossmatching EXM, EXM2 Electronic Crossmatch 197X J, JAT Transfusion Medicine 194X MX1B,

MX1C, MXB,MXC


X MX2B,MX2C, MXB,MXC

HLA Analysis Class II 206-207


196

Cryptococcal antigendetection

X F Mycology 166

X F1 Yeast 166Cryptosporidium GIP Gastrointestinal Panel 179Cryptosporidiumimmunoassay,preserved specimen

X P, P3, P4, P5 Parasitology 169

Crystals BFC Body Fluid Crystals 136UAA Automated Urinalysis 136URC Urine Crystals 136

CSF antigen detection X D Bacteriology 154C-telopeptide (CTX) BMV5 Bone Markers and

Vitamin79

BU Bone and Mineral,Urine

78

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 261


$�

�� Z�� K��

$@<

��#�

��

V�� #

Cyclic citrullinatedpeptide antibody

CCP Anti-cyclic citrullinatedpeptide antibody

186

Cyclobenzaprine FTC Forensic Toxicology,Criminalistics

95


Cyclosporine X CS ImmunosuppressiveDrugs

56

LN31 ImmunosuppressiveDrugs Cal Ver/Lin

119

CYP2C9 PGx Pharmacogenetics 217CYP2C19 PGx Pharmacogenetics 217CYP2D6 PGx Pharmacogenetics 217Cystatin C CYS Cystatin C 68Cystic fibrosis X MGL2,

MGL5Molecular Genetics 215

Cytogenomic microarray CYCGH CytogenomicMicroarray Analysis

211

Cytology proficiencytesting

See CytopathologyGYN proficiency testing

Cytomegalovirus (CMV) ID1 Nucleic Acid Amp,Viruses

177

LN38 CMV Viral Load CalVer/Lin

120

VLS, VLS2 Viral Load 175X VM3 Viral Markers-Series 3 201X VR1 Virology Culture 173X VR2 Virology by DFA 173X VR3 Infectious Disease

Serology180

Cytopathology GYNeducation

APEDK PAP Edu, Online, Indiv.,SurePath

238

APEDL PAP Edu, Online, Indiv.,Combination

238

APEDM PAP Edu, Online, Indiv.,ThinPrep

238

FOVK/FOVK1

Fields of View SurePath 240

FOVM/FOVM1

Fields of View ThinPrep 240

PAPCE1 PAP Edu, Conventional 14PAPJE1 PAP Edu, All

Technologies14

PAPKE1 PAP Edu, SurePath 14PAPME1 PAP Edu, ThinPrep 14PEDK PAP Edu, Online, Lab,

SurePath238

PEDL PAP Edu, Online, Lab, Combination

238

PEDM PAP Edu, Online, Lab,ThinPrep

238

�� Z�� K��

$@<

��#�

��

V�� #

Cytopathology GYNproficiency testing

PAPCPT PAP PT, Conventional 237

PAPJPT PAP PT, Combination 237PAPKPT PAP PT, SurePath 237PAPLPT PAP PT, Combination 237PAPMPT PAP PT, ThinPrep 237PTGDK PAP PT, Sure Path 236PTGDM PAP PT, Thin Prep 236PTGDL PAP PT, Combination 236

Cytopathology,nongynecologic

FNA/FNA1 Fine-NeedleAspiration-online

243

FNAG/FNAG1

Fine-NeedleAspiration-glass

244

NGC/NGC1 NongynecologicCytopath Edu Prgm

242

Cytopreparationdifferential

HFC HemocytometerFluid Count

137

Dabigatran DBGN AnticoagulantMonitoring, Dabigatran

148

D-dimer, qualitative CGDF Coagulation,D-dimer/FDP

146

CGL Coagulation, Ltd 146WBDD Whole Blood D-dimer 151

D-dimer, quantitative X CGDF Coagulation,D-dimer/FDP

146

X CGL Coagulation, Ltd 146LN42 D-dimer Cal Ver/Lin 121

X PCARM,PCARMX


61


49

Delta-9-THC FTC Forensic Toxicology,Criminalistics

95


92


Delta-9-THC-COOH DMPM Drug Monitoring forPain Management

97


95




Carryover124

Deoxypyridinoline (DPD) BU Bone and Mineral,Urine

78

�� Z��J��}

262 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Dermatopathology DPATH/DPATH1

Online Digital SlideProgram

227

Dermatophyteidentification

X F Mycology 166

Desalkylflurazepam T Toxicology 88UT Urine Toxicology 88

Desipramine FTC Forensic Toxicology,Criminalistics

95


X ZT, ZZT TDM, Special 57Desmethylclomipramine T Toxicology 88

UT Urine Toxicology 88Desmethylcycloben-zaprine


95

Dextromethorphan T Toxicology 88UT Urine Toxicology 88

DHEA sulfate X Y/YY Ligand Assay, Special 77DIA (Dimeric inhibin A) X FP/FPX Maternal Screen 80Diazepam FTC Forensic Toxicology,

Criminalistics95


Differential, automated X FH1-FH4,FH6, FH9,FH10, FH1P-FH4P, FH6P,FH9P, FH10P


Differential, manual BMD Bone Marrow CellDifferential

130

HFC HemocytometerFluid Count

137

Digital slide program infine-needle aspiration,online

FNA/FNA1 Online Digital SlideProgram

243

Digoxin X CZ, CZ2,CZ2X, CZX,Z



Digoxin, free X CZ, CZ2,CZ2X, CZX,Z


Dihydrocodeine T Toxicology 88UT Urine Toxicology 88

Diltiazem T Toxicology 88UT Urine Toxicology 88

Dilute prothrombin time CGE/CGEX Coagulation, Extended 146Dilute Russell’s vipervenom time


�� Z�� K��

$@<

��#�

��

V�� #

Dimeric inhibin A (DIA) X FP, FPX Maternal Screen 80Diphenhydramine FTC Forensic Toxicology,

Criminalistics95


Diphenylhydantoin See PhenytoinDirect antiglobulintesting

X DAT Direct AntiglobulinTesting

199

TMCAD Transfusion Medicine,Competency Assessment

196

Direct bilirubin X C1, C3,C3X, CZ,CZ2, CZ2X,CZX



110


110

X NB, NB2 Neonatal Bilirubin 61Disopyramide X CZ, CZ2,

CZ2X, CZX,Z


DMD/Becker X MGL2 Molecular Genetics 215DNA analysis X DL, DML HLA Molecular Typing 207

DNA, DNAF DNA Database 246FID, FIDM Forensic Identity 246

X ML HLA Molecular Typing 207MHO Molecular Oncology 222

X PAR, PARF Parentage/Relationship 204DNA content/cell cycleanalysis

FL, FL2 Flow Cytometry 189

DNA database DNA, DNAF DNA Database 246DNA extraction andamplification

MHO5 Molecular OncologyHematologic

222

DNA fingerprinting IDO Nucelic Acid Amp,Organisms

177

DNA Mismatch Repair MMR DNA Mismatch Repair 232DNA sequencing SEC, SEC1 DNA Sequencing 216Dopamine X N/NX Urine Chemistry,

Special64

Doxepin FTC Forensic Toxicology,Criminalistics

95


Doxylamine T Toxicology 88UT Urine Toxicology 88

Duloxetine T Toxicology 88UT Urine Toxicology 88

Ecgonine ethyl ester FTC Forensic Toxicology,Criminalistics

95

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 263


$�

�� Z�� K��

$@<

��#�

��

V�� #

Ecgonine ethyl ester(cont.)

T Toxicology 88

UT Urine Toxicology 88Ecgonine methyl ester FTC Forensic Toxicology,

Criminalistics95


E. coli O157 GIP Gastrointestinal Panel 179EGFR-Epidermal growthfactor receptor

EGFR Mutation testing 221

MTP Multigene Tumor Panel 221eGFR LN24 Creatinine Accuracy

CalVer/Lin118

Electronic crossmatch EXM, EXM2 Electronic Crossmatch 197Electrophoresis X HG Hemoglobinopathy 131

X LPE LipoproteinElectrophoresis

70

X M, OLI CSF Chemistry andOligoclonal Bands

68

X SPE Protein Electrophoresis 70UBJP Urinary Bence Jones

Protein70

Elution, antibody ELU Eluate 200Embryology EMB Embryology 143Enterotoxigenic E. coli(ETEC)

GIP Gastrointestinal Panel 179

Enterovirus ID1 Nucleic Acid Amp,Viruses

177


178

X VR1 Virology Culture 173Eosinophils, urine SCM2 Special Clinical

Microscopy138

Ephedrine FTC Forensic Toxicology,Criminalistics

95


Epidermal growth factorreceptor (EGFR)

EGFR Mutation testing 221

Epinephrine N/NX Urine Chemistry,Special

64

Epithelial cells, urine UAA1 Automated Urinalysis 136Epstein-Barr virus (EBV) ID1 Nucleic Acid Amp,

Viruses177

ISH In Situ Hybridization 219VLS, VLS2 Viral Load 175VR3 Antibody Detection-

Infectious DiseaseSerology

180

ER, PgR byimmunohistochemistry

X PM2 ER, PgR byimmunohistochemistry

234

�� Z�� K��

$@<

��#�

��

V�� #

Erythrocytesedimentation rate

ESR, ESR1,ESR2, ESR3

ErythrocyteSedimentation Rate

128

Erythropoietin EPO Erythropoietin 79Escherichia coli O157 GIP Gastrointestinal Panel 179Estradiol ABS Accuracy-Based 101

LN8 ReproductiveEndocrinology CalVer/Lin

113

X Y/YY Ligand Assay, Special 77Estimated glomerularfiltration rate (eGFR)

LN24 Creatinine AccuracyCal Ver/Lin

118

Estriol, unconjugated(uE3)


X Y/YY Ligand Assay, Special 77Estrogen receptors byimmunohistochemistry

X PM2 ER, PgR byImmunohistochemistry

234

Ethanol X AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93


93

LN11 Serum Ethanol CalVer/Lin

114


115

UDS, UDS6 Urine Drug Screen 90Ethanol, vitreous fluid VF Vitreous Fluid, Post-

mortem92

ETEC(Enterotoxigenic E. coli)


Ethosuximide X CZ, CZ2,CZ2X, CZX,Z


Ethylene glycol AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93

AL2 Serum Alcohol/EthyleneGlycol/Volatiles

93

Ethyl glucuronide (EtG) ETB Ethanol Biomarkers 93Ethyl sulfate (EtS) ETB Ethanol Biomarkers 93Euglobin test CGE/CGEX Coagulation, Extended 146Everolimus EV Everolimus 57Factor II CGE/CGEX Coagulation, Extended 146Factor II mutation TPM Thrombophilia

Mutations217

Factor V CGE/CGEX Coagulation, Extended 146Factor V Leiden mutation X MGL1 Molecular Genetics 215

TPM ThrombophiliaMutations

217

Factor VII CGE/CGEX Coagulation, Extended 146Factor VIII X CGE/CGEX Coagulation, Extended 146

X CGS3 Coag Special, Series 3 147Factor VIII Inhibitor CGE/CGEX Coagulation, Extended 146

�� Z��J��}

264 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Factor IX CGE/CGEX Coagulation, Extended 146Factor X CGE/CGEX Coagulation, Extended 146Factor XI CGE/CGEX Coagulation, Extended 146Factor XII CGE/CGEX Coagulation, Extended 146Factor XIII CGE/CGEX Coagulation, Extended 146Familial dysautonomia MGL4 Molecular Genetics 215Fanconi anemia MGL4 Molecular Genetics 215Fecal fat, qualitative FCFS Fecal Fat 69Fecal lactoferrin FLAC Fecal Lactoferrin 161Fentanyl DMPM Drug Monitoring for

Pain Management97


95


Fern test X CMMP Clinical Microscopy,Misc

134

Ferritin X C3, C3X,CZ, CZ2,CZ2X, CZX



Ver/Lin112


112

Fetal fibronectin X FF Fetal Fibronectin 79Fetal hemoglobin(gastric fluid)

APT Fetal Hemoglobin 137

Fetal hemoglobinidentification

X HBF Fetal Red CellDetermination

200

X HG Hemoglobinopathy 131Fetal lung maturity X LM, LM1 Lung Maturity 70Fetal membrane rupture(PAMG-1)

ROM Rupture of FetalMembrane

138

Fetal red cellquantitation

X HBF Fetal Red Cell 200

TMCAF Transfusion Medicine,Competency Assessment

196

Fetal screen (Rosettetesting)

X HBF Fetal Red Cell 200


196

Fibrin monomer CGE/CGEX Coagulation, Extended 146Fibrinogen X CGL Coagulation, Ltd 146Fibrinogen antigen CGE/CGEX Coagulation, Extended 146Fibrinogen degradationprograms, plasma

CGDF Coagulation,D-dimer/FDP

146

CGL Coagulation, Ltd 146Fibrinogen degradationprograms, serum

CGDF Coagulation,D-dimer/FDP

146

�� Z�� K��

$@<

��#�

��

V�� #

Fibrinogen degradationprograms, serum

CGL Coagulation, Ltd 146

Fields of view FOVK/FOVK1

Fields of View SurePath 240

FOVM/FOVM1

Fields of View ThinPrep 240

Fine-needle aspiration,digital slide program

FNA/FNA1 Online Digital SlideProgram

243

Fine-needle aspiration,glass slides

FNAG/FNAG1

Fine-Needle Aspiration 244

FISH for breastcarcinoma hybridizationand interpretationon site (HER2 geneamplification)

X CYH Fluorescence In SituHybridization-BreastCancer

211

FISH for brain/glioma CYJ Fluorescence In SituHybridization,Brain/Glioma Tissue

211

FISH for constitutionaland hematologicdisorders

CYF Fluorescence In SituHybridization

210

FISH for lymphoma CYL Fluorescence InSitu Hybridization,Lymphoma

211

FISH for paraffin-embedded tissue

CYH Fluorescence In SituHybridization-BreastCancer

211

CYJ Fluorescence In SituHybridization,Brain/Glioma Tissue

211

CYK Fluorescence In SituHybridization, SarcomaTissue or PediatricNeoplasm

211

CYL Fluorescence InSitu Hybridization,Lymphoma

211

FISH for sarcoma CYK Fluorescence In SituHybridization, SarcomaTissue or PediatricNeoplasm

211

FISH for urothelialcarcinoma hybridizationand interpretation on-site

X CYI Fluorescence InSitu Hybridization,Urothelial Carcinoma

210

Flunitrazepam T Toxicology 88UT Urine Toxicology 88

Fluorescent microscopecheck


Fluorescent polarizationassay

X LM, LM1 Lung Maturity 70

Fluoxetine FTC Forensic Toxicology,Criminalistics

95

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 265


$�

�� Z�� K��

$@<

��#�

��

V�� #

Fluoxetine (cont.) T Toxicology 88UT Urine Toxicology 88

Flurazepam FTC Forensic Toxicology,Criminalistics

95


Folate, RBC X FOL RBC Folate 81Folate, serum X K/KK Ligand Assay, General 76

LN5 Ligand Assay CalVer/Lin

112


112

Follicle-stimulatinghormone (FSH)


113

X Y/YY Ligand Assay, Special 77Fondaparinux FNPX Anticoagulant

Monitoring,Fondaparinux

148

Forensic identity (DNA) FID, FIDM Forensic Identity 246Forensic pathology FR/FR1 Forensic Pathology 247Forensic toxicology FTC Forensic Toxicology,

Criminalistics95

Fragile X X MGL1 Molecular Genetics 215Free Beta hCG FP1B First Trimester Maternal

Screening, Free Beta80

Free testosterone X DY Ligand Assay, Special 77Friedreich ataxia X MGL2 Molecular Genetics 215Fructosamine FT Fructosamine 69Fungal culture CBT Cord Blood Testing 199

SCP Stem Cell Processing 199Fungal serology FSER Fungal Serology 167Fungus identification X F Mycology 166

X F1 Yeast 166Galactomannan FGAL Galactomannan 167Gamma globulin M, OL1 CSF Chemistry 68

SPE Serum Electrophoresis 70Gamma glutamyltransferase (GGT)






110

Gamma hydroxybutyrate FTC Forensic Toxicology,Criminalistics

95

Gardnerella vaginalis,DNA Probe

X VS Vaginitis Screen 163

Gastric occult blood GOCB Gastric Occult Blood 137

�� Z�� K��

$@<

��#�

��

V�� #

Gastric pH GOCB Gastric Occult Blood 137Gastrin X ING Insulin, Gastrin,

C-Peptide, PTH79

Gaucher disease MGL4 Molecular Genetics 215Genomic copy numberarray

CYCGH CytogenomicMicroarray Analysis

211

Gentamicin X CZ, CZ2,CZ2X, CZX,Z


LN3 TDM Cal Ver/Lin 111Giardia GIP Gastrointestinal Panel 179Giardia immunoassay,preserved specimen

X P, P3, P4, P5 Parasitology 169

Giemsa stain X BP Blood Parasite 170X P Parasitology 169

Glioma by FISH CYJ Fluorescence In SituHybridization,Brain/Glioma Tissue

211

Glucose X AQ2, AQ4 Aqueous Blood Gas 84X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX



59




110

LN13C Blood Gas Cal Ver/Lin 115Glucose, CSF X M, OLI CSF Chemistry and

Oligoclonal Bands68

Glucose, urine X CMP, CMP1 Clinical Microscopy 134LN6 Urine Chemistry Cal

Ver/Lin112

POC3 POC Urine DipstickCompetency

48


63

Glucose, vitreous fluid VF Vitreous Fluid, Post-mortem

92

Glucose, whole blood X HCC Waived Combination 62X LCW Ltd Chem, Waived 61

LN17 Whole Blood GlucoseCal Ver/Lin

116

POC2 POC GlucoseCompetency

48

POC7 POC/Waived Chemistry Glucose Hgb

48

�� Z��J��}

266 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Glucose, whole blood(cont.)

X WB2 Whole Blood Glucose,Waived

62

X WBG Whole Blood Glucose 62Glucose-6-phosphatedehydrogenase

G6PDS Glucose-6 PhosphateDehydrogenase

69

Glutaraldehyde, urine DAI Urine Drug Adulterant/Integrity Testing

90

Glycated Serum albumin GSA Glycated SerumAlbumin

60

Glycogen storagedisease type 1A

MGL4 Molecular Genetics 215

Glycohemoglobin X GH2 Hemoglobin A1c 60LN15 Hemoglobin A1c Cal

Ver/Lin115

Glycosaminoglycans(mucopolysaccharides)


Gram stain X D Bacteriology 154X D2, D3, D7 Throat, Urine, GC

Cultures156

X D4 Bacteriology, Ltd 157X D5 Gram Stain 157

VGS1 Virtual Gram StainBasic

158

VGS2 Virtual Gram StainAdvanced

158

VS2 Vaginitis Screen, VirtualGram stain

164

Group A Streptococcusantigen detection


X D4 Bacteriology, Ltd 157X D6 Rapid Group A Strep 158X D9 Rapid Group A Strep,

Waived158

POC4 POC Strep ScreenCompetency

48

Group B Streptococcus X D8 Group B Strep 159Growth hormone X Y/YY Ligand Assay, Special 77Gyn cytopathology See Cytopathology

GYN proficiency testingGyn cytopathologyeducation

See CytopathologyGYN education

Haptoglobin X IG/IGX Immunology, General 182X S2/S4 Immunology, Special 183

HBeAg X VM2 Viral Markers-Series 2 201HBsAg X VM1 Viral Markers-Series 1 201HBV HBVL, HBVL5 Hepatitis Viral Load 175

X NAT Nucleic Acid Testing 203HCV HCVN,

HCV2Hepatitis Viral Load,Genotyping andQualitative

175

X NAT Nucleic Acid Testing 203

�� Z�� K��

$@<

��#�

��

V�� #

HDL cholesterol ABL Accuracy-Based Lipid 100X C1, C3, C3X,

CZ, CZ2,CZ3X, CZX


X LCW Ltd Chem, Waived 61LN2 Chemistry, Lipid,



110

Helicobacter pylori X HPS H. pylori Antigen, Stool 161POC13 Competency H. pylori

antibody49

X S2, S4 H. pylori IgG Antibody 183X S5 H. pylori IgG Antibody 183X VR3 H. pylori IgG Antibody 180

Hematocrit X AQ, AQ2,AQ3, AQ4


CBT Cord Blood Testing 199X FH1-FH4,

FH6, FH9,FH10, FH1P-FH4P, FH6P,FH9P, FH10P


X HE, HEP Basic Hematology 128POC10,POC11


49

SCP Stem Cell Processing 199X SO Blood Oximetry 85

Hematology case studies EHE1 Expanded VirtualPeripheral Blood Smear

133

Hemochromatosis X MGL1 Molecular Genetics 215Hemocytometerfluid count

X HFC HemocytometerFluid Count

137

Hemoglobin CBT Cord Blood Testing 199X FH1-FH4,

FH6, FH9-FH10,FH1P-FH4P,FH6P, FH9P-FH10P


X HCC Waived Combination 62X HE, HEP Basic Hematology 128

LN9 Hematology Cal Ver/Lin 114POC7 POC/Waived

Chemistry Glucose Hgb48

SCP Stem Cell Processing 199X SO Blood Oximetry 85

Hemoglobinelectrophoresis

X HG Hemoglobinopathy 131

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 267


$�

�� Z�� K��

$@<

��#�

��

V�� #

Hemoglobin, estimated X AQ, AQ2,AQ3, AQ4


POC10,POC11


49

Hemoglobin, plasma PHG Plasma Hemoglobin 71Hemoglobin, urine X CMP, CMP1 Clinical Microscopy 134


48

Hemoglobin A1c X GH2 Hemoglobin A1c 60LN15 Hemoglobin A1c Cal

Ver/Lin115

Hemoglobin A2 X HG Hemoglobinopathy 131Hemoglobin F X HG Hemoglobinopathy 131

SCS Sickle Cell Screen 131Hemoglobin S/C HGM Hemoglobinopathies,

Molecular Methods214

MGL2 Molecular Genetics 215Hemolytic complement,total

CH50 Total HemolyticComplement

188

Hemosiderin, urine SCM1 Special ClinicalMicroscopy

138

Heparin assay CGS4 Coag Special, Series 4 147Heparin-inducedthrombocytopenia


CGS5 Coag, Special, HIT 147CGS6 Coagulation Special 147

Heparin, low molecularweight

LN36 Heparin, LMW CalVer/Lin

120

Heparin/platelet FactorIV

CGS5 Coag, Special, HIT 147

CGS6 Coagulation Special 147Hepatitis B virus HBVL, HBVL5 Hepatitis Viral Load 175Hepatitis C virus HCVN,

HCV2Hepatitis Viral Load,Genotyping andQualitative

175

HER2, gastric GHER2 Gastric HER2 234HER2 gene amplificationby ISH

ISH2 In Situ Hybridization 219

HER2 gene amplificationby FISH, hybridizationand interpretation on site

X CYH Fluorescence In SituHybridization-BreastCancer

211

HER2 byimmunohistochemistry

X HER2 HER2 byImmunohistochemistry

234

Herpes simplex virus(HSV)

X HC2 HSV by DFA 174

X HC4 HSV Culture 174ID1 Nucleic Acid Amp,

Viruses177

X VR1 Virology Culture 173X VR2 Viral Antigen by DFA 173

�� Z�� K��

$@<

��#�

��

V�� #

Herpes simplex virus(HSV) (cont.)

X VR3 Antibody Detection-Infectious DiseaseSerology

180

HHV6 ID1 Nucleic Acid Amp,Viruses

177

VLS2 Viral Load 175HHV8 ID1 Nucleic Acid Amp,

Viruses177

High molecular weightkininogen


High-sensitivityC-reactive protein

X hsCRP hsCRP 60


117

Histotechnology qualityimprovement

HQIP,HQIPBX,HQBX1,HQBX2,HQBX3,HQIHC

HistoQIP 229-231

HIV X HIV, HV2 HIV Viral Load 175LN39 HIV Viral Load Cal

Ver/Lin120

X NAT Nucleic Acid Testing 203HIV genotyping HIVG HIV Viral Genotyping 175HIV-1 p24 antigen X VM3 Viral Markers-Series 3 201HIV-1 p24 antigen,Anti HIV 1/2

X VM6 Viral Markers-Series 6 202

HLA-A,B,C antibodyidentification





HLA-(Class I/II)crossmatching

X MX1B,MX1CMX1E, MXB,MXC




HLA-(Class I/II) antibodyscreen

MX1B,MX1C,MX1E,MX2B,MX2C,MX2E, MXB,MXC

HLA Analysis, Class I/II 206-207

�� Z��J��}

268 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

HLA-A,B,C typing(serologic)

X HLAS,HLAS1

HLA Serologic Typing 207

HLA-B27 typing X B27 HLA-B27 Typing 208HLA-B*5701 PGX2 Pharmacogenetics 217HLA-DR, DQ typing(serologic)

X HLAS HLA Serologic Typing 207

HLA molecular typing X DL, DML, ML HLA Molecular Typing 207Homocysteine X HMS Homocysteine 60

LN16 Homocysteine CalVer/Lin

116

Homovanillic acid X N/NX Urine Chemistry,Special

64

HPV (cytology), high-risk

X CHPVD Digene SpecimenTransport Medium

240

X CHPVJ Mixed Medium 240X CHPVK SurePath Preservative

Fluid Transport Medium240

X CHPVM ThinPrep PreservCytTransport Medium

240

X HPV Digene Hybrid CaptureTechnology Only

176

ISH In Situ Hybridization 219HSV X HC2 HSV by DFA 174

X HC4 HSV Culture 174ID1 Nucleic Acid Amp,

Viruses177

X VR1 Virology Culture 173X VR2 Viral Antigen by DFA 173X VR3 Antibody Detection-

Infectious DiseaseSerology

180

Human chorionicgonadotropin (hCG),serum



X FP/FPX,FP1T

Maternal Screen 80

X HCG, IL Immunology 182X K/KK Ligand Assay, General 76


112


112


113

SCO Serum Carryover 124Human chorionicgonadotropin (hCG),urine

X CMP, CMP1 Clinical Microscopy 134

�� Z�� K��

$@<

��#�

��

V�� #

Human chorionicgonadotropin (hCG),urine (cont.)

POC1 POC hCG Competency 48


48

Human herpesvirus 6 ID1 Nucleic Acid Amp,Viruses

177

VLS2 Viral Load 175Human herpesvirus 8 ID1 Nucleic Acid Amp,

Viruses177

Human immuno-deficiency virus (HIV)

X HIV, HV2 HIV Viral Load 175

HIVG HIV Genotyping 175LN39 HIV Viral Load Cal

Ver/Lin120

Humanmetapneumovirus

ID2 Nucleic Acid Amp,Respiratory

178


178

Human papillomavirus(cytology) high-risk

X CHPVD Digene SpecimenTransport Medium

240

X CHPVJ Mixed Medium 240X CHPVK SurePath Preservative


X CHPVM ThinPrep PreservCytTransport Medium

240

X HPV Digene Hybrid CaptureTechnology Only

176

ISH In Situ Hybridization 219Human papillomavirus(cytology) high-riskgenotyping

CHPVD Digene SpecimenTransport Medium

240

CHPVJ Mixed Medium 240CHPVK SurePath Preservative


CHPVM ThinPrep PreservCytTransport Medium

240

Huntington disease X MGL2 Molecular Genetics 215Hydrocodone DMPM Drug Monitoring for

Pain Management97


95


92



UT Urine Toxicology 88Hydromorphone DMPM Drug Monitoring for

Pain Management97

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 269


$�

�� Z�� K��

$@<

��#�

��

V�� #

Hydromorphone (cont.) FTC Forensic Toxicology,Criminalistics

95


92



UT Urine Toxicology 88Hydroxyzine T Toxicology 88

UT Urine Toxicology 88Ibuprofen T Toxicology 88

UT Urine Toxicology 88IDH1 GLI Glioma 221IDH2 GLI Glioma 221IgA X IG/IGX Immunology, General 182

LN7 Immunology Cal Ver/Lin 113X SPE Protein Electrophoresis 70

IgA kappa and lambda HL Heavy Chain/LightChain Analysis

IgD S2, S4 Immunology, Special 183IgE X IG/IGX Immunology, General 182

X K/KK Ligand Assay, General 76X SE Diagnostic Allergy 186

IgE allergen-specific,quantitative

SE Diagnostic Allergy 186

IgE multi-allergen screen X SE Diagnostic Allergy 186IGF-1 (somatomedin C) X BGS Bone and Growth 78

X Y/YY Ligand Assay, Special 77IgG X IG/IGX Immunology, General 182

LN7 Immunology Cal Ver/Lin 113S2, S4 Immunology, Special 183

X SPE Protein Electrophoresis 70IgG, CSF X M, OLI CSF Chemistry and

Oligoclonal Bands68

IgG subclass proteins S2, S4 Immunology, Special 183IgM X IG/IGX Immunology, General 182

LN7 Immunology Cal Ver/Lin 113X SPE Protein Electrophoresis 70

IL-2 CTKN Cytokines 186IL-6 CTKN Cytokines 186IL-8 CTKN Cytokines 186IL-10 CTKN Cytokines 186IL28B PGX1 Pharmacogenetics 217Imipramine FTC Forensic Toxicology,

Criminalistics95


X ZT, ZZT TDM, Special 57Immature granulocyteparameter

FH9, FH9P Hematology, Auto Diff 129

�� Z�� K��

$@<

��#�

��

V�� #

Immunohistochemistry X HER2 HER2 byImmunohistochemistry

234

MK Immunohistochemistry 232PM1 CD117 by

Immunohistochemistry232

X PM2 ER, PR byImmunohistochemistry

234

PM3 CD20 byImmunohistochemistry

232

India ink IND India Ink 168Infectiousmononucleosis (IM)

X IL, IM Immunology 182

X IMW InfectiousMononucleosis, Waived

183

Influenza virus ID2 Nucleic Acid Amp,Resp

178


178

POC8 POC Influenza A/B Ag 48X VR1 Virology Culture 173X VR2 Viral Antigen Detection

by DFA173


174

In situ hybridization ISH In Situ Hybridization 219ISH2 In Situ Hybridization

HER2219

Instrument function I Instrumentation 122Instrument linearity I Instrumentation 122


110


110

LN3 TDM Cal Ver/Lin 111LN5 Ligand Assay Cal

Ver/Lin112

LN6 Urine Chemistry CalVer/Lin

112

LN7 Immunology Cal Ver/Lin 113LN8 Reproductive

Endocrinology CalVer/Lin

113

LN9 Hematology Cal Ver/Lin 114LN11 Serum Ethanol Cal

Ver/Lin114

LN12 C-Reactive Protein CalVer/Lin

114

LN13 Blood Gas Cal Ver/Lin 115LN13C Blood Gas Cal Ver/Lin 115

�� Z��J��}

270 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Instrument linearity(cont.)


115

LN15 Hemoglobin A1c CalVer/Lin

115

LN16 Homocysteine CalVer/Lin

116

LN17 Whole Blood GlucoseCal Ver/Lin

116

LN18, LN19 Reticulocyte Cal Ver/Lin 116LN20 Urine Albumin Cal

Ver/Lin116


117


117

LN23 PSA Cal Ver/Lin 117LN24 Creatinine Accuracy

Cal Ver/Lin118

LN25 Troponin I Cal Ver/Lin 118LN27 Troponin T Cal Ver/Lin 118LN30 BNP Cal Ver/Lin 118LN31 Immunosuppressive

Drugs Cal Ver/Lin119

LN32 Ammonia Cal Ver/Lin 119LN33 Serum Myoglobin Cal

Ver/Lin119

LN34 CA-125 Cal Ver/Lin 119LN35 Thrombophilia Cal

Ver/Lin120

LN36 Heparin Cal Ver/Lin 120LN37 von Willebrand Factor

Ag Cal Ver/Lin120

LN38 CMV viral load CalVer/Lin

120

LN39 HIV Viral Load CalVer/Lin

120

LN40 Vitamin D Cal Ver/Lin 120LN41 Procalcitonin Cal

Ver/Lin121

LN42 D-Dimer Cal Ver/Lin 121Insulin X ING Insulin, Gastrin,

C-Peptide, PTH79

Interferon (IFN) gamma CTKN Cytokines 186Interleukin (IL)-1 beta CTKN Cytokines 186International normalizedratio (INR)

X CGL Coagulation, Ltd 146

CGS1 Coag Special, Series 1 147CGS4 Coag Special, Series 4 147POC5 POC PT/INR, i-STAT 48POC6 POC PT/INR,

CoaguChek XS Plus48

�� Z�� K��

$@<

��#�

��

V�� #

International normalizedratio (INR) (cont.)

X WP3, WP4,WP6, WP9

Whole BloodCoagulation

150

WP10 Whole BloodCoagulation

150

Ionized calcium X AQ, AQ2,AQ3, AQ4


X C3, CZ,CZ2, CZX


POC10,POC11


49

LN13C Blood Gas Cal Ver/Lin 115Iron X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX



59




110

Isopropanol X AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93


93

JC virus ID1T Nucleic Acid Amp, JCand BK

177

Jo-1 (antihistidyl t-RNAsynthetase)

RDS Rheumatic DiseaseSpecial

187

JWH-018 N-(4-hydroxypentyl)metabolite

SCDD Synthetic Cannabinoid/Designer Drugs

96



96

JWH-018 N-PentanoicAcid


96

JWH-073 N-(3-hydroxybutyl) metabolite


96

JWH-073 N-(4-hydroxybutyl) metabolite


96

JWH-073 N-ButanoicAcid


96



96



96

Kaolin activated APTT CGE/CGEX Coagluation, Extended 146Kaolin activated CT CGE/CGEX Coagluation, Extended 146Kappa/lambda ISH In Situ Hybridization 219

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 271


$�

�� Z�� K��

$@<

��#�

��

V�� #

Kappa/lambda ratio IG/IGX Immunology, General 182S2, S4 Immunology, Special 183

Free Kappa/Lambdaratio

SFLC Serum Free LightChains

188

Karyotype nomenclature X CY, CYBK Cytogenetics 210Kearns-Sayre syndrome IMD1 Mitochondrial DNA

Deletion Syndromes216

Ketamine FTC Forensic Toxicology,Criminalistics

95


Ketones, serum KET Ketones 60Ketones, urine X CMP, CMP1 Clinical Microscopy 134


48

Kidney stone assessment KSA Kidney StoneAssessment

64

KIT/PDGFRA KIT KIT/PDGFRA 221KOH prep X CMMP Clinical Microscopy,

Misc134

FSM Fungal Smear 167KRAS KRAS Colorectal Cancer

Mutation221

MTP Multigene Tumor Panel 221Laboratory PreparednessExercise

LPX LaboratoryPreparedness Exercise

161

Laboratory ManagementIndex Program

LMB Quality ManagementTools

43

Lactate X AQ, AQ2,AQ3, AQ4




FLD Body Fluid 67POC10,POC11


49

LN13C Blood Gas Cal Ver/Lin 115Lactate, CSF X M, OLI CSF Chemistry and

Oligoclonal Bands68

Lactate dehydrogenase(LD)






110

SCO Serum Carryover 124

�� Z�� K��

$@<

��#�

��

V�� #

Lactate dehydrogenase(LD), CSF

X M, OLI CSF Chemistry andOligclonal Bands

68

Lamellar body count LBC Lamellar Body Count 137Lamotrigine T Toxicology 88

UT Urine Toxicology 88ZE Therapeutic Drug

Monitoring, Extended57

Large unclassified cells(LUC)

FH4, FH4P Hematology, Auto Diff 129

LD isoenzymes X CRTI Cardiac Markers 59LD1/LD2 ratio X CRTI Cardiac Markers 59LDL cholesterol ABL Accuracy-Based Lipid 100LDL cholesterol,calculated

C1, C3,C3X, CZ,CZ2, CZ2X,CZX


LDL cholesterol,measured

X C1, C3,C3X, CZ,CZ2, CZ2X,CZX


LDL cholesterol, waived X LCW Ltd Chem, Waived 61Lead (blood) X BL Blood Lead 94Lead, urine TMU Trace Metals, Urine 94Leber hereditary opticneuropathy

IMD3 Mitochondrialcytopathies

216

Lecithin:sphingomyelin(L:S) ratio

LM, LM1 Lung Maturity 70

Legionella pneumophila IDO Nucleic Acid Amp,Organisms

177

Legionella X LBAS Legionella Ag 159Leigh syndrome IMD1 Mitochondrial DNA

Deletion Syndromes216

Leukemia/lymphomaimmunophenotype

FL3, FL3CD Flow Cytometry 189

Leukemia/lymphomainterpretation only

FL5 Flow CytometryInterpretation Only

190

Leukocyte esterase, urine X CMP, CMP1 Clinical Microscopy 134POC3 POC Urine Dipstick

Competency48

Leukocyte-reducedplatelets

TRC Transfusion-Related CellCount

200

Leukocyte-reduced RBC TRC Transfusion-Related CellCount

200

Leukocyte, stool, Wright-Giemsa

X CMMP Clinical Microscopy,Misc

134

Levetiracetam ZE Therapeutic DrugMonitoring, Extended

57

Lidocaine X CZ, CZ2,CZ2X, CZX,Z


LN3 TDM Cal Ver/Lin 111

�� Z��J��}

272 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Lidocaine (cont.) T Toxicology 88UT Urine Toxicology 88

Lipase X C3, C3X,CZ, CZ2,CZ2X, CZX





110

Lipids ABL Accuracy-Based Lipid 100X C1, C3, C3X,

CZ, CZ2,CZ2X, CZX



110


110

Lipoprotein (a) X ABL Accuracy-Based Lipid 100X C1, C3,

C3X, CZ,CZ2, CZ2X,CZX


Lipoprotein-associatedphospholipase

PLA Lp-PLA2 69

Lipoproteinelectrophoresis

LPE LipoproteinElectrophoresis

70

Lithium X C1, C3,C3X, CZ,CZ2, CZ2X,CZX, Z


LN3 TDM Cal Ver/Lin 111Liver-kidney microsomalantibody

LKM Liver-KidneyMicrosomal Antibody

187

Lorazepam DMPM Drug Monitoring forPain Management

97


95



UT Urine Toxicology 88Lupus anticoagulant(screen, conf)


CGS1 Coag Special, Series 1 147Luteinizing hormone (LH) LN8 Reproductive


113

X Y/YY Ligand Assay, Special 77

�� Z�� K��

$@<

��#�

��

V�� #

Lyme disease TTD Tick-TransmittedDisease

180

Lymphocyteimmunophenotyping

X FL, FL1 Flow Cytometry 189

Lymphoma by FISH CYL Fluorescence InSitu Hybridization,Lymphoma

211

Lysergic aciddiethylamide (LSD)


95


Magnesium X C1, C3, C3X,CZ, CZ2,CZ2X, CZX



59




110

Magnesium, ionized X AQ, AQ2,AQ3, AQ4




49

Magnesium, urine X U Urine Chemistry,General

63

Malaria RMAL Rapid Malaria 170Manganese R Trace Metals 72Maprotiline T Toxicology 88

UT Urine Toxicology 88MCAD IMD2 MCAD 216MCH FH1-FH4,



MCHC FH1-FH4,FH6, FH9,FH10, FH1P-FH4P, FH6P,FH9P, FH10P


MECP2 genotyping RETT RETT SyndromeGenotyping

217

Mercury, urine TMU Trace Metals, Urine 94MEN2 X MGL3 Molecular Genetics 215Meperidine DMPM Drug Monitoring for

Pain Management97

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 273


$�

�� Z�� K��

$@<

��#�

��

V�� #

Meperidine (cont.) FTC Forensic Toxicology,Criminalistics

95


Mephedrone SCDD Synthetic Cannabinoid/Designer Drugs

96

Meprobamate DMPM Drug Monitoring forPain Management

97


95


Metabolic disease testing BGL Biochemical Genetics 213Metanephrine X N/NX Urine Chemistry,

Special64

Methadone DMPM Drug Monitoring forPain Management

97


95


92




Methadone metabolite(EDDP)


97


95




Methamphetamine DMPM Drug Monitoring forPain Management

97


95


92




Methanol X AL1 Whole Blood Alcohol/Ethylene Glycol/Volatiles

93


93

�� Z�� K��

$@<

��#�

��

V�� #

Methaqualone UDC Forensic Urine DrugTesting, Confirmatory

91

UDS, UDS6 Urine Drug Screen 90Methicillin-resistantStaphylococcus aureus(MRSA)


159


177

X MRS, MRS5 Methicillin-ResistantS. aureus

162

Methemoglobin X SO Blood Oximetry 85Methotrexate X CZ, CZ2,

CZ2X, CZX,Z


Methotrimeprazine T Toxicology 88UT Urine Toxicology 88

Methylenedioxy-amphetamine (MDA)


97


95


92



UT Urine Toxicology 88Methylenedioxyethyl-amphetamine (MDEA)


91

Methylenedioxymeth-amphetamine (MDMA)


97


95


92




Methylenedioxy-pyrovalerone (MDPV)


96

Methylenetetra-hydrofolate reductase(MTHFR)

X MGL1 Molecular Genetics 215

Methylone SCDD Synthetic Cannabinoid/Designer Drugs

96

Methylphenidate T Toxicology 88UT Urine Toxicology 88

Metoprolol T Toxicology 88UT Urine Toxicology 88

MGMT GLI Glioma 221

�� Z��J��}

274 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Microalbumin, urine LN20 Urine AlbuminCalVer/Lin

116

X U Urine Chemistry 63X UMC Urine Albumin

(Microalbumin)/Creatinine

138

Microsatellite instability MSI Microsatellite Instability 219Microtiter plate readerlinearity


Minimal residual disease MRD Minimal ResidualDisease, BCR/ABL1p210

222

MRD1 Minimal ResidualDisease, BCR/ABL1p190

222

MRD2 Minimal ResidualDisease, PML/RARA

222

Mirtazapine T Toxicology 88UT Urine Toxicology 88

Mite identification TMO Ticks, Mites, and OtherArthropods

171

Mitochondrial DNA,forensic

DNA, DNAF DNA Database 246

FIDM Forensic Identity 246Mixing studies, PT CGE/CGEX Coagulation, Extended 146Mixing studies, APTT CGE/CGEX Coagulation, Extended 146

CGS1 Coag Special, Series 1 147Modified acid-fast stain X P, P3, P4, P5 Parasitology 169Mold identification X F Mycology 166Molecular genetics X MGL1,

MGL2,MGL3,MGL4,MGL5

Molecular Genetics 215

Molecular HLA typing X DL, DML, ML HLA Molecular Typing 207Molecular hematologiconcology

MHO,MHO1,MHO2,MHO3,MHO5

Molecular HematologicOncology

222

Molecular typing IDO Nucleic Acid Amp,Organisms

177

Monitoring engraftment X ME Monitoring Engraftment 208Mononuclear cell count CBT Cord Blood Testing 199

SCP Stem Cell Processing 199Morphine DMPM Drug Monitoring for

Pain Management97


95


92

�� Z�� K��

$@<

��#�

��

V�� #

Morphine (cont.) T Toxicology 88UDC Forensic Urine Drug


UT Urine Toxicology 88M-protein (paraprotein)identification

X SPE Protein Electrophoresis 70

MRSA BCS1 Blood CultureStaphylococcus aureus

159


177


162

Mucolipidosis IV MGL4 Molecular Genetics 215Mucopolysaccharide(Glycosaminoglycan)

X BGL Biochemical Genetics 213

Multiple endocrineneoplasia type 2 (MEN2)


Mumps-IgG VR3M Virology 180Mycobacterial culture X E1 Mycobacteriology, Ltd 165Mycobacterialidentification

X E Mycobacteriology 165

Mycobacteriumtuberculosis


177

Mycobacteriumtuberculosis antibodydetection

QF M. tuberculosis InfectionDetection

187

Mycophenolic acid X MPA Mycophenolic Acid 57Mycoplasmapneumoniae


177

VR3 Antibody Detection-Infectious DiseaseSerology

180

Myoclonus epilepsywith ragged red fibers(MERRF)

IMD3 Mitochondrialcytopathies

216

Myoglobin X CRT, CRTI Cardiac Markers 59LN33 Serum Myoglobin Cal

Ver/Lin119

X PCARM,PCARMX


61


49

Myoglobin, urine MYG Myoglobin, Urine 64Myotonic dystrophy X MGL2 Molecular Genetics 215N-acetylprocainamide(NAPA)

X CZ, CZ2,CZ2X, CZX,Z


LN3 TDM Cal Ver/Lin 111Naproxen T Toxicology 88

UT Urine Toxicology 88

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 275


$�

�� Z�� K��

$@<

��#�

��

V�� #

Nasal smears,eosinophil

X CMMP Clinical Microscopy,Misc.

134

Neisseria gonorrhoeae X D3 GC Cultures 156X D4 Bacteriology, Ltd 157X HC6/HC6X C. trachomatis/GC by

Nucleic Acid Amp176

Neoplastic cellularity NEO Neoplastic Cellularity 220Neoplastic disorder byFISH

CYF Fluorescence In SituHybridization

210

Neuropathology NP/NP1 NeuropathologyProgram

235

Neutral fats FCFS Fecal Fat 69Nicotine T Toxicology 88

UT Urine Toxicology 88Niemann-Pick disease MGL4 Molecular Genetics 215Nitrite, urine X CMP, CMP1 Clinical Microscopy 134

DAI Urine Drug Adulterant/Integrity Testing

90


48

Nitrogen, total, urine U Urine Chemistry,General

63

Nongynecologiccytopathology

FNA/FNA1 Fine-NeedleAspiration-Digital

243

FNAG/FNAG1

Fine-NeedleAspiration-Glass

244

NGC/NGC1 NongynecologicCytopathologyEducation Program

242

Norbuprenorphine DMPM Drug Monitoring forPain Management

97


Norchlordiazepoxide T Toxicology 88UT Urine Toxicology 88

Norcodeine T Toxicology 88UT Urine Toxicology 88

Norcyclobenzaprine T Toxicology 88UT Urine Toxicology 88

Nordiazepam DMPM Drug Monitoring forPain Management

97


95



UT Urine Toxicology 88Nordoxepin FTC Forensic Toxicology,

Criminalistics95


�� Z�� K��

$@<

��#�

��

V�� #

Norepinephrine X N/NX Urine Chemistry,Special

64

Norfentanyl DMPM Drug Monitoring forPain Management

97


Norfluoxetine FTC Forensic Toxicology,Criminalistics

95


Norketamine T Toxicology 88UT Urine Toxicology 88

Normeperidine T Toxicology 88UT Urine Toxicology 88

Normetanephrine X N/NX Urine Chemistry Special 64Norovirus GIP Gastrointestinal Panel 179

SP1 Stool Pathogens 162Norpropoxyphene DMPM Drug Monitoring for

Pain Management97


95



UT Urine Toxicology 88Norsertraline T Toxicology 88

UT Urine Toxicology 88Nortrimipramine T Toxicology 88

UT Urine Toxicology 88Nortriptyline FTC Forensic Toxicology,

Criminalistics95


X ZT, ZZT TDM, Special 57Norverapamil T Toxicology 88

UT Urine Toxicology 88nRBC FH3, FH3P,

FH9, FH9PHematology, Auto Diff 129

NT-pro B-type natriureticpeptides

X BNP BNP 58

LN30 BNP Cal Ver/Lin 118N-telopeptide (NTX) BMV6 Bone Markers and

Vitamin79

X BU Bone and Mineral,Urine

78

Nucleated cells, total CBT Cord Blood Testing 199SCP Stem Cell Processing 199

Nucleated red cells, total ABF3 Automated Body Fluid 135CBT Cord Blood Testing 199SCP Stem Cell Processing 199

�� Z��J��}

276 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Nucleated red blood cellcount

FH3, FH3P,FH9, FH9P


Nucleic acidamplification

BSTE Bacterial Strain TypingEnterococcus

176

BSTS Bacterial Strain TypingStaphylococcus

176

HBVL, HBVL5HCVN,HCV2

Hepatitis Viral Load 175

X HC6/HC6X C. trachomatis/GC byNucleic Acid Amp

176

X HIV, HV2 HIV Viral Load 175IDO Nucleic Acid Amp,

Organisms177

ID1, ID1T Nucleic Acid Amp,Viruses

177


178


162

SP, SP1 Stool Pathogens 162VLS, VLS2 Viral Load 175VRE Vancomycin-Resistant

Enterococcus164

Nucleic acid testing X NAT Nucleic Acid Testing 203O-desmethyltramadol T Toxicology 88

UT Urine Toxicology 88Occult blood OCB Occult Blood 138

POC9 POC Fecal Occult Blood 48Occult blood, gastric GOCB Gastric Occult Blood 137Ocular micrometer check I Instrumentation 122Olanzapine T Toxicology 88

UT Urine Toxicology 88Oligoclonal bands X OLI Oligoclonal Bands 68Opiate group DMPM Drug Monitoring for

Pain Management97


92

T Toxicology 88UDS, UDS6 Urine Drug Screen 90UT Urine Toxicology 88UTCO Urine Toxicology

Carryover124

Organic acids, urinequalitative

X BGL Biochemical Genetics 213

Organic acids, urinequantitative


Osmolality, measured X C3, C3X,CZ, CZ2,CZ2X, CZX


IFS Interfering Substances 123

�� Z�� K��

$@<

��#�

��

V�� #

Osmolality, measured(cont.)


110


110

Osmolality, sweat X SW1, SW2,SW3, SW4


Osmolality, urine X CMP, CMP1 Clinical Microscopy 134LN6 Urine Chemistry Cal

Ver/Lin112


48


63

Osmometer check I Instrumentation 122Osteocalcin BGS Bone and Growth 78Oxazepam FTC Forensic Toxicology,

Criminalistics95



UT Urine Toxicology 88Oxcarbazepinemetabolite

ZE Therapeutic DrugMonitoring, Extended

57

Oxidants, urine DAI Urine Drug Adulterant/Integrity Testing

90

Oxycodone DMPM Drug Monitoring forPain Management

97


95


92




Oxyhemoglobin X SO Blood Oximetry 85Oxymorphone DMPM Drug Monitoring for

Pain Management97


95


92



UT Urine Toxicology 88p63 PM5 Immunohistochemistry

TMA233

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 277


$�

�� Z�� K��

$@<

��#�

��

V�� #

Pancreatic amylase X C1, C3, C3X,CZ, CZ2,CZ2X, CZX


PAPP-A FP1B First Trimester MaternalScreening, Free Beta

80

FP1T First Trimester MaternalScreening, Total hCG

80

Parainfluenza virus ID2 Nucleic Acid Amp,Respiratory

178


178

X VR1 Virology Culture 173X VR2 Viral Antigen Detection

by DFA173

Paraproteinidentification


Parasite identification X BP Blood Parasite 170X P, P3, P4, P5 Parasitology 169

Parathyroid hormone(PTH)

X ING Insulin, Gastrin,C-Peptide, PTH

79

Parentage/relationshiptesting

X PAR, PARF Parentage/Relationship 204

Paroxetine FTC Forensic Toxicology,Criminalistics

95


Parvovirus B19 ID1 Nucleic Acid Amp,Viruses

177

PCO2 X AQ, AQ2,AQ3, AQ4


POC10,POC11


49

LN13,LN13C

Blood Gas Cal Ver/Lin 115

Pearson syndrome IMD1 Mitochondrial DNADeletion Syndromes

216

PerformanceImprovement Program inSurgical Pathology

PIP/PIP1,PIPW/PIPW1

PerformanceImprovement Programin Surgical Pathology

224-225

Peripheral blood smear,virtual

VPBS Virtual Peripheral BloodSmear

132

pH AFL Amniotic Fluid Leakage 135X AQ, AQ2,

AQ3, AQ4Aqueous Blood Gas 84

FLD Body Fluid 67GOCB Gastric Occult Blood 137POC10,POC11


49

LN13,LN13C


pH, urine X CMP, CMP1 Clinical Microscopy 134

�� Z�� K��

$@<

��#�

��

V�� #

pH, urine (cont.) DAI Urine Drug Adulterant/Integrity Testing

90


48


91

pH meters I Instrumentation 122Phencyclidine FTC Forensic Toxicology,

Criminalistics95


92




Phenethylamine FTC Forensic Toxicology,Criminalistics

95


Pheniramines T Toxicology 88UT Urine Toxicology 88

Phenobarbital X CZ, CZ2,CZ2X, CZX, Z



95

LN3 TDM Cal Ver/Lin 111T Toxicology 88UDC Forensic Urine Drug


UT Urine Toxicology 88Phentermine FTC Forensic Toxicology,

Criminalistics95


Phenylephrine T Toxicology 88UT Urine Toxicology 88

Phenylpropanolamine T Toxicology 88UT Urine Toxicology 88

Phenytoin X CZ, CZ2,CZ2X, CZX, Z



95

LN3 TDM Cal Ver/Lin 111SCO Serum Carryover 124T Toxicology 88UT Urine Toxicology 88

Phenytoin, free X CZ, CZ2,CZ2X, CZX, Z


Phosphatidylglycerol(PG)

X LM, LM1 Lung Maturity 70

�� Z��J��}

278 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Phosphorus X C3, C3X,CZ, CZX,CZ2, CZ2X



59




110

Phosphorus, urine LN6 Urine Chemistry CalVer/Lin

112


63

Pinworm prep X CMMP Clinical Microscopy,Misc

134

Pipette calibration-gravimetric


Plasma hemogloblin PHG Plasma Hemoglobin 71Plasminogen antigen CGE/CGEX Coagulation, Extended 146Plasminogen activatorinhibitor


Plasminogen activatorinhibitor (PAI)-1

MGL1 Molecular Genetics 215

Platelet aggregation PF Platelet Function 149Platelet inducedaggregation

PIA Platelet Function 151

Platelet antibodydetection

X PS Platelet Serology 200

Platelet count X FH1-FH4,FH6, FH9,FH10, FH1P-FH4P, FH6P,FH9P, FH10P


X HE, HEP Basic Hematology 128LN9 Hematology Cal Ver/Lin 114

Platelet count (Platelet-rich plasma)

X TRC Transfusion-Related CellCount

200

Platelet crossmatch PS Platelet Serology 200Platelet dysfunction PF1 Platelet Function 149Platelet mapping PLTM Platelet Mapping 151Platelet morphology EHE1 Expanded Virtual

Peripheral Blood Smear133

PML/RARA MRD2 Minimal ResidualDisease

222

PNA FISH-Enterococcus PNA3 PNA FISH forEnterococcus

160

PNA FISH-Gram-Negative Rods

PNA4 PNA FISH for Gram-Negative Rods

160

PNA FISH-Staphylococcus

PNA1 PNA FISH forStaphylococcus

160

�� Z�� K��

$@<

��#�

��

V�� #

PNA FISH-Yeast PNA2 PNA FISH for Yeast 160Pneumocystis detection PCP1 Pneumocystis jiroveci,

Calcofluor White Stain168

PCP2 Pneumocystis jiroveci,DFA Stain

168

PCP3 Pneumocystis jiroveci,Giemsa Stain

168

PCP4 Pneumocystis jiroveci,GMS Stain

168

PNH immunophenotype PNH Paroxysmal NocturnalHemoglobinuria, RBC

190

PO2 X AQ, AQ2,AQ3, AQ4


LN13,LN13C


POC10,POC11


49

Postanalytical DNAsequencing

SEC DNA Sequencing Count 216

Postvasectomy spermcount

X PV Postvasectomy SpermCount

142

Potassium X AQ, AQ2,AQ3, AQ4


X C1, C3, C3X,CZ, CZX,CZ2, CZ2X



59




110



49

Potassium, urine LN6 Urine Chemistry CalVer/Lin

112


63

Potassium, vitreous fluid VF Vitreous Fluid, Post-mortem

92

PRA MX1B,MX1C,MX1E, MXB,MXC


MX2B,MX2C,MX2E, MXB,MXC


�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 279


$�

�� Z�� K��

$@<

��#�

��

V�� #

Prader-Willi/AngelmanSyndrome


Prealbumin(transthyretin)

X C3, C3X,CZ, CZX,CZ2, CZ2X


X S2, S4 Immunology, Special 183Prekallikrein CGE/CGEX Coagulation, Extended 146Predictive markers byimmunohistochemistry

X HER2 HER2 byImmunohistochemistry

234


232


234


232

Primidone X CZ, CZX,CZ2, CZ2X,Z


LN3 TDM Cal Ver/Lin 111Pro B-type natriureticpeptides

X BNP B-Type NatriureticPeptides

58

Procainamide X CZ, CZX,CZ2, CZ2X,Z


LN3 TDM Cal Ver/Lin 111Procalcitonin LN41 Procalcitonin Cal

Ver/Lin121

PCT Procalcitonin 71Progesterone LN8 Reproductive


113

X Y/YY Ligand Assay, Special 77Progesterone receptorsby immunohistochemistry


234

Prolactin LN8 ReproductiveEndocrinology CalVer/Lin

113

X Y/YY Ligand Assay, Special 77Propoxyphene DMPM Drug Monitoring for

Pain Management97


95




Carryover124

Propranolol T Toxicology 88UT Urine Toxicology 88

�� Z�� K��

$@<

��#�

��

V�� #

Prostate-specific antigen(PSA)

X K/KK Ligand Assay, General 76

LN23 PSA Cal Ver/Lin 117Prostate-specific antigen,complexed (cPSA)


Prostate-specific antigen,free (PSA, free)


Prostatic acidphosphatase (PAP)


Protein electrophoresis,serum, interpretation


Protein C CGE/CGEX Coagulation, Extended 146CGS2 Coag Special, Series 2 147LN35 Thrombophilia Cal

Ver/Lin120

Protein S CGE/CGEX Coagulation, Extended 146CGS2 Coag Special, Series 2 147

Protein, total X C1, C3, C3X,CZ, CZX,CZ2, CZ2X



59




110

SPE Lipoprotein and ProteinElectrophoresis

70

Protein, CSF X M, OLI CSF Chemistry andOligoclonal Bands

68

Protein, urine X CMP, CMP1 Clinical Microscopy 134DSC Dipstick Confirmatory 136LN6 Urine Chemistry Cal

Ver/Lin112


48


63

Prothrombin mutation X MGL1 Molecular Genetics 215TPM Thrombophilia

Mutations217

Prothrombin fragment1.2


Prothrombin time X CGL Coagulation, Ltd 146CGS1 Coag Special, Series 1 147CGS4 Coag Special, Series 4 147DBGN Anticoagulant

Monitoring, Dabigatran148

�� Z��J��}

280 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Prothrombin time (cont.) FNPX AnticoagulantMonitoring,Fondaparinux

148

POC5 POC PT/INR, i-STAT 48POC6 POC PT/INR,

CoaguChek XS Plus48

RVBN AnticoagulantMonitoringRivaroxaban

148

X WP3, WP4,WP6, WP9

Whole BloodCoagulation

150

Prothrombin time, dilute CGE/CGEX Coagulation, Extended 146Provider-performedmicroscopy

X CMMP Clinical Microscopy,Misc

134

Pseudocholinesterase X C7 Pseudocholinesterase 71Pseudoephedrine FTC Forensic Toxicology,

Criminalistics95


Pyridinoline (PYD) BU Bone and Mineral,Urine

78

Q-MONITORS QM1 Quality ManagementTools

41

Q-PROBES QP 141 Quality ManagementTools

28

QP 142 Quality ManagementTools

29


30


31

Q-TRACKS QT1-5 Quality ManagementTools

33-34,38

QT7, 8, 10 Quality ManagementTools

35-36

QT15-17,19

Quality ManagementTools

36-37,39

Quetiapine T Toxicology 88UT Urine Toxicology 88

Quinidine X CZ, CZX,CZ2, CZ2X, Z



Quinine T Toxicology 88UT Urine Toxicology 88

Ranitidine T Toxicology 88UT Urine Toxicology 88

Rapamycin (sirolimus) X CS ImmunosuppressiveDrugs

56

Rapid Group A Strep X D Bacteriology 154

�� Z�� K��

$@<

��#�

��

V�� #

Rapid Group A Strep(cont.)

X D4 Bacteriology, Ltd 157

X D6 Rapid Group A Strep 158X D9 Rapid Group A Strep,

Waived158

RBC count ABF1, ABF2,ABF3




X HE, HEP Basic Hematology 128X HFC Hemocytometer

Fluid Count137

LN9 Hematology Cal Ver/Lin 114RBC count, urine UAA, UAA1 Automated Urinalysis 136RBC folate X FOL RBC Folate 81RBC morphology EHE1 Expanded Virtual

Peripheral Blood Smear133

Red blood cell antigendetection

J, J1 Transfusion Medicine 194

PAR Parentage/Relationship 204Red blood cell antigengenotyping

RAG Red blood cell antigengenotyping

200

Reducing substance,urine



48

Refractometer check I Instrumentation 122Renin X RAP Renin and Aldosterone 81Reptilase time CGE/CGEX Coagulation, Extended 146Respiratory syncytialvirus (RSV)


178


178


by DFA173

X VR4 Virology AntigenDetection by EIA andLatex

174

Reticulocyte count,percent

LN18, LN19 Reticulocyte Cal Ver/Lin 116

X RT, RT2, RT3,RT4

Reticulocyte 131

Reticulocyte count,absolute

RT, RT2, RT3,RT4

Reticulocyte 131

RETT Syndrome RETT RETT SyndromeGenotyping

217

RhD X MGL2 Molecular Genetics 215

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 281


$�

�� Z�� K��

$@<

��#�

��

V�� #

RhD typing X J, J1 Transfusion Medicine 194X JAT Transfusion Medicine,

Automated194


195


196

Rheumatoid factor X IL, RF/RFX Immunology 182Rhinovirus ID2 Nucleic Acid Amp,

Respiratory178


178

Rotavirus GIP Gastrointestinal Panel 179SP Stool Pathogens 162


174

RSV ID2 Nucleic Acid Amp,Respiratory

178


by DFA173


174

Rubella antibody, IgG X IL, RUB/RUBX

Immunology 182

Rubeola antibody(English measles)


180

Rupture of FetalMembranes

ROM1 Rupture of FetalMembranes

138

Russell’s viper venomtime, dilute


Salicylate X CZ, CZX,CZ2, CZ2X,Z


LN3 TDM Cal Ver/Lin 111X SDS Serum Drug Screen 93


Salmonella GIP Gastrointestinal Panel 179Sarcoma by FISH CYK Fluorescence In Situ

Hybridization211

Sarcoma translocation SARC Sarcoma Translocation 220Scl-70 (anti-DNAtopoisomerase)

RDS Rheumatic DiseaseSpecial

187

Secobarbital FTC Forensic Toxicology,Criminalistics

95


91

Selenium X R Trace Metals 72Selenium, urine TMU Trace Metals, Urine 94

�� Z�� K��

$@<

��#�

��

V�� #

Semen analysis X ASA, SC,SV, PV

Semen Analysis 142

SC1, SM Semen Analysis 142SMCD,SM1CD,SM2CD

Semen Analysis,CD-ROM

142

Sertraline FTC Forensic Toxicology,Criminalistics

95


Serum free light chains SFLC Serum Free LightChains

188

Sex hormone-bindingglobulin (SHBG)

X DY Ligand Assay, Special 77

Shiga toxin SP Stool Pathogens-Rapidand Molecular

162

ST Shiga Toxin 163Shiga-like toxinproducing E. coli (STEC)


Shigella GIP Gastrointestinal Panel 179Sickle cell screen X HG Hemoglobinopathy 131

X SCS Sickle Cell Screen 131Sirolimus (Rapamycin) X CS Immunosuppressive

Drugs56

Sodium X AQ, AQ2,AQ3, AQ4





59




110



49

Sodium, sweat X SW1, SW2,SW3, SW4


Sodium, urine LN6 Urine Chemistry CalVer/Lin

112


63

Sodium, vitreous fluid VF Vitreous Fluid, Post-mortem

92

Soluble transferrinreceptor

STFR Soluble TransferrinReceptor

74

Somatomedin C (IGF-1) X Y, YY Ligand Assay, Special 77

�� Z��J��}

282 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Specific gravity X CMP, CMP1 Clinical Microscopy 134DAI Urine Drug Adulterant/

Integrity Testing90


48


91

Spectrophotometerlinearity


Sperm count X SMCD Semen Analysis,CD-ROM

142

Sperm count, automated SC1 Semen Analysis 142Sperm count, manual X SC Semen Analysis 142

X PV Postvasectomy SpermCount

142

Sperm morphology SM Semen Analysis 142SM1CD Semen Analysis,

CD-ROM142

Sperm motility SMCD Semen Analysis,CD-ROM

142

Sperm viability SM2CD Semen Analysis,CD-ROM

142

X SV Semen Analysis 142Spinal fluid meningitispanel


Spinal muscular atrophy X MGL2 Molecular Genetics 215Spinocerebellar ataxia X MGL2 Molecular Genetics 215Split fats FCFS Fecal Fat 69Staphylococcus aureus-blood culture


159

STEC (Shiga-like toxinproducing E. coli)


Strep screen POC4 POC/Waived StrepScreen Competency

48

Streptococcusagalactiae

X D8 Group B Strep 159

Streptococcuspneumoniae

X SBAS S. pneumoniae AgDetection

159

Streptococcus pyogenes X D Bacteriology 154X D1, D7 Throat, Urine Cultures 156X D4 Bacteriology, Ltd 157X D6 Rapid Group A Strep 158X D9 Rapid Group A Strep,

Waived158

Strychnine T Toxicology 88UT Urine Toxicology 88

Sulfosalicylic acid (SSA) DSC Dipstick Confirmatory 136Surgical pathology DPATH/

DPATH1Online Digital SlideProgram

227

�� Z�� K��

$@<

��#�

��

V�� #

Surgical pathology(cont.)

PIP/PIP1,PIPW/PIPW1

PerformanceImprovement Programin Surgical Pathology

224-225

PCSP, PCSP1 Practicum in CancerSurgical Pathology

228

VBP/VBP1 Online Virtual BiopsiesProgram

226

Synthetic Cannabanoid/Designer Drugs

SCDD SyntheticCannabanoid/Designer Drugs

96

Syphilis X G Syphilis Serology 187T3, free(triiodothyronine)

ABTH Accuracy-BasedThyroid

102



X K/KK Ligand Assay, General 76T3, total(triiodothyronine)


102




Ver/Lin112


112

T3 uptake & relatedtests



X K/KK Ligand Assay, General 76T4, free (thyroxine, free) ABTH Accuracy-Based

Thyroid102



X K/KK Ligand Assay, General 76T4, total (thyroxine,total)


102




59


Ver/Lin112


112

Tacrolimus X CS ImmunosuppressiveDrugs

56

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 283


$�

�� Z�� K��

$@<

��#�

��

V�� #

Tacrolimus (cont.) LN31 ImmunosuppressiveDrugs Cal Ver/Lin

119

Tay Sachs MGL4 Molecular Genetics 215tCO2 AQ, AQ2,

AQ3, AQ4Aqueous Blood Gas 84

POC10,POC11


49

Temazepam DMPM Drug Monitoring forPain Management

97


95



UT Urine Toxicology 88Testosterone ABS Accuracy-Based 101


113

X Y/YY Ligand Assay, Special 77Testosterone,bioavailable

DY Ligand Assay, Special 77

Testosterone, free X DY Ligand Assay, Special 77Thallium, urine TMU Trace Metals, Urine 94Theophylline X CZ, CZX,

CZ2, CZ2X, ZChemistry and TDM 54-56


Thioridazine T Toxicology 88UT Urine Toxicology 88

Throat culture X D1, D7 Throat, Urine Cultures 156X D4 Bacteriology, Ltd 157

Thrombin time CGE/CGEX Coagulation, Extended 146CGS4 Coag Special, Series 4 147DBGN Dabigatran 148

Thrombin-antithrombin CGE/CGEX Coagulation, Extended 146Thromboelastogram TEG Thromboelastogram 149Thrombophilia Mutations TPM Thrombophilia

Mutations217

Thyroglobulin X TM/TMX Tumor Markers 82Thyroid-stimulatinghormone (TSH)

ABS Accuracy-Based 101


102




�� Z�� K��

$@<

��#�

��

V�� #

Thyroid-stimulatinghormone (TSH) (cont.)


112

Thyroxine, free ABTH Accuracy-BasedThyroid

102



X K/KK Ligand Assay, General 76Thyroxine, total ABTH Accuracy-Based

Thyroid102




59


Ver/Lin112


112

Tick identification TMO Ticks, Mites, and OtherArthropods

171

Tissue parasiteidentification

X BP Blood Parasite 170

X P Parasitology 169Tissue plasminogenactivator


Tobramycin X CZ, CZX,CZ2, CZ2X, Z


LN3 TDM Cal Ver/Lin 111Total bile acids TBLA Total Bile Acid 72Total bilirubin X C1, C3, C3X,

CZ, CZX,CZ2, CZ2X


FLD2 Body Fluid Chemistry 2 67IFS Interfering Substances 123LM1 Lung Maturity 70LN2 Chemistry, Lipid,



110

X NB, NB2 Neonatal Bilirubin 61Total bilirubin, urine X CMP, CMP1 Clinical Microscopy 134

DSC Dipstick Confirmatory 136Total free fatty acids FCFS Fecal Fat 69Total hCG X FP1T First Trimester Maternal

Screening, Total hCG80

Total hemolyticcomplement

CH50 Total HemolyticComplement

188

�� Z��J��}

284 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Total iron bindingcapacity, measured and% saturation

X C3, C3X, CZCZX, CZ2,CZ2X


Total nitrogen, urine U Urine Chemistry,General

63

Total nucleated cells CBT Cord Blood Testing 199SCP Stem Cell Processing 199

Total nucleated red cells CBT Cord Blood Testing 199SCP Stem Cell Processing 199

Total protein X C1, C3, C3X,CZ, CZX,CZ2, CZ2X



59




110

SPE Protein Electrophoresis 70Total protein, CSF X M, OLI CSF Chemistry and

Oligoclonal Bands68

Total protein, urine LN6 Urine Chemistry CalVer/Lin

112


63

Total tricyclics X SDS Serum Drug Screen 93X ZT, ZZT TDM, Special 57

Touch imprint/Crushprep

TICP, TICP1 Touch Imprint/CrushPrep

241

Toxicology, serum,qualitative

X SDS Serum Drug Screen 93

X T Toxicology 88Toxicology, urine,qualitative

X T Toxicology 88

X UDS, UDS6 Urine Drug Screen 90X UT Urine Toxicology 88

Toxicology, urine,qualitative/quantitative

X UDC Forensic Urine DrugTesting, Confirmatory

91

Toxoplasma gondii X VR3 Antibody Detection-Infectious DiseaseSerology

180

Tramadol DMPM Drug Monitoring forPain Management

97


95


�� Z�� K��

$@<

��#�

��

V�� #

Transferrin X C3, C3X,CZ, CZX,CZ2, CZ2X


LN7 Immunology Cal Ver/Lin 113X S2, S4 Immunology, Special 183

Transfusion medicine ETME1 Expanded TransfusionMedicine Exercises

195

EXM, EXM2 Electronic Crossmatch 197X J, J1 Transfusion Medicine 194X JAT, JATE1 Transfusion Medicine,

Automated194

JE1 Transfusion Medicine,Education

194


196

TMCAD Transfusion Medicine,Competency Assessment

196


196

X TRC Transfusion-Related CellCount

200

Trazodone FTC Forensic Toxicology,Criminalistics

95


Treponema pallidum X G Syphilis Serology 187Trichomonas vaginalis X VS, VS1 Vaginitis Screen 163Tricyclic group T Toxicology 88


Tricyclics, total X SDS Serum Drug Screen 93X ZT, ZZT TDM, Special 57

Triglycerides ABL Accuracy-Based Lipid 100X C1, C3, C3X,

CZ, CZX,CZ2, CZ2X


FCFS Fecal Fat 69FLD Body Fluid 67

X LCW Ltd Chem, Waived 61LN2 Chemistry, Lipid,



110

Triiodothyronine (T3) ABTH Accuracy-BasedThyroid

102




�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 285


$�

�� Z�� K��

$@<

��#�

��

V�� #

Triiodothyronine (T3)(cont.)


112


112

Triiodothyronine (T3),Free


102



X K/KK Ligand Assay, General 76Trimipramine T Toxicology 88

UT Urine Toxicology 88Troponin I, plasma X PCARM,

PCARMXPlasma CardiacMarkers

61


49

Troponin I, serum X CRT, CRTI Cardiac Markers 59LN25 Troponin I Cal Ver/Lin 118

Troponin T, serum LN27 Troponin T Cal Ver/Lin 118X TNT Troponin T 59

Tumor necrosis factor(TNF)-alpha

CTKN Cytokines 186

UGT1A1 PGX Pharmacogenetics 217Unsaturated iron bindingcapacity, measured

X C3, C3X,CZ, CZX,CZ2, CZ2X


UR-144 N-(4-hydroxypentyl)metabolite

SCDD SyntheticCannabanoid/DesignerStimulant

96

UR-144 N-(5-hydroxypentyl)metabolite


96

UR-144 N-pentanoicacid metabolite


96

Urea nitrogen X AQ2, AQ4 Aqueous Blood Gas 84X C1, C3, C3X,

CZ, CZX,CZ2, CZ2X



59




110

Urea nitrogen, urine LN6 Urine Chemistry CalVer/Lin

112


63

�� Z�� K��

$@<

��#�

��

V�� #

Urea nitrogen, vitreousfluid

VF Vitreous Fluid, Post-mortem

92

Urease X RUR Rapid Urease 162Uric acid X C1, C3, C3X,

CZ, CZX,CZ2, CZ2X



59




110

Uric acid, urine LN6 Urine Chemistry CalVer/Lin

112


63

Urine albumin LN20 Urine albumin Cal Ver/Lin

116


63

X UMC Urine AlbuminCreatinine

138

Urine albumin:creatinine ratio

ABU Accuracy-Based Urine 101

U Urine Chemistry,General

63

UMC Urine AlbuminCreatinine

138

Urine crystals UAA Automated Urinalysis 136URC Crystals 136

Urine culture X D2, D7 Throat, Urine Cultures 156X D4 Bacteriology, Ltd 157

Urine dipstick POC3 POC/Waived UrineDipstick Competency

48

Urine drug screen X UDS, UDS6 Urine Drug Screen 90Urine sediment, colorphotographs


Urobilinogen X CMP, CMP1 Clinical Microscopy 134POC3 POC Urine Dipstick

Competency48

Uroporphyrin X N/NX Urine Chemistry,Special

64

Urothelial carcinoma byFISH, hybridization andinterpretation on-site

X CYI Fluorescence InSitu Hybridization,Urothelial Carcinoma

210

Vaginal wetpreparations

X CMMP Clinical Microscopy,Misc.

134

Vaginitis screen BV Bacterial Vaginosis 163

�� Z��J��}

286 ��#�� #�� !"�� #��$�� #� �

Ana

lyte

/Pro

cedu

re In

dex

$�

�� Z�� K��

$@<

��#�

��

V�� #

Vaginitis screen (cont.) X VS BD Affirm VP III AntigenDetection

163

X VS1 Genzyme OSOMTrichomonas

163

VS2 Vaginitis Screen, VirtualGram Stain

164

Valproic acid X CZ, CZX,CZ2, CZ2X, Z



Valproic acid, free X CZ, CZX,CZ2, CZ2X, Z


Vancomycin X CZ, CZX,CZ2, CZ2X, Z


LN3 TDM Cal Ver/Lin 111Vancomycin-resistantEnterococcus


177

VRE Vancomycin-resistantEnterococcus

164

Vanillylmandelic acid X N/NX Urine Chemistry,Special

64

Varicella-zoster virus(VZV)

ID1 Nucleic AcidAmplification

177


by DFA173


180

Vascular endothelialgrowth factor (VEGF)

CTKN Cytokines 186

Verapamil T Toxicology 88UT Urine Toxicology 88

Viability CBT Cord Blood Testing 199SCP Stem Cell Processing 199

Viral antigen detection X HC2 HSV by DFA 174POC8 POC Influenza A/B Ag 48

X VR2 Viral Antigen Detectionby DFA

173


174

Viral isolation/identification

X HC4 HSV Culture 174

X VR1 Virology Culture 173Virtual biopsy program,online

VBP/VBP1 Online Virtual BiopsiesProgram

226

Virtual Gram Stain VGS1 Virtual Gram StainBasic

158

VGS2 Virtual Gram StainAdvanced

158

�� Z�� K��

$@<

��#�

��

V�� #

Virtual peripheral bloodsmear

VPBS Virtual Peripheral BloodSmear

132

Viscosity V Viscosity 188Vitamin A BMV3 Bone Markers and

Vitamins79

Vitamin B12 X K/KK Ligand Assay, General 76LN5 Ligand Assay Cal

Ver/Lin112


112

Vitamin D, 25-OH X ABVD Accuracy-BasedVitamin D

78

X BGS Bone and Growth 78LN40 Vitamin D Cal Ver/Lin 120

Vitamin D, 1, 25Dihydroxy


79

Vitamin E BMV4 Bone Markers andVitamins

79

VKORC1 PGX Pharmacogenetics 217Volatiles X AL1 Whole Blood Alcohol/

Ethylene Glycol/Volatiles93


93

von Willebrand factor CGE/CGEX Coagulation, Extended 146CGS3 Coag Special, Series 3 147LN37 von Willebrand Factor

Ag Cal Ver/Lin120

VZV ID1 Nucleic AcidAmplification

177


by DFA173


180

Wavelength andphotometric calibration


WBC count ABF1, ABF2,ABF3


CBT Cord Blood Testing 199X FH1-FH4,



FL4 Flow Cytometry CD34+ 190X HE, HEP Basic Hematology 128X HFC Hemocytometer

Fluid Count137

LN9 Hematology Cal Ver/Lin 114

�� Z��J��}

'��%�%�"�"� _�'"+�'%��+��9��! _�� # 287


$�

�� Z�� K��

$@<

��#�

��

V�� #

WBC count (cont.) X RWBC Rapid Total WhiteBlood Cell Count

132

SCP Stem Cell Processing 199UAA, UAA1 Automated Urinalysis 136

WBC count (leukocyte-reduced platelets)


200

WBC count (leukocyte-reduced RBCs)


200

WBC differential EHE1 Expanded VirtualPeripheral Blood Smear

133

WBC differential,automated



WBC differential-bodyfluid

VBF Virtual Body Fluid 135

WBC morphology EHE1 Expanded VirtualPeripheral Blood Smear

133

West Nile virus X NAT Nucleic Acid Testing 203Worm identification WID Worm Identification 171Yeast identification X F Mycology 166

X F1 Yeast 166X F3 Candida culture 167

ZAP-70 ZAP70 ZAP-70 Analysis byFlow Cytometry

191

Zinc X R Trace Metals 72Zinc, urine TMU Trace Metals, Urine 94Zolpidem FTC Forensic Toxicology,

Criminalistics95


��B��$:�'K��^��# ��#��

�� #��$�� #� �

��

��

��

�

��

cap.org/eLabConnect

What is it worth?��

Gain 500 more hours of time and resources using e-LAB Solutions Connect™

It’s about

��

cap.org© 2013 College of American Pathologists. All rights reserved.

Expertise. Experience. Excellence.That’s the CAP’s promise—to share the knowledge and insight provided by expert pathologists volunteering more than 178,000 hours annually to help laboratories be their best. And as laboratory medicine advances, we’ll be there with solutions that help you deliver world-class care. That’s our commitment to you.

TM

2014 Surveys Catalog - College of American Pathologists · Glass Slide Program with Online PAP...

Documents

Transcript of 2014 Surveys Catalog - College of American Pathologists · Glass Slide Program with Online PAP...